Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Multiple Sclerosis

  Free Subscription


Articles published in Mult Scler

Retrieve available abstracts of 951 articles:
HTML format



Single Articles


    July 2021
  1. LONGINETTI E, Frisell T, Englund S, Reutfors J, et al
    Risk of depression in multiple sclerosis across disease-modifying therapies.
    Mult Scler. 2021 Jul 15:13524585211031128. doi: 10.1177/13524585211031128.
    PubMed     Abstract available


  2. BOUMAN PM, Strijbis VI, Jonkman LE, Hulst HE, et al
    Artificial double inversion recovery images for (juxta)cortical lesion visualization in multiple sclerosis.
    Mult Scler. 2021 Jul 14:13524585211029860. doi: 10.1177/13524585211029860.
    PubMed     Abstract available


  3. MONTALBAN X, Graves J, Midaglia L, Mulero P, et al
    A smartphone sensor-based digital outcome assessment of multiple sclerosis.
    Mult Scler. 2021 Jul 14:13524585211028561. doi: 10.1177/13524585211028561.
    PubMed     Abstract available


  4. HOGESTOL EA, Ghezzo S, Nygaard GO, Espeseth T, et al
    Functional connectivity in multiple sclerosis modelled as connectome stability: A 5-year follow-up study.
    Mult Scler. 2021 Jul 14:13524585211030212. doi: 10.1177/13524585211030212.
    PubMed     Abstract available


  5. WIJERATNE T, Carroll W
    World Brain Day 2021: Global campaign to stop multiple sclerosis.
    Mult Scler. 2021 Jul 14:13524585211030147. doi: 10.1177/13524585211030147.
    PubMed    


  6. HARTUNG HP, Derfuss T, Cree BA, Sormani MP, et al
    Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study.
    Mult Scler. 2021 Jul 9:13524585211024997. doi: 10.1177/13524585211024997.
    PubMed     Abstract available


  7. VAN LIEROP ZY, Toorop AA, van Ballegoij WJ, Olde Dubbelink TB, et al
    Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic.
    Mult Scler. 2021 Jul 9:13524585211028833. doi: 10.1177/13524585211028833.
    PubMed     Abstract available


  8. SPELMAN T, Forsberg L, McKay K, Glaser A, et al
    Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry.
    Mult Scler. 2021 Jul 2:13524585211026272. doi: 10.1177/13524585211026272.
    PubMed     Abstract available


  9. KALINOWSKA-LYSZCZARZ A, Tillema JM, Tobin WO, Guo Y, et al
    Long-term clinical, MRI, and cognitive follow-up in a large cohort of pathologically confirmed, predominantly tumefactive multiple sclerosis.
    Mult Scler. 2021 Jul 2:13524585211024162. doi: 10.1177/13524585211024162.
    PubMed     Abstract available


  10. NAUTA IM, Bertens D, van Dam M, Huiskamp M, et al
    Performance validity in outpatients with multiple sclerosis and cognitive complaints.
    Mult Scler. 2021 Jul 2:13524585211025780. doi: 10.1177/13524585211025780.
    PubMed     Abstract available


  11. ESHAGHI A
    Towards an objective classification of multiple sclerosis.
    Mult Scler. 2021;27:1151-1152.
    PubMed    


    June 2021
  12. SCHONFELDER K, Schuh H, Pfister F, Kramer J, et al
    Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment.
    Mult Scler. 2021 Jun 24:13524585211022719. doi: 10.1177/13524585211022719.
    PubMed     Abstract available


  13. MIZELL R, Chen H, Lambe J, Saidha S, et al
    Association of retinal atrophy with cortical lesions and leptomeningeal enhancement in multiple sclerosis on 7T MRI.
    Mult Scler. 2021 Jun 14:13524585211023343. doi: 10.1177/13524585211023343.
    PubMed     Abstract available


  14. BOMMARITO G, Tarun A, Farouj Y, Preti MG, et al
    Altered anterior default mode network dynamics in progressive multiple sclerosis.
    Mult Scler. 2021 Jun 14:13524585211018116. doi: 10.1177/13524585211018116.
    PubMed     Abstract available


  15. HIDALGO DE LA CRUZ M, Valsasina P, Meani A, Gallo A, et al
    Differential association of cortical, subcortical and spinal cord damage with multiple sclerosis disability milestones: A multiparametric MRI study.
    Mult Scler. 2021 Jun 14:13524585211020296. doi: 10.1177/13524585211020296.
    PubMed     Abstract available


  16. WU J, Engdahl E, Gustafsson R, Fogdell-Hahn A, et al
    High antibody levels against human herpesvirus-6A interact with lifestyle factors in multiple sclerosis development.
    Mult Scler. 2021 Jun 14:13524585211022011. doi: 10.1177/13524585211022011.
    PubMed     Abstract available


  17. VERCELLINO M, Marasciulo S, Grifoni S, Vallino-Costassa E, et al
    Acute and chronic synaptic pathology in multiple sclerosis gray matter.
    Mult Scler. 2021 Jun 14:13524585211022174. doi: 10.1177/13524585211022174.
    PubMed     Abstract available


  18. CORTESE R, Battaglini M, Parodi F, Stromillo ML, et al
    Mild gray matter atrophy in patients with long-standing multiple sclerosis and favorable clinical course.
    Mult Scler. 2021 Jun 8:13524585211019650. doi: 10.1177/13524585211019650.
    PubMed     Abstract available


  19. SADOVNICK AD, Yee IM, Criscuoli M, DeLuca GC, et al
    Genes and environment in multiple sclerosis: Impact of temporal changes in the sex ratio on recurrence risks.
    Mult Scler. 2021 Jun 8:13524585211020221. doi: 10.1177/13524585211020221.
    PubMed     Abstract available


  20. KALINOWSKI A, Cutter G, Bozinov N, Hinman JA, et al
    The timed 25-foot walk in a large cohort of multiple sclerosis patients.
    Mult Scler. 2021 Jun 8:13524585211017013. doi: 10.1177/13524585211017013.
    PubMed     Abstract available


  21. GARJANI A, Hunter R, Law GR, Middleton RM, et al
    Mental health of people with multiple sclerosis during the COVID-19 outbreak: A prospective cohort and cross-sectional case-control study of the UK MS Register.
    Mult Scler. 2021 Jun 3:13524585211020435. doi: 10.1177/13524585211020435.
    PubMed     Abstract available


    May 2021
  22. MESSINA S, Mariano R, Roca-Fernandez A, Cavey A, et al
    Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis.
    Mult Scler. 2021 May 28:13524585211018987. doi: 10.1177/13524585211018987.
    PubMed     Abstract available


  23. SINGH M, Gavidia R, Dunietz GL, Washnock-Schmid E, et al
    Validation of an obstructive sleep apnea symptom inventory in persons with multiple sclerosis.
    Mult Scler. 2021 May 28:13524585211013014. doi: 10.1177/13524585211013014.
    PubMed     Abstract available


  24. ROUX J, Kingwell E, Zhu F, Tremlett H, et al
    Care consumption of people with multiple sclerosis: A multichannel sequence analysis in a population-based setting in British Columbia, Canada.
    Mult Scler. 2021 May 28:13524585211016726. doi: 10.1177/13524585211016726.
    PubMed     Abstract available


  25. MCMURRAN CE
    Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - No.
    Mult Scler. 2021 May 28:13524585211016722. doi: 10.1177/13524585211016722.
    PubMed    


  26. CALVO-BARREIRO L, Clerico M, Espejo C
    Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - Yes.
    Mult Scler. 2021 May 28:13524585211016723. doi: 10.1177/13524585211016723.
    PubMed    


  27. HOHLFELD R
    Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - Commentary.
    Mult Scler. 2021 May 28:13524585211018990. doi: 10.1177/13524585211018990.
    PubMed    


  28. KEVER A, Buyukturkoglu K, Levin SN, Riley CS, et al
    Associations of social network structure with cognition and amygdala volume in multiple sclerosis: An exploratory investigation.
    Mult Scler. 2021 May 26:13524585211018349. doi: 10.1177/13524585211018349.
    PubMed     Abstract available


  29. LAM KH, van Oirschot P, den Teuling B, Hulst HE, et al
    Reliability, construct and concurrent validity of a smartphone-based cognition test in multiple sclerosis.
    Mult Scler. 2021 May 26:13524585211018103. doi: 10.1177/13524585211018103.
    PubMed     Abstract available


  30. DE STEFANO N, Sormani MP, Giovannoni G, Rammohan K, et al
    Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies.
    Mult Scler. 2021 May 10:13524585211010294. doi: 10.1177/13524585211010294.
    PubMed     Abstract available


  31. WOJCIK C, Fuchs TA, Tran H, Dwyer MG, et al
    Staging and stratifying cognitive dysfunction in multiple sclerosis.
    Mult Scler. 2021 May 6:13524585211011390. doi: 10.1177/13524585211011390.
    PubMed     Abstract available


  32. BROWNLEE WJ, Solomon AJ
    Misdiagnosis of multiple sclerosis: Time for action.
    Mult Scler. 2021;27:805-806.
    PubMed    


    April 2021
  33. HOLLEN C, Rice J, Park M, Yadav V, et al
    Rituximab for treatment of refractory multiple sclerosis relapses during pregnancy.
    Mult Scler. 2021 Apr 30:1352458521998937. doi: 10.1177/1352458521998937.
    PubMed     Abstract available


  34. GUNGOR F, Tarakci E, Ozdemir-Acar Z, Soysal A, et al
    The effects of supervised versus home Pilates-based core stability training on lower extremity muscle strength and postural sway in people with multiple sclerosis.
    Mult Scler. 2021 Apr 28:13524585211012202. doi: 10.1177/13524585211012202.
    PubMed     Abstract available


  35. VAN LIEROP ZY, Wieske L, Koel-Simmelink MJ, Chatterjee M, et al
    Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis.
    Mult Scler. 2021 Apr 23:13524585211010097. doi: 10.1177/13524585211010097.
    PubMed     Abstract available


  36. KHADADAH S, Kimoff RJ, Duquette P, Jobin V, et al
    Effect of continuous positive airway pressure treatment of obstructive sleep apnea-hypopnea in multiple sclerosis: A randomized, double-blind, placebo-controlled trial (SAMS-PAP study).
    Mult Scler. 2021 Apr 23:13524585211010390. doi: 10.1177/13524585211010390.
    PubMed     Abstract available


  37. HARRISON AM, Safari R, Mercer T, Picariello F, et al
    Which exercise and behavioural interventions show most promise for treating fatigue in multiple sclerosis? A network meta-analysis.
    Mult Scler. 2021 Apr 20:1352458521996002. doi: 10.1177/1352458521996002.
    PubMed     Abstract available


  38. ALLANACH JR, Farrell JW 3rd, Mesidor M, Karimi-Abdolrezaee S, et al
    Current status of neuroprotective and neuroregenerative strategies in multiple sclerosis: A systematic review.
    Mult Scler. 2021 Apr 19:13524585211008760. doi: 10.1177/13524585211008760.
    PubMed     Abstract available


  39. ZHOU Y, Cuellar-Partida G, Simpson Yap S, Lin X, et al
    Utilising multi-large omics data to elucidate biological mechanisms within multiple sclerosis genetic susceptibly loci.
    Mult Scler. 2021 Apr 19:13524585211004422. doi: 10.1177/13524585211004422.
    PubMed     Abstract available


  40. PAPEIX C, Mazoyer J, Maillart E, Bensa C, et al
    Multiple sclerosis: Is there a risk of worsening after yellow fever vaccination?
    Mult Scler. 2021 Apr 19:13524585211006372. doi: 10.1177/13524585211006372.
    PubMed     Abstract available


  41. CHATTERTON S, Withers B, Sutton IJ, Milliken ST, et al
    Pregnancy post autologous stem cell transplant with BEAM conditioning for multiple sclerosis.
    Mult Scler. 2021 Apr 19:13524585211005660. doi: 10.1177/13524585211005660.
    PubMed     Abstract available


  42. CIOTTI JR, Eby NS, Brier MR, Wu GF, et al
    Central vein sign and other radiographic features distinguishing myelin oligodendrocyte glycoprotein antibody disease from multiple sclerosis and aquaporin-4 antibody-positive neuromyelitis optica.
    Mult Scler. 2021 Apr 19:13524585211007086. doi: 10.1177/13524585211007086.
    PubMed     Abstract available


  43. FLEMING KM, Coote SB, Herring MP
    Home-based Pilates for symptoms of anxiety, depression and fatigue among persons with multiple sclerosis: An 8-week randomized controlled trial.
    Mult Scler. 2021 Apr 19:13524585211009216. doi: 10.1177/13524585211009216.
    PubMed     Abstract available


  44. SCHOONHEIM MM, Pinter D, Prouskas SE, Broeders TA, et al
    Disability in multiple sclerosis is related to thalamic connectivity and cortical network atrophy.
    Mult Scler. 2021 Apr 19:13524585211008743. doi: 10.1177/13524585211008743.
    PubMed     Abstract available


  45. D'AMICO E, Zanghi A, Calogero AE, Patti F, et al
    Male fertility in relapsing-remitting multiple sclerosis patients treated with natalizumab and ocrelizumab: A prospective case-control study.
    Mult Scler. 2021 Apr 19:13524585211009208. doi: 10.1177/13524585211009208.
    PubMed     Abstract available


  46. CORTESE M, Bjornevik K, Chitnis T, Ascherio A, et al
    Aging with multiple sclerosis: A longitudinal study of physical function, mental health, and memory in two cohorts of US women.
    Mult Scler. 2021 Apr 16:13524585211007739. doi: 10.1177/13524585211007739.
    PubMed     Abstract available


  47. COOPER G, Chien C, Zimmermann H, Bellmann-Strobl J, et al
    Longitudinal analysis of T1w/T2w ratio in patients with multiple sclerosis from first clinical presentation.
    Mult Scler. 2021 Apr 15:13524585211003479. doi: 10.1177/13524585211003479.
    PubMed     Abstract available


  48. ACHIRON A, Dolev M, Menascu S, Zohar DN, et al
    COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021.
    Mult Scler. 2021 Apr 15:13524585211003476. doi: 10.1177/13524585211003476.
    PubMed     Abstract available


  49. TROJANO M, Ramio-Torrenta L, Grimaldi LM, Lubetzki C, et al
    A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis.
    Mult Scler. 2021 Apr 6:13524585211003020. doi: 10.1177/13524585211003020.
    PubMed     Abstract available


  50. BESSING B, Honan CA, van der Mei I, Taylor BV, et al
    Development and psychometric properties of the Multiple Sclerosis Knowledge Assessment Scale: Rasch analysis of a novel tool for evaluating MS knowledge.
    Mult Scler. 2021;27:767-777.
    PubMed     Abstract available


  51. VAN DAM M, Hulst HE, Schoonheim MM
    Coupling structure and function in early MS: How a less diverse repertoire of brain function could lead to clinical progression.
    Mult Scler. 2021;27:491-493.
    PubMed    


    March 2021
  52. HOWLETT-PRIETO Q, Feng X, Kramer JF, Kramer KJ, et al
    Anti-CD20 therapy corrects a CD8 regulatory T cell deficit in multiple sclerosis.
    Mult Scler. 2021 Mar 30:13524585211003301. doi: 10.1177/13524585211003301.
    PubMed     Abstract available


  53. THEODORSDOTTIR A, Debrabant B, Magyari M, Kant M, et al
    Alemtuzumab treatment in Denmark: A national study based on the Danish Multiple Sclerosis Registry.
    Mult Scler. 2021 Mar 29:13524585211003291. doi: 10.1177/13524585211003291.
    PubMed     Abstract available


  54. CREE BA, Cohen JA, Reder AT, Tomic D, et al
    Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis.
    Mult Scler. 2021 Mar 26:13524585211000280. doi: 10.1177/13524585211000280.
    PubMed     Abstract available


  55. PORTACCIO E, Fonderico M, Hemmer B, Derfuss T, et al
    Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey.
    Mult Scler. 2021 Mar 25:13524585211005339. doi: 10.1177/13524585211005339.
    PubMed     Abstract available


  56. LEE LE, Vavasour IM, Dvorak A, Liu H, et al
    Cervical cord myelin abnormality is associated with clinical disability in multiple sclerosis.
    Mult Scler. 2021 Mar 22:13524585211001780. doi: 10.1177/13524585211001780.
    PubMed     Abstract available


  57. HARROUD A, Mitchell RE, Richardson TG, Morris JA, et al
    Childhood obesity and multiple sclerosis: A Mendelian randomization study.
    Mult Scler. 2021 Mar 22:13524585211001781. doi: 10.1177/13524585211001781.
    PubMed     Abstract available


  58. BRIGGS FB, Krill D, Hill E, Conway DS, et al
    Age of hypertension onset in multiple sclerosis patients.
    Mult Scler. 2021 Mar 18:13524585211003016. doi: 10.1177/13524585211003016.
    PubMed     Abstract available


  59. MASSAROTTI C, Sbragia E, Boffa G, Vercelli C, et al
    Menstrual cycle resumption and female fertility after autologous hematopoietic stem cell transplantation for multiple sclerosis.
    Mult Scler. 2021 Mar 12:13524585211000616. doi: 10.1177/13524585211000616.
    PubMed     Abstract available


  60. SCHOONHEIM MM, Douw L, Broeders TA, Eijlers AJ, et al
    The cerebellum and its network: Disrupted static and dynamic functional connectivity patterns and cognitive impairment in multiple sclerosis.
    Mult Scler. 2021 Mar 8:1352458521999274. doi: 10.1177/1352458521999274.
    PubMed     Abstract available


  61. MACHLANSKA A, Helbig G, Chromik K, Zapala M, et al
    Hemophagocytic lymphohistiocytosis associated with ocrelizumab treatment in a patient with multiple sclerosis.
    Mult Scler. 2021 Mar 5:1352458521993070. doi: 10.1177/1352458521993070.
    PubMed     Abstract available


  62. LORSCHEIDER J
    When does a heap become a heap?
    Mult Scler. 2021;27:329-330.
    PubMed    


    February 2021
  63. SZILASIOVA J, Mikula P, Rosenberger J, Fedicova M, et al
    Plasma neurofilament light chain levels are predictors of disease activity in multiple sclerosis as measured by four-domain NEDA status, including brain volume loss.
    Mult Scler. 2021 Feb 26:1352458521998039. doi: 10.1177/1352458521998039.
    PubMed     Abstract available


  64. FOX RJ, Raska P, Barro C, Karafa M, et al
    Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis.
    Mult Scler. 2021 Feb 26:1352458520986956. doi: 10.1177/1352458520986956.
    PubMed     Abstract available


  65. COPETTI M, Liu D
    Machine and deep learning in multiple sclerosis research are just powerful statistics - Commentary.
    Mult Scler. 2021 Feb 24:1352458521996699. doi: 10.1177/1352458521996699.
    PubMed    


  66. HARROUD A, Manousaki D, Butler-Laporte G, Mitchell RE, et al
    The relative contributions of obesity, vitamin D, leptin, and adiponectin to multiple sclerosis risk: A Mendelian randomization mediation analysis.
    Mult Scler. 2021 Feb 19:1352458521995484. doi: 10.1177/1352458521995484.
    PubMed     Abstract available


  67. BINZER S, Jiang X, Hillert J, Manouchehrinia A, et al
    Depression and multiple sclerosis: A bidirectional Mendelian randomisation study.
    Mult Scler. 2021 Feb 19:1352458521996601. doi: 10.1177/1352458521996601.
    PubMed     Abstract available


  68. LEMA DOPICO A, Choi S, Hua J, Li X, et al
    Multi-layer analysis of quantitative 7 T magnetic resonance imaging in the cortex of multiple sclerosis patients reveals pathology associated with disability.
    Mult Scler. 2021 Feb 18:1352458521994556. doi: 10.1177/1352458521994556.
    PubMed     Abstract available


  69. HARROUD A, Marrie RA, Fitzgerald KC, Salter A, et al
    Mendelian randomization provides no evidence for a causal role in the bidirectional relationship between depression and multiple sclerosis.
    Mult Scler. 2021 Feb 16:1352458521993075. doi: 10.1177/1352458521993075.
    PubMed     Abstract available


  70. BESSING B, Hussain MA, Claflin SB, Chen J, et al
    Changes in multiple sclerosis symptoms are associated with changes in work productivity of people living with multiple sclerosis.
    Mult Scler. 2021 Feb 16:1352458521994557. doi: 10.1177/1352458521994557.
    PubMed     Abstract available


  71. BELVISI D, Canevelli M, Baione V, Buscarinu MC, et al
    Operationalization of a frailty index in patients with multiple sclerosis: A cross-sectional investigation.
    Mult Scler. 2021 Feb 10:1352458520987541. doi: 10.1177/1352458520987541.
    PubMed     Abstract available


  72. MIDAGLIA L, Sastre-Garriga J, Pappolla A, Quibus L, et al
    The frequency and characteristics of MS misdiagnosis in patients referred to the multiple sclerosis centre of Catalonia.
    Mult Scler. 2021 Feb 10:1352458520988148. doi: 10.1177/1352458520988148.
    PubMed     Abstract available


  73. VELDKAMP R, Kalron A, Baert I, Hamalainen P, et al
    Differential effects and discriminative validity of motor and cognitive tasks varying in difficulty on cognitive-motor interference in persons with multiple sclerosis.
    Mult Scler. 2021 Feb 10:1352458520986960. doi: 10.1177/1352458520986960.
    PubMed     Abstract available


  74. KRASNIUK S, Classen S, Morrow SA, Alvarez L, et al
    Clinical predictors of driving simulator performance in drivers with multiple sclerosis.
    Mult Scler. 2021 Feb 10:1352458521992507. doi: 10.1177/1352458521992507.
    PubMed     Abstract available


  75. DAS J, Snowden JA, Burman J, Freedman MS, et al
    Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with 'aggressive' multiple sclerosis.
    Mult Scler. 2021 Feb 10:1352458520985238. doi: 10.1177/1352458520985238.
    PubMed     Abstract available



  76. Incidence and clinical outcome of Coronavirus disease 2019 in a cohort of 11,560 Brazilian patients with multiple sclerosis.
    Mult Scler. 2021 Feb 2:1352458520978354. doi: 10.1177/1352458520978354.
    PubMed     Abstract available


  77. NYIRENDA MH, Fadda G, Healy LM, Mexhitaj I, et al
    Pro-inflammatory adiponectin in pediatric-onset multiple sclerosis.
    Mult Scler. 2021 Feb 1:1352458521989090. doi: 10.1177/1352458521989090.
    PubMed     Abstract available


  78. YEH EA
    Real-world outcomes in pediatric MS: Psychiatric comorbidities and school performance.
    Mult Scler. 2021;27:165-166.
    PubMed    


    January 2021
  79. MANOUCHEHRINIA A, Kingwell E, Zhu F, Tremlett H, et al
    A multiple sclerosis disease progression measure based on cumulative disability.
    Mult Scler. 2021 Jan 25:1352458520988632. doi: 10.1177/1352458520988632.
    PubMed     Abstract available


  80. JALUSIC KO, Ellenberger D, Rommer P, Stahmann A, et al
    Effect of applying inclusion and exclusion criteria of phase III clinical trials to multiple sclerosis patients in routine clinical care.
    Mult Scler. 2021 Jan 20:1352458520985118. doi: 10.1177/1352458520985118.
    PubMed     Abstract available


  81. BLACK LJ, Hetherton S, Forkan M, Gonzales EG, et al
    An exploratory study of diet in childhood and young adulthood and adult-onset multiple sclerosis.
    Mult Scler. 2021 Jan 19:1352458520986964. doi: 10.1177/1352458520986964.
    PubMed     Abstract available


  82. ROOS I, Leray E, Frascoli F, Casey R, et al
    Determinants of therapeutic lag in multiple sclerosis.
    Mult Scler. 2021 Jan 11:1352458520981300. doi: 10.1177/1352458520981300.
    PubMed     Abstract available


  83. FITZGERALD KC, Damian A, Conway D, Mowry EM, et al
    Vascular comorbidity is associated with lower brain volumes and lower neuroperformance in a large multiple sclerosis cohort.
    Mult Scler. 2021 Jan 8:1352458520984746. doi: 10.1177/1352458520984746.
    PubMed     Abstract available


  84. GONZALEZ-ESCAMILLA G, Groppa S
    7 Tesla MRI will soon be helpful to guide clinical practice in multiple sclerosis centres - No.
    Mult Scler. 2021 Jan 6:1352458520969662. doi: 10.1177/1352458520969662.
    PubMed    


  85. SATI P, Reich DS
    7 Tesla MRI will soon be helpful to guide clinical practice in multiple sclerosis centers - Commentary.
    Mult Scler. 2021 Jan 6:1352458520981738. doi: 10.1177/1352458520981738.
    PubMed    


  86. LOUAPRE C, Beigneux Y
    7 Tesla MRI will soon be helpful to guide clinical practice in multiple sclerosis centres - Yes.
    Mult Scler. 2021 Jan 6:1352458520972270. doi: 10.1177/1352458520972270.
    PubMed    


  87. ROLLOT F, Casey R, Leray E, Debouverie M, et al
    Cumulative effects of therapies on disability in relapsing multiple sclerosis.
    Mult Scler. 2021 Jan 6:1352458520980366. doi: 10.1177/1352458520980366.
    PubMed     Abstract available


  88. MARRIE RA, Leung S, Cutter GR, Fox RJ, et al
    Comparative responsiveness of the health utilities index and the RAND-12 for multiple sclerosis.
    Mult Scler. 2021 Jan 5:1352458520981370. doi: 10.1177/1352458520981370.
    PubMed     Abstract available


  89. AMATO MP, Portaccio E, De Meo E
    Understanding the pathophysiology of cognitive changes in MS: A step forward.
    Mult Scler. 2021;27:4-5.
    PubMed    


  90. BISTROM M, Hultdin J, Sundstrom P
    Response to 'Mendelian randomization analysis does not support a role for leptin in multiple sclerosis'.
    Mult Scler. 2021;27:161-162.
    PubMed    


  91. AL-ARAJI S, Ciccarelli O
    A possible case of serum sickness after ocrelizumab infusion - Commentary.
    Mult Scler. 2021;27:158-159.
    PubMed     Abstract available


    December 2020
  92. NIELSEN NM, Gortz S, Hjalgrim H, Rostgaard K, et al
    Maternal diabetes and risk of multiple sclerosis in the offspring: A Danish nationwide register-based cohort study.
    Mult Scler. 2020 Dec 17:1352458520977120. doi: 10.1177/1352458520977120.
    PubMed     Abstract available


  93. GALLO A, Bisecco A
    Psychological resilience explains functional variability across people with multiple sclerosis - Commentary.
    Mult Scler. 2020 Dec 17:1352458520978213. doi: 10.1177/1352458520978213.
    PubMed    


  94. LEAVITT VM, Kever A
    Psychological resilience explains functional variability across people with multiple sclerosis - Yes.
    Mult Scler. 2020 Dec 17:1352458520972263. doi: 10.1177/1352458520972263.
    PubMed    


  95. PLOUGHMAN M
    Psychological resilience explains functional variability across people with multiple sclerosis - No.
    Mult Scler. 2020 Dec 17:1352458520973633. doi: 10.1177/1352458520973633.
    PubMed    


  96. COMABELLA M, Deutschmann C, Midaglia L, Schierack P, et al
    Chitinase 3-like 1 is not a target antigen in patients with multiple sclerosis.
    Mult Scler. 2020 Dec 17:1352458520980141. doi: 10.1177/1352458520980141.
    PubMed     Abstract available


  97. HYLAND MH, Robb JF
    Teleconsultation will replace most face-to-face interactions in the multiple sclerosis clinic - Yes.
    Mult Scler. 2020 Dec 16:1352458520973640. doi: 10.1177/1352458520973640.
    PubMed    


  98. MOCCIA M
    Teleconsultation will replace most face-to-face interactions in the multiple sclerosis clinic - No.
    Mult Scler. 2020 Dec 16:1352458520968815. doi: 10.1177/1352458520968815.
    PubMed    


  99. D'HAESELEER M
    Teleconsultation will replace most face-to-face interactions in the multiple sclerosis clinic - Commentary.
    Mult Scler. 2020 Dec 16:1352458520979303. doi: 10.1177/1352458520979303.
    PubMed    


  100. CALABRESI PA, Arnold DL, Sangurdekar D, Singh CM, et al
    Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring.
    Mult Scler. 2020 Dec 14:1352458520972573. doi: 10.1177/1352458520972573.
    PubMed     Abstract available


  101. FILIPPATOU AG, Moniruzzaman M, Sotirchos ES, Fitzgerald KC, et al
    Serum ceramide levels are altered in multiple sclerosis.
    Mult Scler. 2020 Dec 14:1352458520971816. doi: 10.1177/1352458520971816.
    PubMed     Abstract available


  102. CHAN CK, Tian F, Pimentel Maldonado D, Mowry EM, et al
    Depression in multiple sclerosis across the adult lifespan.
    Mult Scler. 2020 Dec 14:1352458520979304. doi: 10.1177/1352458520979304.
    PubMed     Abstract available


  103. TAPIA-MALTOS MA, Trevino-Frenk I, Garcia-Gonzalez HB, Rosetti M, et al
    Identification of regulatory T cell molecules associated with severity of multiple sclerosis.
    Mult Scler. 2020 Dec 10:1352458520977045. doi: 10.1177/1352458520977045.
    PubMed     Abstract available


  104. NAUTA IM, Kulik SD, Breedt LC, Eijlers AJ, et al
    Functional brain network organization measured with magnetoencephalography predicts cognitive decline in multiple sclerosis.
    Mult Scler. 2020 Dec 9:1352458520977160. doi: 10.1177/1352458520977160.
    PubMed     Abstract available


  105. JACOBS BM, Smets I, Giovannoni G, Noyce A, et al
    Regarding: Nicotinic acetylcholine receptors alpha7 and alpha9 modify tobacco smoke risk for multiple sclerosis.
    Mult Scler. 2020 Dec 8:1352458520969941. doi: 10.1177/1352458520969941.
    PubMed    


  106. BRIGGS F
    Response to Jacobs et al, Nicotinic acetylcholine receptors alpha7 and alpha9 modify tobacco smoke risk for multiple sclerosis.
    Mult Scler. 2020 Dec 8:1352458520977027. doi: 10.1177/1352458520977027.
    PubMed    


  107. KOUBIYR I, Deloire M, Brochet B, Besson P, et al
    Structural constraints of functional connectivity drive cognitive impairment in the early stages of multiple sclerosis.
    Mult Scler. 2020 Dec 7:1352458520971807. doi: 10.1177/1352458520971807.
    PubMed     Abstract available


  108. VUKUSIC S, Ionescu I, Cornu C, Bossard N, et al
    Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study.
    Mult Scler. 2020 Dec 3:1352458520978218. doi: 10.1177/1352458520978218.
    PubMed     Abstract available


  109. RAMANUJAM R, Zhu F, Fink K, Karrenbauer VD, et al
    Accurate classification of secondary progression in multiple sclerosis using a decision tree.
    Mult Scler. 2020 Dec 2:1352458520975323. doi: 10.1177/1352458520975323.
    PubMed     Abstract available


  110. SHAH S
    Real-world evidence: One tweet at a time.
    Mult Scler. 2020;26:1965-1966.
    PubMed    


  111. COETZEE T, Thompson AJ
    Atlas of MS 2020: Informing global policy change.
    Mult Scler. 2020;26:1807-1808.
    PubMed    


  112. PILUTTI LA, Fakolade A
    Rehabilitation should be prescribed acutely in motor relapses - Commentary.
    Mult Scler. 2020;26:1825-1827.
    PubMed    


    November 2020
  113. STEPHENS S, Berenbaum T, Finlayson M, Motl RW, et al
    Youth with multiple sclerosis have low levels of fitness.
    Mult Scler. 2020 Nov 27:1352458520974360. doi: 10.1177/1352458520974360.
    PubMed     Abstract available


  114. ROMEO AR, Rowles WM, Schleimer ES, Barba P, et al
    An electronic, unsupervised patient-reported Expanded Disability Status Scale for multiple sclerosis.
    Mult Scler. 2020 Nov 25:1352458520968814. doi: 10.1177/1352458520968814.
    PubMed     Abstract available


  115. LANGESKOV-CHRISTENSEN M, Hvid LG, Jensen HB, Nielsen HH, et al
    Efficacy of high-intensity aerobic exercise on cognitive performance in people with multiple sclerosis: A randomized controlled trial.
    Mult Scler. 2020 Nov 24:1352458520973619. doi: 10.1177/1352458520973619.
    PubMed     Abstract available


  116. KLISTORNER S, Barnett MH, Yiannikas C, Barton J, et al
    Expansion of chronic lesions is linked to disease progression in relapsing-remitting multiple sclerosis patients.
    Mult Scler. 2020 Nov 20:1352458520974357. doi: 10.1177/1352458520974357.
    PubMed     Abstract available


  117. IAFFALDANO P, Lucisano G, Patti F, Brescia Morra V, et al
    Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors.
    Mult Scler. 2020 Nov 19:1352458520974366. doi: 10.1177/1352458520974366.
    PubMed     Abstract available


  118. LARONI A, Schiavetti I, Sormani MP, Uccelli A, et al
    COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments.
    Mult Scler. 2020 Nov 18:1352458520971817. doi: 10.1177/1352458520971817.
    PubMed     Abstract available


  119. CREE BA, Magnusson B, Rouyrre N, Fox RJ, et al
    Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis.
    Mult Scler. 2020 Nov 18:1352458520971819. doi: 10.1177/1352458520971819.
    PubMed     Abstract available


  120. GLUKHOVSKY L, Kurz D, Brandstadter R, Leavitt VM, et al
    Depression and cognitive function in early multiple sclerosis: Multitasking is more sensitive than traditional assessments.
    Mult Scler. 2020 Nov 16:1352458520958359. doi: 10.1177/1352458520958359.
    PubMed     Abstract available


  121. PREZIOSA P, Pagani E, Moiola L, Rodegher M, et al
    Occurrence and microstructural features of slowly expanding lesions on fingolimod or natalizumab treatment in multiple sclerosis.
    Mult Scler. 2020 Nov 13:1352458520969105. doi: 10.1177/1352458520969105.
    PubMed     Abstract available


  122. HEITMANN H, Andlauer TFM, Korn T, Muhlau M, et al
    Fatigue, depression, and pain in multiple sclerosis: How neuroinflammation translates into dysfunctional reward processing and anhedonic symptoms.
    Mult Scler. 2020 Nov 12:1352458520972279. doi: 10.1177/1352458520972279.
    PubMed     Abstract available


  123. SACCO R, Braga A, Disanto G, Digesu GA, et al
    Effectiveness of percutaneous posterior tibial nerve stimulation for the management of bowel dysfunction in multiple sclerosis patients.
    Mult Scler. 2020 Nov 12:1352458520972267. doi: 10.1177/1352458520972267.
    PubMed     Abstract available


  124. KARIM ME, Pellegrini F, Platt RW, Simoneau G, et al
    The use and quality of reporting of propensity score methods in multiple sclerosis literature: A review.
    Mult Scler. 2020 Nov 12:1352458520972557. doi: 10.1177/1352458520972557.
    PubMed     Abstract available


  125. AVILA M, Okai A, Thakolwiboon S, O'Bryan C, et al
    The effect of tonsillectomy on John Cunningham virus serological status in multiple sclerosis patients: A retrospective case-control study.
    Mult Scler. 2020 Nov 12:1352458520971822. doi: 10.1177/1352458520971822.
    PubMed     Abstract available


  126. WALTON C, King R, Rechtman L, Kaye W, et al
    Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition.
    Mult Scler. 2020 Nov 11:1352458520970841. doi: 10.1177/1352458520970841.
    PubMed     Abstract available


  127. HEDSTROM AK, Olsson T, Alfredsson L
    Cotinine as a measure of smoking in observational studies of multiple sclerosis.
    Mult Scler. 2020 Nov 10:1352458520968803. doi: 10.1177/1352458520968803.
    PubMed     Abstract available


  128. LAM KH, Meijer KA, Loonstra FC, Coerver E, et al
    Real-world keystroke dynamics are a potentially valid biomarker for clinical disability in multiple sclerosis.
    Mult Scler. 2020 Nov 5:1352458520968797. doi: 10.1177/1352458520968797.
    PubMed     Abstract available


  129. BUYUKTURKOGLU K, Zeng D, Bharadwaj S, Tozlu C, et al
    Classifying multiple sclerosis patients on the basis of SDMT performance using machine learning.
    Mult Scler. 2020 Nov 4:1352458520958362. doi: 10.1177/1352458520958362.
    PubMed     Abstract available


    October 2020
  130. LOZINSKI BM, Yong VW
    Exercise and the brain in multiple sclerosis.
    Mult Scler. 2020 Oct 30:1352458520969099. doi: 10.1177/1352458520969099.
    PubMed     Abstract available


  131. AFZAL HMR, Luo S, Ramadan S, Lechner-Scott J, et al
    The emerging role of artificial intelligence in multiple sclerosis imaging.
    Mult Scler. 2020 Oct 28:1352458520966298. doi: 10.1177/1352458520966298.
    PubMed     Abstract available


  132. PROSPERINI L, Haggiag S, Tortorella C, Galgani S, et al
    Age-related adverse events of disease-modifying treatments for multiple sclerosis: A meta-regression.
    Mult Scler. 2020 Oct 26:1352458520964778. doi: 10.1177/1352458520964778.
    PubMed     Abstract available


  133. STRIK M, Chard DT, Dekker I, Meijer KA, et al
    Increased functional sensorimotor network efficiency relates to disability in multiple sclerosis.
    Mult Scler. 2020 Oct 26:1352458520966292. doi: 10.1177/1352458520966292.
    PubMed     Abstract available


  134. KOSCH R, Schiffmann I, Daumer M, Lederer C, et al
    Long-term prognostic counselling in people with multiple sclerosis using an online analytical processing tool.
    Mult Scler. 2020 Oct 26:1352458520964774. doi: 10.1177/1352458520964774.
    PubMed     Abstract available


  135. TECCHIO F, Bertoli M, Gianni E, L'Abbate T, et al
    Parietal dysfunctional connectivity in depression in multiple sclerosis.
    Mult Scler. 2020 Oct 21:1352458520964412. doi: 10.1177/1352458520964412.
    PubMed    


  136. JAEGER S, Paul F, Finke C
    Functional connectivity alterations of striato-cortical circuits in multiple sclerosis.
    Mult Scler. 2020 Oct 21:1352458520966303. doi: 10.1177/1352458520966303.
    PubMed    


  137. BERMEL RA, Fedler JK, Kaiser P, Novalis C, et al
    Optical coherence tomography outcomes from SPRINT-MS, a multicenter, randomized, double-blind trial of ibudilast in progressive multiple sclerosis.
    Mult Scler. 2020 Oct 15:1352458520964409. doi: 10.1177/1352458520964409.
    PubMed     Abstract available


  138. MARRIE RA, Walld R, Bolton JM, Sareen J, et al
    Effect of mood and anxiety disorders on health care utilization in multiple sclerosis.
    Mult Scler. 2020 Oct 13:1352458520963880. doi: 10.1177/1352458520963880.
    PubMed     Abstract available


  139. CASTELLI L, Quartuccio ME, Ruggieri S, De Giglio L, et al
    'Posture second' strategy predicts disability progression in multiple sclerosis.
    Mult Scler. 2020 Oct 13:1352458520963926. doi: 10.1177/1352458520963926.
    PubMed     Abstract available


  140. VEREB D, Toth E, Bozsik B, Kiraly A, et al
    Altered brain network function during attention-modulated visual processing in multiple sclerosis.
    Mult Scler. 2020 Oct 5:1352458520958360. doi: 10.1177/1352458520958360.
    PubMed     Abstract available


  141. LANGER-GOULD A, Black LJ, Waubant E, Smith JB, et al
    Seafood, fatty acid biosynthesis genes, and multiple sclerosis susceptibility.
    Mult Scler. 2020;26:1476-1485.
    PubMed     Abstract available


  142. CHEN J, Taylor B, Winzenberg T, Palmer AJ, et al
    Comorbidities are prevalent and detrimental for employment outcomes in people of working age with multiple sclerosis.
    Mult Scler. 2020;26:1550-1559.
    PubMed     Abstract available


  143. HULST HE, Penner IK
    Cognition and its relation to brain health in patients with MS.
    Mult Scler. 2020;26:1611-1613.
    PubMed    


  144. HOBART J, Giovannoni G
    Cognition and its relation to brain health in patients with MS: Response to letter.
    Mult Scler. 2020;26:1613-1614.
    PubMed    


  145. AZEVEDO CJ, Zamvil SS
    New cases of vasculitis after alemtuzumab.
    Mult Scler. 2020;26:1606-1608.
    PubMed    


    September 2020
  146. PISA M, Chieffo R, Congiu M, Dalla Costa G, et al
    Intracortical motor conduction is associated with hand dexterity in progressive multiple sclerosis.
    Mult Scler. 2020 Sep 25:1352458520960374. doi: 10.1177/1352458520960374.
    PubMed     Abstract available


  147. FERRE L, Mogavero A, Clarelli F, Moiola L, et al
    Early evidence of disease activity during fingolimod predicts medium-term inefficacy in relapsing-remitting multiple sclerosis.
    Mult Scler. 2020 Sep 25:1352458520961690. doi: 10.1177/1352458520961690.
    PubMed     Abstract available


  148. BOESEN MS, Blinkenberg M, Thygesen LC, Eriksson F, et al
    School performance, psychiatric comorbidity, and healthcare utilization in pediatric multiple sclerosis: A nationwide population-based observational study.
    Mult Scler. 2020 Sep 25:1352458520959673. doi: 10.1177/1352458520959673.
    PubMed     Abstract available


  149. CALVI A, Haider L, Prados F, Tur C, et al
    In vivo imaging of chronic active lesions in multiple sclerosis.
    Mult Scler. 2020 Sep 23:1352458520958589. doi: 10.1177/1352458520958589.
    PubMed     Abstract available


  150. RIVA A, Barcella V, Benatti SV, Capobianco M, et al
    Vaccinations in patients with multiple sclerosis: A Delphi consensus statement.
    Mult Scler. 2020 Sep 17:1352458520952310. doi: 10.1177/1352458520952310.
    PubMed     Abstract available


  151. MOIOLA L, Barcella V, Benatti S, Capobianco M, et al
    The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement.
    Mult Scler. 2020 Sep 17:1352458520952311. doi: 10.1177/1352458520952311.
    PubMed     Abstract available


  152. FEYS P, Swinnen E
    Powered exoskeletons for walking in multiple sclerosis.
    Mult Scler. 2020 Sep 15:1352458520958351. doi: 10.1177/1352458520958351.
    PubMed    


  153. WEE SK, Ho CY, Tan SL, Ong CH, et al
    Enhancing quality of life in progressive multiple sclerosis with powered robotic exoskeleton.
    Mult Scler. 2020 Sep 15:1352458520943080. doi: 10.1177/1352458520943080.
    PubMed     Abstract available


  154. CORDANI C, Hidalgo de la Cruz M, Meani A, Valsasina P, et al
    MRI correlates of clinical disability and hand-motor performance in multiple sclerosis phenotypes.
    Mult Scler. 2020 Sep 14:1352458520958356. doi: 10.1177/1352458520958356.
    PubMed     Abstract available


  155. ZHANG Y, Taylor BV, Simpson S Jr, Blizzard L, et al
    Feelings of depression, pain and walking difficulties have the largest impact on the quality of life of people with multiple sclerosis, irrespective of clinical phenotype.
    Mult Scler. 2020 Sep 14:1352458520958369. doi: 10.1177/1352458520958369.
    PubMed     Abstract available


  156. BRIGGS FB
    Nicotinic acetylcholine receptors alpha7 and alpha9 modifies tobacco smoke risk for multiple sclerosis.
    Mult Scler. 2020 Sep 14:1352458520958361. doi: 10.1177/1352458520958361.
    PubMed     Abstract available


  157. MARTINO M, Magioncalda P, El Mendili MM, Droby A, et al
    Depression is associated with disconnection of neurotransmitter-related nuclei in multiple sclerosis.
    Mult Scler. 2020 Sep 10:1352458520948214. doi: 10.1177/1352458520948214.
    PubMed     Abstract available


  158. CHEN J, Taylor B, Blizzard L, Simpson-Yap S, et al
    Risk factors for leaving employment due to multiple sclerosis and changes in risk over the past decades: Using competing risk survival analysis.
    Mult Scler. 2020 Sep 3:1352458520954167. doi: 10.1177/1352458520954167.
    PubMed     Abstract available


  159. YILMAZER C, Lamers I, Solaro C, Feys P, et al
    Clinical perspective on pain in multiple sclerosis.
    Mult Scler. 2020 Sep 3:1352458520952015. doi: 10.1177/1352458520952015.
    PubMed     Abstract available


  160. HAWTON A, Goodwin E, Boddy K, Freeman J, et al
    Measuring the cost-effectiveness of treatments for people with multiple sclerosis: Beyond quality-adjusted life-years.
    Mult Scler. 2020 Sep 3:1352458520954172. doi: 10.1177/1352458520954172.
    PubMed     Abstract available


  161. JOISTEN N, Proschinger S, Rademacher A, Schenk A, et al
    High-intensity interval training reduces neutrophil-to-lymphocyte ratio in persons with multiple sclerosis during inpatient rehabilitation.
    Mult Scler. 2020 Sep 3:1352458520951382. doi: 10.1177/1352458520951382.
    PubMed     Abstract available


  162. CICCARELLI O, Cohen JA, Thompson A
    Response of the multiple sclerosis community to COVID-19.
    Mult Scler. 2020;26:1134-1136.
    PubMed    


  163. YAM C, Jokubaitis V, Hellwig K, Dobson R, et al
    MS, pregnancy and COVID-19.
    Mult Scler. 2020;26:1137-1146.
    PubMed     Abstract available


  164. MECA-LALLANA V
    COVID-19 will change MS care forever - Yes.
    Mult Scler. 2020;26:1147-1148.
    PubMed    


  165. PREZIOSA P, Rocca MA, Filippi M
    COVID-19 will change MS care forever - No.
    Mult Scler. 2020;26:1149-1151.
    PubMed    


    August 2020
  166. MIDAGLIA L, Otero S, Baro F, Montalban X, et al
    Menopause and multiple sclerosis: Influence on prognosis and role of disease-modifying drugs and hormonal replacement therapy.
    Mult Scler. 2020 Aug 28:1352458520952022. doi: 10.1177/1352458520952022.
    PubMed     Abstract available


  167. DISANTO G, Ripellino P, Riccitelli GC, Sacco R, et al
    De-escalating rituximab dose results in stability of clinical, radiological, and serum neurofilament levels in multiple sclerosis.
    Mult Scler. 2020 Aug 25:1352458520952036. doi: 10.1177/1352458520952036.
    PubMed     Abstract available


  168. BOFFA G, Sbragia E, Raiola AM, Varaldo R, et al
    Autologous hematopoietic stem cell transplantation following alemtuzumab therapy in aggressive multiple sclerosis: A report of three cases.
    Mult Scler. 2020 Aug 25:1352458520914818. doi: 10.1177/1352458520914818.
    PubMed     Abstract available


  169. SMITH AD, Prokopiusova T, Jones R, Burge T, et al
    Functional electrical stimulation for foot drop in people with multiple sclerosis: The relevance and importance of addressing quality of movement.
    Mult Scler. 2020 Aug 24:1352458520923958. doi: 10.1177/1352458520923958.
    PubMed     Abstract available


  170. SADIGH G, Lava N, Switchenko J, Duszak R Jr, et al
    Patient-reported financial toxicity in multiple sclerosis: Predictors and association with care non-adherence.
    Mult Scler. 2020 Aug 18:1352458520913977. doi: 10.1177/1352458520913977.
    PubMed     Abstract available


  171. JORDAN AL, Yang J, Fisher CJ, Racke MK, et al
    Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients.
    Mult Scler. 2020 Aug 18:1352458520949158. doi: 10.1177/1352458520949158.
    PubMed     Abstract available


  172. SEYMAN E, Jones A, Guenette M, Vosoughi R, et al
    Clinical and MRI characteristics of multiple sclerosis in patients of Middle Eastern and North African ancestry residing in Ontario, Canada.
    Mult Scler. 2020 Aug 11:1352458520948212. doi: 10.1177/1352458520948212.
    PubMed     Abstract available


  173. MOSS BP, Mahajan KR, Bermel RA, Hellisz K, et al
    Multiple sclerosis management during the COVID-19 pandemic.
    Mult Scler. 2020 Aug 10:1352458520948231. doi: 10.1177/1352458520948231.
    PubMed     Abstract available


  174. BROWNLEE WJ
    COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual?
    Mult Scler. 2020 Aug 7:1352458520948211. doi: 10.1177/1352458520948211.
    PubMed    


  175. WURM H, Attfield K, Iversen AK, Gold R, et al
    Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient.
    Mult Scler. 2020 Aug 7:1352458520943791. doi: 10.1177/1352458520943791.
    PubMed     Abstract available


  176. DERSCH R, Wehrum T, Fahndrich S, Engelhardt M, et al
    COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment.
    Mult Scler. 2020 Aug 7:1352458520943783. doi: 10.1177/1352458520943783.
    PubMed     Abstract available


  177. JAWORSKI MG 3RD, Fuchs TA, Dwyer MG, Wojcik C, et al
    Conscientiousness and deterioration in employment status in multiple sclerosis over 3 years.
    Mult Scler. 2020 Aug 6:1352458520946019. doi: 10.1177/1352458520946019.
    PubMed     Abstract available


  178. GERALDES R, Jurynczyk M, Dos Passos GR, Pichler A, et al
    The role of pontine lesion location in differentiating multiple sclerosis from vascular risk factor-related small vessel disease.
    Mult Scler. 2020 Aug 6:1352458520943777. doi: 10.1177/1352458520943777.
    PubMed     Abstract available


  179. GUISSET F, Lolli V, Bugli C, Perrotta G, et al
    The central vein sign in multiple sclerosis patients with vascular comorbidities.
    Mult Scler. 2020 Aug 4:1352458520943785. doi: 10.1177/1352458520943785.
    PubMed     Abstract available


  180. ALEXANDER S, Peryer G, Gray E, Barkhof F, et al
    Wearable technologies to measure clinical outcomes in multiple sclerosis: A scoping review.
    Mult Scler. 2020 Aug 4:1352458520946005. doi: 10.1177/1352458520946005.
    PubMed     Abstract available


  181. LIPP I, Foster C, Stickland R, Sgarlata E, et al
    Predictors of training-related improvement in visuomotor performance in patients with multiple sclerosis: A behavioural and MRI study.
    Mult Scler. 2020 Aug 4:1352458520943788. doi: 10.1177/1352458520943788.
    PubMed     Abstract available


  182. ABBOUD H
    Iatrogenic demyelinating disorders: New insights, new culprits.
    Mult Scler. 2020;26:1129-1130.
    PubMed    


    July 2020
  183. RINGH MV, Hagemann-Jensen M, Needhamsen M, Kullberg S, et al
    Methylome and transcriptome signature of bronchoalveolar cells from multiple sclerosis patients in relation to smoking.
    Mult Scler. 2020 Jul 30:1352458520943768. doi: 10.1177/1352458520943768.
    PubMed     Abstract available



  184. CORRIGENDUM to "Effectiveness of the transcutaneous tibial nerve stimulation and pelvic floor muscle training with biofeedback in women with multiple sclerosis for the management of overactive bladder".
    Mult Scler. 2020 Jul 24:1352458520945512. doi: 10.1177/1352458520945512.
    PubMed    


  185. SIMPSON-YAP S, Oddy WH, Taylor B, Lucas RM, et al
    High Prudent diet factor score predicts lower relapse hazard in early multiple sclerosis.
    Mult Scler. 2020 Jul 23:1352458520943087. doi: 10.1177/1352458520943087.
    PubMed     Abstract available


  186. INOJOSA H, Ziemssen T
    How to reduce the delay of diagnosing secondary progression in multiple sclerosis.
    Mult Scler. 2020 Jul 22:1352458520943799. doi: 10.1177/1352458520943799.
    PubMed    


  187. CONWAY DS, Thompson NR, Meng X, Johnson K, et al
    Patient reported outcomes and performance metrics at diagnosis of secondary progressive multiple sclerosis.
    Mult Scler. 2020 Jul 16:1352458520936214. doi: 10.1177/1352458520936214.
    PubMed     Abstract available


  188. HUBBARD AL, Golla H, Lausberg H
    What's in a name? That which we call Multiple Sclerosis Fatigue.
    Mult Scler. 2020 Jul 16:1352458520941481. doi: 10.1177/1352458520941481.
    PubMed     Abstract available


  189. PEETERS LM, Parciak T, Walton C, Geys L, et al
    COVID-19 in people with multiple sclerosis: A global data sharing initiative.
    Mult Scler. 2020 Jul 14:1352458520941485. doi: 10.1177/1352458520941485.
    PubMed     Abstract available


  190. HIDALGO DE LA CRUZ M, Valsasina P, Gobbi C, Gallo A, et al
    Longitudinal cortical thinning progression differs across multiple sclerosis phenotypes and is clinically relevant: A multicentre study.
    Mult Scler. 2020 Jul 14:1352458520940548. doi: 10.1177/1352458520940548.
    PubMed     Abstract available


  191. BARCELLOS LF, Horton M, Shao X, Bellesis KH, et al
    A validation study for remote testing of cognitive function in multiple sclerosis.
    Mult Scler. 2020 Jul 14:1352458520937385. doi: 10.1177/1352458520937385.
    PubMed     Abstract available


  192. LOONSTRA FC, Hoitsma E, van Kempen ZL, Killestein J, et al
    COVID-19 in multiple sclerosis: The Dutch experience.
    Mult Scler. 2020 Jul 14:1352458520942198. doi: 10.1177/1352458520942198.
    PubMed     Abstract available


  193. STORELLI L, Pagani E, Preziosa P, Filippi M, et al
    Measurement of white matter fiber-bundle cross-section in multiple sclerosis using diffusion-weighted imaging.
    Mult Scler. 2020 Jul 14:1352458520938999. doi: 10.1177/1352458520938999.
    PubMed     Abstract available


  194. ABBATEMARCO JR, Griffin A, Jones NG, Hartman J, et al
    Long-term outcomes of intrathecal baclofen in ambulatory multiple sclerosis patients: A single-center experience.
    Mult Scler. 2020 Jul 14:1352458520936912. doi: 10.1177/1352458520936912.
    PubMed     Abstract available


  195. WU P, Li R, Zhang W, Lu H, et al
    Mendelian randomization analysis does not support a role for leptin in multiple sclerosis.
    Mult Scler. 2020 Jul 14:1352458520938990. doi: 10.1177/1352458520938990.
    PubMed    


  196. PINTER D, Khalil M, Pirpamer L, Damulina A, et al
    Long-term course and morphological MRI correlates of cognitive function in multiple sclerosis.
    Mult Scler. 2020 Jul 14:1352458520941474. doi: 10.1177/1352458520941474.
    PubMed     Abstract available


  197. CROTEAU D, Tobenkin A, Brinker A, Kortepeter CM, et al
    Tumefactive multiple sclerosis in association with fingolimod initiation and discontinuation.
    Mult Scler. 2020 Jul 14:1352458520938354. doi: 10.1177/1352458520938354.
    PubMed     Abstract available


  198. GERALDES R
    Two-armed active comparator trials are unethical in pediatric multiple sclerosis - No.
    Mult Scler. 2020 Jul 10:1352458520931784. doi: 10.1177/1352458520931784.
    PubMed    


  199. WAUBANT E
    Two-armed active comparator trials are unethical in paediatric multiple sclerosis - Commentary.
    Mult Scler. 2020 Jul 10:1352458520936243. doi: 10.1177/1352458520936243.
    PubMed    


  200. KRUPP LB, Charvet LE
    Two-armed active comparator trials are unethical in pediatric multiple sclerosis - Yes.
    Mult Scler. 2020 Jul 10:1352458520931796. doi: 10.1177/1352458520931796.
    PubMed    


  201. CHITNIS T, Banwell B, Krupp L, Arnold DL, et al
    Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIGMS study.
    Mult Scler. 2020 Jul 7:1352458520936934. doi: 10.1177/1352458520936934.
    PubMed     Abstract available


  202. FITZGERALD KC, Morris B, Soroosh A, Balshi A, et al
    Pilot randomized active-placebo-controlled trial of low-dose ketamine for the treatment of multiple sclerosis-related fatigue.
    Mult Scler. 2020 Jul 7:1352458520936226. doi: 10.1177/1352458520936226.
    PubMed     Abstract available


  203. HACOHEN Y, Banwell B, Ciccarelli O
    What does first-line therapy mean for paediatric multiple sclerosis in the current era?
    Mult Scler. 2020 Jul 7:1352458520937644. doi: 10.1177/1352458520937644.
    PubMed     Abstract available


  204. BSTEH G, Berek K, Hegen H, Altmann P, et al
    Macular ganglion cell-inner plexiform layer thinning as a biomarker of disability progression in relapsing multiple sclerosis.
    Mult Scler. 2020 Jul 2:1352458520935724. doi: 10.1177/1352458520935724.
    PubMed     Abstract available


  205. THRUE C, Riemenschneider M, Hvid LG, Stenager E, et al
    Time matters: Early-phase multiple sclerosis is accompanied by considerable impairments across multiple domains.
    Mult Scler. 2020 Jul 2:1352458520936231. doi: 10.1177/1352458520936231.
    PubMed     Abstract available


    June 2020
  206. FEINSTEIN A, Meza C, Stefan C, Staines WR, et al
    Discontinuing cannabis improves depression in people with multiple sclerosis: A short report.
    Mult Scler. 2020 Jun 26:1352458520934070. doi: 10.1177/1352458520934070.
    PubMed     Abstract available


  207. SIGNORI A, Boffa G, Bovis F, Mariottini A, et al
    Prevalence of disability improvement as a potential outcome for multiple sclerosis trials.
    Mult Scler. 2020 Jun 26:1352458520936236. doi: 10.1177/1352458520936236.
    PubMed     Abstract available



  208. Household paired design reduces variance and increases power in multi-city gut microbiome study in multiple sclerosis.
    Mult Scler. 2020 Jun 26:1352458520924594. doi: 10.1177/1352458520924594.
    PubMed     Abstract available


  209. MEHNDIRATTA A, Treaba CA, Barletta V, Herranz E, et al
    Characterization of thalamic lesions and their correlates in multiple sclerosis by ultra-high-field MRI.
    Mult Scler. 2020 Jun 25:1352458520932804. doi: 10.1177/1352458520932804.
    PubMed     Abstract available


  210. BOVE R, Rowles W, Zhao C, Anderson A, et al
    A novel in-home digital treatment to improve processing speed in people with multiple sclerosis: A pilot study.
    Mult Scler. 2020 Jun 25:1352458520930371. doi: 10.1177/1352458520930371.
    PubMed     Abstract available


  211. WIENDL H, Spelman T, Butzkueven H, Kappos L, et al
    Real-world disability improvement in patients with relapsing-remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program.
    Mult Scler. 2020 Jun 24:1352458520926869. doi: 10.1177/1352458520926869.
    PubMed     Abstract available


  212. GLUKHOVSKY L, Brandstadter R, Leavitt VM, Krieger S, et al
    Hippocampal volume is more related to patient-reported memory than objective memory performance in early multiple sclerosis.
    Mult Scler. 2020 Jun 22:1352458520922830. doi: 10.1177/1352458520922830.
    PubMed     Abstract available


  213. SASTRE-GARRIGA J, Tintore M, Montalban X
    Keeping standards of multiple sclerosis care through the COVID-19 pandemic.
    Mult Scler. 2020 Jun 19:1352458520931785. doi: 10.1177/1352458520931785.
    PubMed    


  214. LEVIN SN, Ezuma C, Levine L, Vargas WS, et al
    Switching from natalizumab to ocrelizumab in patients with multiple sclerosis.
    Mult Scler. 2020 Jun 19:1352458520927631. doi: 10.1177/1352458520927631.
    PubMed    


  215. GHEZZI A, Banwell B, Bar-Or A, Chitnis T, et al
    Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: Practical considerations.
    Mult Scler. 2020 Jun 19:1352458520932798. doi: 10.1177/1352458520932798.
    PubMed     Abstract available


  216. BHARGAVA P, Nogueras-Ortiz C, Kim S, Delgado-Peraza F, et al
    Synaptic and complement markers in extracellular vesicles in multiple sclerosis.
    Mult Scler. 2020 Jun 17:1352458520924590. doi: 10.1177/1352458520924590.
    PubMed     Abstract available


  217. RICIGLIANO VA, Tonietto M, Palladino R, Poirion E, et al
    Thalamic energy dysfunction is associated with thalamo-cortical tract damage in multiple sclerosis: A diffusion spectroscopy study.
    Mult Scler. 2020 Jun 17:1352458520921362. doi: 10.1177/1352458520921362.
    PubMed     Abstract available


  218. YAVARPOUR-BALI H, Ghasemi-Kasman M
    The role of inflammasomes in multiple sclerosis.
    Mult Scler. 2020 Jun 16:1352458520932776. doi: 10.1177/1352458520932776.
    PubMed     Abstract available


  219. GHEZZI A, Amato MP, Edan G, Hartung HP, et al
    The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges.
    Mult Scler. 2020 Jun 16:1352458520930620. doi: 10.1177/1352458520930620.
    PubMed     Abstract available


  220. LE M, Malpas C, Sharmin S, Horakova D, et al
    Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis.
    Mult Scler. 2020 Jun 15:1352458520926955. doi: 10.1177/1352458520926955.
    PubMed     Abstract available


  221. IACOBAEUS E, Arrambide G, Pia Amato M, Derfuss T, et al
    Aggressive multiple sclerosis (1): Towards a definition of the phenotype.
    Mult Scler. 2020 Jun 12:1352458520925369. doi: 10.1177/1352458520925369.
    PubMed     Abstract available


  222. ARRAMBIDE G, Iacobaeus E, Amato MP, Derfuss T, et al
    Aggressive multiple sclerosis (2): Treatment.
    Mult Scler. 2020 Jun 12:1352458520924595. doi: 10.1177/1352458520924595.
    PubMed     Abstract available


  223. LIZAK N, Hodgkinson S, Butler E, Lechner-Scott J, et al
    Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy.
    Mult Scler. 2020 Jun 12:1352458520921087. doi: 10.1177/1352458520921087.
    PubMed     Abstract available


  224. POLAT DUNYA C, Tulek Z, Kurtuncu M, Panicker JN, et al
    Effectiveness of the transcutaneous tibial nerve stimulation and pelvic floor muscle training with biofeedback in women with multiple sclerosis for the management of overactive bladder.
    Mult Scler. 2020 Jun 9:1352458520926666. doi: 10.1177/1352458520926666.
    PubMed     Abstract available


  225. SOLARI A, Oliver D
    Palliative care in multiple sclerosis: European guideline.
    Mult Scler. 2020 Jun 9:1352458520926467. doi: 10.1177/1352458520926467.
    PubMed    


  226. XU Y, Hiyoshi A, Brand JS, Smith KA, et al
    Higher body mass index at ages 16 to 20 years is associated with increased risk of a multiple sclerosis diagnosis in subsequent adulthood among men.
    Mult Scler. 2020 Jun 8:1352458520928061. doi: 10.1177/1352458520928061.
    PubMed     Abstract available


  227. BROWN J, Quattrochi B, Everett C, Hong BY, et al
    Gut commensals, dysbiosis, and immune response imbalance in the pathogenesis of multiple sclerosis.
    Mult Scler. 2020 Jun 8:1352458520928301. doi: 10.1177/1352458520928301.
    PubMed     Abstract available


  228. CELIUS EG
    Breastfeeding and treatment of multiple sclerosis.
    Mult Scler. 2020 Jun 8:1352458520931786. doi: 10.1177/1352458520931786.
    PubMed    


  229. PIHL-JENSEN G, Wanscher B, Frederiksen JL
    Predictive value of optical coherence tomography, multifocal visual evoked potentials, and full-field visual evoked potentials of the fellow, non-symptomatic eye for subsequent multiple sclerosis development in patients with acute optic neuritis.
    Mult Scler. 2020 Jun 8:1352458520917924. doi: 10.1177/1352458520917924.
    PubMed     Abstract available


  230. ROJAS JI, Patrucco L, Alonso R, Garcea O, et al
    Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis: Multicenter study in Argentina.
    Mult Scler. 2020 Jun 2:1352458520924586. doi: 10.1177/1352458520924586.
    PubMed     Abstract available


  231. OH J, Chen M, Cybulsky K, Suthiphosuwan S, et al
    Five-year longitudinal changes in quantitative spinal cord MRI in multiple sclerosis.
    Mult Scler. 2020 Jun 1:1352458520923970. doi: 10.1177/1352458520923970.
    PubMed     Abstract available


  232. COSTELLO F, Petzold A
    Weighting evidence in MS: Obesity and neurodegeneration.
    Mult Scler. 2020;26:748-750.
    PubMed    


  233. BOYKO A
    Radiologically isolated syndrome with oligoclonal bands in CSF (RIS + OCB) can be classified as high MS risk group.
    Mult Scler. 2020;26:869-870.
    PubMed    


  234. DE STEFANO N
    Response to Dr Boyko's letter: 'Radiologically isolated syndrome with oligoclonal bands in CSF (RIS + OCB) can be classified as highly MS-risk group'.
    Mult Scler. 2020;26:871.
    PubMed    


  235. VAN DER WALT A
    Addressing the treatment gap in MS-associated tremor: A new door opens.
    Mult Scler. 2020;26:858.
    PubMed    


    May 2020
  236. VARGAS WS, Noble KG, Banwell B, De Jager P, et al
    The educational impact of childhood-onset multiple sclerosis: Why assessing academic achievement is imperative.
    Mult Scler. 2020 May 28:1352458520923946. doi: 10.1177/1352458520923946.
    PubMed     Abstract available


  237. VON WYL V, Benkert P, Moser A, Lorscheider J, et al
    Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate.
    Mult Scler. 2020 May 28:1352458520918489. doi: 10.1177/1352458520918489.
    PubMed     Abstract available


  238. CARANDINI T, Pietroboni AM, Sacchi L, De Riz MA, et al
    Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression.
    Mult Scler. 2020 May 28:1352458520926459. doi: 10.1177/1352458520926459.
    PubMed    


  239. PASQUA G, Tommasin S, Bharti K, Ruggieri S, et al
    Resting-state functional connectivity of anterior and posterior cerebellar lobes is altered in multiple sclerosis.
    Mult Scler. 2020 May 28:1352458520922770. doi: 10.1177/1352458520922770.
    PubMed     Abstract available


  240. AYRIGNAC X, Larochelle C, Keezer M, Roger E, et al
    Frailty in ageing persons with multiple sclerosis.
    Mult Scler. 2020 May 27:1352458520923945. doi: 10.1177/1352458520923945.
    PubMed     Abstract available


  241. CORONADO I, Gabr RE, Narayana PA
    Deep learning segmentation of gadolinium-enhancing lesions in multiple sclerosis.
    Mult Scler. 2020 May 22:1352458520921364. doi: 10.1177/1352458520921364.
    PubMed     Abstract available


  242. WANG FM, Davis MF, Briggs FB
    Predicting self-reported depression after the onset of multiple sclerosis using genetic and non-genetic factors.
    Mult Scler. 2020 May 18:1352458520921073. doi: 10.1177/1352458520921073.
    PubMed     Abstract available


  243. VALBURG C, Sonti A, Stern JN, Najjar S, et al
    Dietary factors in experimental autoimmune encephalomyelitis and multiple sclerosis: A comprehensive review.
    Mult Scler. 2020 May 14:1352458520923955. doi: 10.1177/1352458520923955.
    PubMed     Abstract available


  244. BRUIJSTENS AL, Blok KM, Smolders J, Wokke BH, et al
    Pediatric MS patients with a primary progressive-like disease may still have relevant inflammatory activity and may benefit from regular MS treatment.
    Mult Scler. 2020 May 14:1352458520921367. doi: 10.1177/1352458520921367.
    PubMed    


  245. KILJAN S, Preziosa P, Jonkman LE, van de Berg WD, et al
    Cortical axonal loss is associated with both gray matter demyelination and white matter tract pathology in progressive multiple sclerosis: Evidence from a combined MRI-histopathology study.
    Mult Scler. 2020 May 11:1352458520918978. doi: 10.1177/1352458520918978.
    PubMed     Abstract available


  246. GHARAKHANLOU R, Wesselmann L, Rademacher A, Lampit A, et al
    Exercise training and cognitive performance in persons with multiple sclerosis: A systematic review and multilevel meta-analysis of clinical trials.
    Mult Scler. 2020 May 11:1352458520917935. doi: 10.1177/1352458520917935.
    PubMed     Abstract available


  247. LUNEMANN JD, Diaz-Diaz J, Stankoff B, Young C, et al
    Highlights from the 2019 European Congress on Treatment and Research in Multiple Sclerosis (ECTRIMS 2019).
    Mult Scler. 2020 May 4:1352458520918377. doi: 10.1177/1352458520918377.
    PubMed     Abstract available


  248. BOSE G, Thebault S, Rush CA, Atkins HL, et al
    Autologous hematopoietic stem cell transplantation for multiple sclerosis: A current perspective.
    Mult Scler. 2020 May 4:1352458520917936. doi: 10.1177/1352458520917936.
    PubMed     Abstract available


  249. LAMBE J, Saidha S, Bermel RA
    Optical coherence tomography and multiple sclerosis: Update on clinical application and role in clinical trials.
    Mult Scler. 2020;26:624-639.
    PubMed     Abstract available


  250. HARTUNG HP, Mares J, Barnett MH
    Alemtuzumab: Rare serious adverse events of a high-efficacy drug.
    Mult Scler. 2020;26:737-740.
    PubMed    


  251. KRIEGER SC, Sumowski JF
    Toward biologically meaningful categories of MS-related fatigue.
    Mult Scler. 2020;26:620-621.
    PubMed    


  252. PROSCHMANN U, Sehr T, Akgun K, Ziemssen T, et al
    Letter to the editor regarding "Therapeutic drug monitoring of natalizumab".
    Mult Scler. 2020;26:741-742.
    PubMed    


    April 2020
  253. FOX E, Lovett-Racke AE, Gormley M, Liu Y, et al
    A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis.
    Mult Scler. 2020 Apr 30:1352458520918375. doi: 10.1177/1352458520918375.
    PubMed     Abstract available


  254. KALB R, Brown TR, Coote S, Costello K, et al
    Exercise and lifestyle physical activity recommendations for people with multiple sclerosis throughout the disease course.
    Mult Scler. 2020 Apr 23:1352458520915629. doi: 10.1177/1352458520915629.
    PubMed     Abstract available


  255. AHRABIAN D, Neill L, Bell R, Leary SM, et al
    Acute cardiotoxicity associated with alemtuzumab infusion for multiple sclerosis.
    Mult Scler. 2020 Apr 16:1352458519855725. doi: 10.1177/1352458519855725.
    PubMed     Abstract available


  256. FILIPPATOU AG, Lambe J, Sotirchos ES, Fitzgerald KC, et al
    Association of body mass index with longitudinal rates of retinal atrophy in multiple sclerosis.
    Mult Scler. 2020 Apr 16:1352458519900942. doi: 10.1177/1352458519900942.
    PubMed     Abstract available


  257. UHER T, McComb M, Galkin S, Srpova B, et al
    Neurofilament levels are associated with blood-brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis.
    Mult Scler. 2020 Apr 7:1352458520912379. doi: 10.1177/1352458520912379.
    PubMed     Abstract available


  258. YUSUF F, Wijnands JM, Kingwell E, Zhu F, et al
    Fatigue, sleep disorders, anaemia and pain in the multiple sclerosis prodrome.
    Mult Scler. 2020 Apr 6:1352458520908163. doi: 10.1177/1352458520908163.
    PubMed     Abstract available


  259. BELBASIS L, Bellou V, Evangelou E, Tzoulaki I, et al
    Environmental factors and risk of multiple sclerosis: Findings from meta-analyses and Mendelian randomization studies.
    Mult Scler. 2020;26:397-404.
    PubMed     Abstract available


  260. SOLOMON AJ
    Progress towards a diagnostic biomarker for MS: Central vein sign.
    Mult Scler. 2020;26:394-396.
    PubMed    


    March 2020
  261. HEALY BC, Barker L, Bakshi R, Benedict RHB, et al
    Trajectories of Symbol Digit Modalities Test performance in individuals with multiple sclerosis.
    Mult Scler. 2020 Mar 31:1352458520913439. doi: 10.1177/1352458520913439.
    PubMed     Abstract available


  262. TREMLETT H, Marrie RA
    The multiple sclerosis prodrome: Emerging evidence, challenges, and opportunities.
    Mult Scler. 2020 Mar 31:1352458520914844. doi: 10.1177/1352458520914844.
    PubMed     Abstract available


  263. MOTL RW, Sandroff BM, Benedict RH, Hubbard EM, et al
    Do subcortical gray matter volumes and aerobic capacity account for cognitive-motor coupling in multiple sclerosis?
    Mult Scler. 2020 Mar 31:1352458520914822. doi: 10.1177/1352458520914822.
    PubMed     Abstract available


  264. DEMORTIERE S, Rico A, Maarouf A, Boutiere C, et al
    Maintenance of natalizumab during the first trimester of pregnancy in active multiple sclerosis.
    Mult Scler. 2020 Mar 23:1352458520912637. doi: 10.1177/1352458520912637.
    PubMed     Abstract available


  265. JACOBS BM, Giovannoni G, Cuzick J, Dobson R, et al
    Systematic review and meta-analysis of the association between Epstein-Barr virus, multiple sclerosis and other risk factors.
    Mult Scler. 2020 Mar 23:1352458520907901. doi: 10.1177/1352458520907901.
    PubMed     Abstract available


  266. DADAR M, Narayanan S, Arnold DL, Collins DL, et al
    Conversion of diffusely abnormal white matter to focal lesions is linked to progression in secondary progressive multiple sclerosis.
    Mult Scler. 2020 Mar 23:1352458520912172. doi: 10.1177/1352458520912172.
    PubMed     Abstract available


  267. OTURAI DB, Bach Sondergaard H, Koch-Henriksen N, Andersen C, et al
    Exposure to passive smoking during adolescence is associated with an increased risk of developing multiple sclerosis.
    Mult Scler. 2020 Mar 23:1352458520912500. doi: 10.1177/1352458520912500.
    PubMed     Abstract available


  268. PEREZ T, Rico A, Boutiere C, Maarouf A, et al
    Comparison of rituximab originator (MabThera((R))) to biosimilar (Truxima((R))) in patients with multiple sclerosis.
    Mult Scler. 2020 Mar 17:1352458520912170. doi: 10.1177/1352458520912170.
    PubMed     Abstract available


  269. SOLOMON AJ, Pettigrew R, Naismith RT, Chahin S, et al
    Challenges in multiple sclerosis diagnosis: Misunderstanding and misapplication of the McDonald criteria.
    Mult Scler. 2020 Mar 12:1352458520910496. doi: 10.1177/1352458520910496.
    PubMed     Abstract available


  270. BERTOLI M, Tecchio F
    Fatigue in multiple sclerosis: Does the functional or structural damage prevail?
    Mult Scler. 2020 Mar 12:1352458520912175. doi: 10.1177/1352458520912175.
    PubMed     Abstract available


  271. DALGAS U, Hvid LG, Kwakkel G, Motl RW, et al
    Moving exercise research in multiple sclerosis forward (the MoXFo initiative): Developing consensus statements for research.
    Mult Scler. 2020 Mar 12:1352458520910360. doi: 10.1177/1352458520910360.
    PubMed     Abstract available


  272. NG HS, Kingwell E, Zhu F, Zhang T, et al
    Adherence to laboratory monitoring among people taking oral drugs for multiple sclerosis: A Canadian population-based study.
    Mult Scler. 2020 Mar 6:1352458520910500. doi: 10.1177/1352458520910500.
    PubMed     Abstract available


  273. ABDEL-MANNAN O, Cortese R, Wassmer E, Hemingway C, et al
    Primary progressive multiple sclerosis presenting under the age of 18 years: Fact or fiction?
    Mult Scler. 2020 Mar 3:1352458520910361. doi: 10.1177/1352458520910361.
    PubMed     Abstract available


  274. LEITE MI, Sato DK
    MOG-antibody-associated disease is different from MS and NMOSD and should be considered as a distinct disease entity - Yes.
    Mult Scler. 2020;26:272-274.
    PubMed    


  275. COBO-CALVO A, Marignier R
    MOG-antibody-associated disease is different from MS and NMO and should be considered as a distinct disease entity - No.
    Mult Scler. 2020;26:274-276.
    PubMed    


  276. DURAND-DUBIEF F, Marignier R, Berthezene Y, Cottin J, et al
    Spontaneous multiple cervical artery dissections after alemtuzumab.
    Mult Scler. 2020;26:381-383.
    PubMed     Abstract available


  277. CHIARAVALLOTI ND, Moore NB, DeLuca J
    The efficacy of the modified Story Memory Technique in progressive MS.
    Mult Scler. 2020;26:354-362.
    PubMed     Abstract available


    February 2020
  278. POVOLO CA, Reid JN, Shariff SZ, Welk B, et al
    Concussion in adolescence and the risk of multiple sclerosis: A retrospective cohort study.
    Mult Scler. 2020 Feb 24:1352458520908037. doi: 10.1177/1352458520908037.
    PubMed     Abstract available


  279. FONDERICO M, Biagioli T, Lanzilao L, Bellinvia A, et al
    Prognostic role of intrathecal IgM synthesis in multiple sclerosis: Results from a clinical series.
    Mult Scler. 2020 Feb 24:1352458520907913. doi: 10.1177/1352458520907913.
    PubMed     Abstract available


  280. HORISBERGER A, Pantazou V, Cuendet G, Ribi C, et al
    ANCA-associated life-threatening systemic vasculitis after alemtuzumab treatment for multiple sclerosis.
    Mult Scler. 2020 Feb 21:1352458519895449. doi: 10.1177/1352458519895449.
    PubMed     Abstract available


  281. BIGAUT K, Lambert C, Kremer L, Lebrun C, et al
    Atypical myelitis in patients with multiple sclerosis: Characterization and comparison with typical multiple sclerosis and neuromyelitis optica spectrum disorders.
    Mult Scler. 2020 Feb 20:1352458520906995. doi: 10.1177/1352458520906995.
    PubMed     Abstract available


  282. MAHLANZA TD, Manieri MC, Klawiter EC, Solomon AJ, et al
    Prospective growth and developmental outcomes in infants born to mothers with multiple sclerosis.
    Mult Scler. 2020 Feb 17:1352458520904545. doi: 10.1177/1352458520904545.
    PubMed     Abstract available


  283. SERRA A, Petzold A
    Can stability of visual fixation be a measure for disability in multiple sclerosis?
    Mult Scler. 2020 Feb 7:1352458520903296. doi: 10.1177/1352458520903296.
    PubMed    


  284. SHEEHY CK, Bensinger ES, Romeo A, Rani L, et al
    Fixational microsaccades: A quantitative and objective measure of disability in multiple sclerosis.
    Mult Scler. 2020 Feb 7:1352458519894712. doi: 10.1177/1352458519894712.
    PubMed     Abstract available


  285. BSTEH G, Berger T
    Commentary on "Lymphocytic colitis in the setting of teriflunomide use for relapsing multiple sclerosis".
    Mult Scler. 2020 Feb 7:1352458520904546. doi: 10.1177/1352458520904546.
    PubMed    


  286. SON M, McEwan L, Ubaidat M, Bovell K, et al
    Lymphocytic colitis in the setting of teriflunomide use for relapsing multiple sclerosis.
    Mult Scler. 2020 Feb 7:1352458519900961. doi: 10.1177/1352458519900961.
    PubMed     Abstract available


  287. BISTROM M, Hultdin J, Andersen O, Alonso-Magdalena L, et al
    Leptin levels are associated with multiple sclerosis risk.
    Mult Scler. 2020 Feb 7:1352458520905033. doi: 10.1177/1352458520905033.
    PubMed     Abstract available


  288. BOUVET L, Chassard D
    Is neuraxial anesthesia not associated with increased risk of post-partum relapses in multiple sclerosis? More precise assessment is required.
    Mult Scler. 2020 Feb 5:1352458519898344. doi: 10.1177/1352458519898344.
    PubMed    


  289. MARIOTTINI A, Filippini S, Innocenti C, Forci B, et al
    Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis.
    Mult Scler. 2020 Feb 3:1352458520902392. doi: 10.1177/1352458520902392.
    PubMed     Abstract available


  290. ABSINTA M, Ontaneda D
    Controversial association between leptomeningeal enhancement and demyelinated cortical lesions in multiple sclerosis.
    Mult Scler. 2020;26:135-136.
    PubMed    


  291. THOMPSON AJ, Cohen JA, Kim HJ, Geurts J, et al
    MSJ 2020 - Editorial comment.
    Mult Scler. 2020;26:134.
    PubMed    


  292. LUBLIN F
    Real-world studies provide reliable comparisons of disease modifying therapies in MS - Commentary.
    Mult Scler. 2020;26:163-164.
    PubMed    


  293. SORMANI MP
    Real-world studies provide reliable comparisons of disease modifying therapies in MS - No.
    Mult Scler. 2020;26:161-162.
    PubMed    


  294. KALINCIK T
    Real-world studies provide reliable comparisons of disease modifying therapies in MS - Yes.
    Mult Scler. 2020;26:159-161.
    PubMed    


    January 2020
  295. CHARABATI M, Donkers SJ, Kirkland MC, Osborne LC, et al
    A critical analysis of helminth immunotherapy in multiple sclerosis.
    Mult Scler. 2020 Jan 23:1352458519899040. doi: 10.1177/1352458519899040.
    PubMed     Abstract available


  296. PALOTAI M, Cavallari M, Healy BC, Guttmann CR, et al
    A novel classification of fatigue in multiple sclerosis based on longitudinal assessments.
    Mult Scler. 2020 Jan 23:1352458519898112. doi: 10.1177/1352458519898112.
    PubMed     Abstract available


  297. BENEDICT RH, Pol J, Yasin F, Hojnacki D, et al
    Recovery of cognitive function after relapse in multiple sclerosis.
    Mult Scler. 2020 Jan 23:1352458519898108. doi: 10.1177/1352458519898108.
    PubMed     Abstract available


  298. CHITNIS T, Prat A
    A roadmap to precision medicine for multiple sclerosis.
    Mult Scler. 2020 Jan 22:1352458519881558. doi: 10.1177/1352458519881558.
    PubMed     Abstract available


  299. BOSE G, Freedman MS
    Precision medicine in the multiple sclerosis clinic: Selecting the right patient for the right treatment.
    Mult Scler. 2020 Jan 22:1352458519887324. doi: 10.1177/1352458519887324.
    PubMed     Abstract available


  300. MYCKO MP, Baranzini SE
    microRNA and exosome profiling in multiple sclerosis.
    Mult Scler. 2020 Jan 22:1352458519879303. doi: 10.1177/1352458519879303.
    PubMed     Abstract available


  301. VOSKUHL RR
    The effect of sex on multiple sclerosis risk and disease progression.
    Mult Scler. 2020 Jan 22:1352458519892491. doi: 10.1177/1352458519892491.
    PubMed     Abstract available


  302. PATSOPOULOS NA, De Jager PL
    Genetic and gene expression signatures in multiple sclerosis.
    Mult Scler. 2020 Jan 22:1352458519898332. doi: 10.1177/1352458519898332.
    PubMed     Abstract available


  303. BHARGAVA P, Anthony D
    Metabolomics in multiple sclerosis disease course and progression.
    Mult Scler. 2020 Jan 22:1352458519876020. doi: 10.1177/1352458519876020.
    PubMed     Abstract available


  304. KISTER I, Kantarci OH
    Multiple Sclerosis Severity Score: Concept and applications.
    Mult Scler. 2020 Jan 22:1352458519880125. doi: 10.1177/1352458519880125.
    PubMed     Abstract available


  305. CARNERO CONTENTTI E, Giachello S, Correale J
    Barriers to access and utilization of multiple sclerosis care services in a large cohort of Latin American patients.
    Mult Scler. 2020 Jan 21:1352458519898590. doi: 10.1177/1352458519898590.
    PubMed     Abstract available


  306. SRPOVA B, Uher T, Hrnciarova T, Barro C, et al
    Serum neurofilament light chain reflects inflammation-driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis.
    Mult Scler. 2020 Jan 21:1352458519901272. doi: 10.1177/1352458519901272.
    PubMed     Abstract available


  307. CORTESE R, Tur C, Prados F, Schneider T, et al
    Ongoing microstructural changes in the cervical cord underpin disability progression in early primary progressive multiple sclerosis.
    Mult Scler. 2020 Jan 21:1352458519900971. doi: 10.1177/1352458519900971.
    PubMed     Abstract available


  308. MCDONELL J, Costello K, Laurson-Doube J, Rijke N, et al
    World Health Organization Essential Medicines List: Multiple sclerosis disease-modifying therapies application.
    Mult Scler. 2020 Jan 16:1352458519898340. doi: 10.1177/1352458519898340.
    PubMed     Abstract available


  309. SALTER A, Fox RJ, Tyry T, Cutter G, et al
    New applications for independent activities of daily living in measuring disability in multiple sclerosis.
    Mult Scler. 2020 Jan 14:1352458519898591. doi: 10.1177/1352458519898591.
    PubMed     Abstract available


  310. WARNKE C, Hartung HP
    Big data in MS-What can we learn from large international observational studies such as MSBase?
    Mult Scler. 2020;26:4-5.
    PubMed    


  311. REDDEL SW
    Clinical commentary on 'Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis'.
    Mult Scler. 2020;26:126-127.
    PubMed    


  312. VUKUSIC S, Casey R, Rollot F, Brochet B, et al
    Observatoire Francais de la Sclerose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France.
    Mult Scler. 2020;26:118-122.
    PubMed     Abstract available


  313. MELI R, Roccatagliata L, Capello E, Bruschi N, et al
    Ecological impact of isolated cognitive relapses in MS.
    Mult Scler. 2020;26:114-117.
    PubMed     Abstract available


    December 2019
  314. CROUSE DL, Foroughi I, Gupta N
    Neighbourhood environments and the risk of hospital admission for cardiometabolic and mental health comorbidities in multiple sclerosis: A population cohort analysis using linked administrative data.
    Mult Scler. 2019 Dec 20:1352458519895985. doi: 10.1177/1352458519895985.
    PubMed     Abstract available


  315. COULOUME L, Barbin L, Leray E, Wiertlewski S, et al
    High-dose biotin in progressive multiple sclerosis: A prospective study of 178 patients in routine clinical practice.
    Mult Scler. 2019 Dec 17:1352458519894713. doi: 10.1177/1352458519894713.
    PubMed     Abstract available


  316. KALKERS NF, Galan I, Kerbrat A, Tacchino A, et al
    Differential item functioning of the Arm function in Multiple Sclerosis Questionnaire (AMSQ) by language, a study in six countries.
    Mult Scler. 2019 Dec 17:1352458519895450. doi: 10.1177/1352458519895450.
    PubMed     Abstract available


  317. KVISTAD SAS, Lehmann AK, Trovik LH, Kristoffersen EK, et al
    Safety and efficacy of autologous hematopoietic stem cell transplantation for multiple sclerosis in Norway.
    Mult Scler. 2019 Dec 13:1352458519893926. doi: 10.1177/1352458519893926.
    PubMed     Abstract available


  318. HOLTON KF, Kirkland AE
    Moving past antioxidant supplementation for the dietary treatment of multiple sclerosis.
    Mult Scler. 2019 Dec 11:1352458519893925. doi: 10.1177/1352458519893925.
    PubMed     Abstract available


  319. RAHNAMA'I MS
    Neuromodulation for functional bladder disorders in patients with multiple sclerosis.
    Mult Scler. 2019 Dec 9:1352458519894714. doi: 10.1177/1352458519894714.
    PubMed     Abstract available


  320. BISECCO A, Capuano R, Caiazzo G, d'Ambrosio A, et al
    Regional changes in thalamic shape and volume are related to cognitive performance in multiple sclerosis.
    Mult Scler. 2019 Dec 3:1352458519892552. doi: 10.1177/1352458519892552.
    PubMed     Abstract available


  321. HARDY TA
    Regulatory B cells: The key to post-alemtuzumab rebound phenomena in multiple sclerosis?
    Mult Scler. 2019;25:1945-1946.
    PubMed    


    November 2019
  322. GONZALEZ CAMPO C, Salamone PC, Rodriguez-Arriagada N, Richter F, et al
    Fatigue in multiple sclerosis is associated with multimodal interoceptive abnormalities.
    Mult Scler. 2019 Nov 28:1352458519888881. doi: 10.1177/1352458519888881.
    PubMed     Abstract available


  323. COHEN JA, Trojano M, Mowry EM, Uitdehaag BM, et al
    Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment.
    Mult Scler. 2019 Nov 28:1352458519892555. doi: 10.1177/1352458519892555.
    PubMed     Abstract available


  324. WALLACH AI, Waltz M, Casper TC, Aaen G, et al
    Cognitive processing speed in pediatric-onset multiple sclerosis: Baseline characteristics of impairment and prediction of decline.
    Mult Scler. 2019 Nov 28:1352458519891984. doi: 10.1177/1352458519891984.
    PubMed     Abstract available


  325. LI CMF, Hung PS, Chu PP, Tohyama S, et al
    Trigeminal neuralgia associated with multiple sclerosis: A multimodal assessment of brainstem plaques and response to Gamma Knife radiosurgery.
    Mult Scler. 2019 Nov 26:1352458519886070. doi: 10.1177/1352458519886070.
    PubMed     Abstract available


  326. KIM JE, Park SH, Han K, Kim HJ, et al
    Prevalence and incidence of neuromyelitis optica spectrum disorder and multiple sclerosis in Korea.
    Mult Scler. 2019 Nov 21:1352458519888609. doi: 10.1177/1352458519888609.
    PubMed     Abstract available


  327. BRANDSTADTER R, Fabian M, Leavitt VM, Krieger S, et al
    Word-finding difficulty is a prevalent disease-related deficit in early multiple sclerosis.
    Mult Scler. 2019 Nov 19:1352458519881760. doi: 10.1177/1352458519881760.
    PubMed     Abstract available


  328. BAETGE SJ, Filser M, Renner A, Ullrich S, et al
    On the validity of single tests, two-test combinations and the full Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) in detecting patients with cognitive impairment.
    Mult Scler. 2019 Nov 19:1352458519887897. doi: 10.1177/1352458519887897.
    PubMed     Abstract available


  329. ZURAWSKI J, Tauhid S, Chu R, Khalid F, et al
    7T MRI cerebral leptomeningeal enhancement is common in relapsing-remitting multiple sclerosis and is associated with cortical and thalamic lesions.
    Mult Scler. 2019 Nov 12:1352458519885106. doi: 10.1177/1352458519885106.
    PubMed     Abstract available


  330. PELLEGRINI F, Copetti M, Sormani MP, Bovis F, et al
    Predicting disability progression in multiple sclerosis: Insights from advanced statistical modeling.
    Mult Scler. 2019 Nov 5:1352458519887343. doi: 10.1177/1352458519887343.
    PubMed     Abstract available


  331. CORDANI C, Valsasina P, Preziosa P, Meani A, et al
    Action observation training promotes motor improvement and modulates functional network dynamic connectivity in multiple sclerosis.
    Mult Scler. 2019 Nov 5:1352458519887332. doi: 10.1177/1352458519887332.
    PubMed     Abstract available


  332. COLLORONE S, Cawley N, Grussu F, Prados F, et al
    Reduced neurite density in the brain and cervical spinal cord in relapsing-remitting multiple sclerosis: A NODDI study.
    Mult Scler. 2019 Nov 4:1352458519885107. doi: 10.1177/1352458519885107.
    PubMed     Abstract available


  333. MILO R, Korczyn AD, Manouchehri N, Stuve O, et al
    The temporal and causal relationship between inflammation and neurodegeneration in multiple sclerosis.
    Mult Scler. 2019 Nov 4:1352458519886943. doi: 10.1177/1352458519886943.
    PubMed     Abstract available


  334. NAISMITH RT, Wolinsky JS, Wundes A, LaGanke C, et al
    Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
    Mult Scler. 2019 Nov 4:1352458519881761. doi: 10.1177/1352458519881761.
    PubMed     Abstract available


  335. KUHLE J, Plavina T, Barro C, Disanto G, et al
    Neurofilament light levels are associated with long-term outcomes in multiple sclerosis.
    Mult Scler. 2019 Nov 4:1352458519885613. doi: 10.1177/1352458519885613.
    PubMed     Abstract available


  336. VAN WIJMEERSCH B, Singer BA, Boster A, Broadley S, et al
    Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.
    Mult Scler. 2019 Nov 1:1352458519881759. doi: 10.1177/1352458519881759.
    PubMed     Abstract available


  337. MOSTERT JP, De Keyser J
    Response to Grech et al.: FLOUX-PMS study sample considerations.
    Mult Scler. 2019;25:1820-1821.
    PubMed    


  338. GRECH LB, Butler E, Stuckey S, Hester R, et al
    Letter to the editor: FLOUX-PMS study sample considerations.
    Mult Scler. 2019;25:1819-1820.
    PubMed    


    October 2019
  339. RYAN JM, Fortune J, Stennett A, Kilbride C, et al
    Safety, feasibility, acceptability and effects of a behaviour-change intervention to change physical activity behaviour among people with multiple sclerosis: Results from the iStep-MS randomised controlled trial.
    Mult Scler. 2019 Oct 31:1352458519886231. doi: 10.1177/1352458519886231.
    PubMed     Abstract available


  340. LEAVITT VM, Riley CS, De Jager PL, Bloom S, et al
    eSupport: Feasibility trial of telehealth support group participation to reduce loneliness in multiple sclerosis.
    Mult Scler. 2019 Oct 31:1352458519884241. doi: 10.1177/1352458519884241.
    PubMed     Abstract available


  341. ZHOU Y, Claflin SB, Stankovich J, van der Mei I, et al
    Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype.
    Mult Scler. 2019 Oct 31:1352458519881994. doi: 10.1177/1352458519881994.
    PubMed     Abstract available


  342. CLARKE MA, Samaraweera AP, Falah Y, Pitiot A, et al
    Single Test to ARrive at Multiple Sclerosis (STAR-MS) diagnosis: A prospective pilot study assessing the accuracy of the central vein sign in predicting multiple sclerosis in cases of diagnostic uncertainty.
    Mult Scler. 2019 Oct 31:1352458519882282. doi: 10.1177/1352458519882282.
    PubMed     Abstract available


  343. BSTEH G, Berek K, Hegen H, Teuchner B, et al
    Serum neurofilament levels correlate with retinal nerve fiber layer thinning in multiple sclerosis.
    Mult Scler. 2019 Oct 31:1352458519882279. doi: 10.1177/1352458519882279.
    PubMed     Abstract available


  344. WOJCIK CM, Beier M, Costello K, DeLuca J, et al
    Computerized neuropsychological assessment devices in multiple sclerosis: A systematic review.
    Mult Scler. 2019 Oct 22:1352458519879094. doi: 10.1177/1352458519879094.
    PubMed     Abstract available


  345. CHITNIS T
    Serum NFL levels should be used to monitor multiple sclerosis evolution - Commentary.
    Mult Scler. 2019 Oct 18:1352458519880471. doi: 10.1177/1352458519880471.
    PubMed    


  346. MYHR KM, Torkildsen O
    Serum NFL levels should be used to monitor multiple sclerosis evolution - No.
    Mult Scler. 2019 Oct 18:1352458519872891. doi: 10.1177/1352458519872891.
    PubMed    


  347. LEPPERT D, Kuhle J
    Serum NfL levels should be used to monitor multiple sclerosis evolution - Yes.
    Mult Scler. 2019 Oct 18:1352458519872921. doi: 10.1177/1352458519872921.
    PubMed    


  348. JOHANSSON S, Ytterberg C, Gottberg K, Holmqvist LW, et al
    Participation in social/lifestyle activities in people with multiple sclerosis: Changes across 10 years and predictors of sustained participation.
    Mult Scler. 2019 Oct 17:1352458519881991. doi: 10.1177/1352458519881991.
    PubMed     Abstract available


  349. MANEZ-MIRO JU, Martinez-Fernandez R, Del Alamo M, Pineda-Pardo JA, et al
    Focused ultrasound thalamotomy for multiple sclerosis-associated tremor.
    Mult Scler. 2019 Oct 16:1352458519861597. doi: 10.1177/1352458519861597.
    PubMed     Abstract available


  350. JAKIMOVSKI D, Zivadinov R, Ramanthan M, Hagemeier J, et al
    Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study.
    Mult Scler. 2019 Oct 15:1352458519881428. doi: 10.1177/1352458519881428.
    PubMed     Abstract available


  351. DAMASCENO A, Pimentel-Silva LR, Damasceno BP, Cendes F, et al
    Cognitive trajectories in relapsing-remitting multiple sclerosis: A longitudinal 6-year study.
    Mult Scler. 2019 Oct 11:1352458519878685. doi: 10.1177/1352458519878685.
    PubMed     Abstract available


  352. BIANCHI A, Ciccarelli O
    Daclizumab-induced encephalitis in multiple sclerosis.
    Mult Scler. 2019;25:1557-1559.
    PubMed    


  353. IGHANI M, Jonas S, Izbudak I, Choi S, et al
    No association between cortical lesions and leptomeningeal enhancement on 7-Tesla MRI in multiple sclerosis.
    Mult Scler. 2019 Oct 1:1352458519876037. doi: 10.1177/1352458519876037.
    PubMed     Abstract available


  354. GRYTTEN N, Myhr KM, Celius EG, Benjaminsen E, et al
    Risk of cancer among multiple sclerosis patients, siblings, and population controls: A prospective cohort study.
    Mult Scler. 2019 Oct 1:1352458519877244. doi: 10.1177/1352458519877244.
    PubMed     Abstract available


  355. ZECCA C, Bovis F, Novi G, Capobianco M, et al
    Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience.
    Mult Scler. 2019 Oct 1:1352458519872889. doi: 10.1177/1352458519872889.
    PubMed     Abstract available


  356. MACARON G, Ontaneda D
    Clinical commentary on "Warts and all: Fingolimod and unusual HPV associated lesions".
    Mult Scler. 2019;25:1550-1552.
    PubMed    


  357. BERGER JR
    PML with dimethyl fumarate-No role for natalizumab?
    Mult Scler. 2019;25:1686-1687.
    PubMed    


    September 2019
  358. PALOTAI M, Guttmann CR
    Brain anatomical correlates of fatigue in multiple sclerosis.
    Mult Scler. 2019 Sep 19:1352458519876032. doi: 10.1177/1352458519876032.
    PubMed     Abstract available


  359. MAGGI P, Absinta M, Sati P, Perrotta G, et al
    The "central vein sign" in patients with diagnostic "red flags" for multiple sclerosis: A prospective multicenter 3T study.
    Mult Scler. 2019 Sep 19:1352458519876031. doi: 10.1177/1352458519876031.
    PubMed     Abstract available


  360. MARRIE RA, Tremlett H, Kingwell E, Schaffer SA, et al
    Disparities in management and outcomes of myocardial infarction in multiple sclerosis: A matched cohort study.
    Mult Scler. 2019 Sep 13:1352458519876038. doi: 10.1177/1352458519876038.
    PubMed     Abstract available


  361. VAN GEEL F, Veldkamp R, Severijns D, Dalgas U, et al
    Day-to-day reliability, agreement and discriminative validity of measuring walking-related performance fatigability in persons with multiple sclerosis.
    Mult Scler. 2019 Sep 9:1352458519872465. doi: 10.1177/1352458519872465.
    PubMed     Abstract available


  362. BRANDSTADTER R, Katz Sand I, Sumowski JF
    Beyond rehabilitation: A prevention model of reserve and brain maintenance in multiple sclerosis.
    Mult Scler. 2019;25:1372-1378.
    PubMed     Abstract available


  363. WEBER E, Goverover Y, DeLuca J
    Beyond cognitive dysfunction: Relevance of ecological validity of neuropsychological tests in multiple sclerosis.
    Mult Scler. 2019;25:1412-1419.
    PubMed     Abstract available


    August 2019
  364. PALOTAI M, Cavallari M, Koubiyr I, Morales Pinzon A, et al
    Microstructural fronto-striatal and temporo-insular alterations are associated with fatigue in patients with multiple sclerosis independent of white matter lesion load and depression.
    Mult Scler. 2019 Aug 16:1352458519869185. doi: 10.1177/1352458519869185.
    PubMed     Abstract available


  365. FAMBIATOS A, Jokubaitis V, Horakova D, Kubala Havrdova E, et al
    Risk of secondary progressive multiple sclerosis: A longitudinal study.
    Mult Scler. 2019 Aug 9:1352458519868990. doi: 10.1177/1352458519868990.
    PubMed     Abstract available


  366. PISA M, Ratti F, Vabanesi M, Radaelli M, et al
    Subclinical neurodegeneration in multiple sclerosis and neuromyelitis optica spectrum disorder revealed by optical coherence tomography.
    Mult Scler. 2019 Aug 8:1352458519861603. doi: 10.1177/1352458519861603.
    PubMed     Abstract available


  367. SIVAKOLUNDU DK, West KL, Maruthy GB, Zuppichini M, et al
    Reduced arterial compliance along the cerebrovascular tree predicts cognitive slowing in multiple sclerosis: Evidence for a neurovascular uncoupling hypothesis.
    Mult Scler. 2019 Aug 2:1352458519866605. doi: 10.1177/1352458519866605.
    PubMed     Abstract available


  368. HERRANZ E, Louapre C, Treaba CA, Govindarajan ST, et al
    Profiles of cortical inflammation in multiple sclerosis by (11)C-PBR28 MR-PET and 7 Tesla imaging.
    Mult Scler. 2019 Aug 1:1352458519867320. doi: 10.1177/1352458519867320.
    PubMed     Abstract available


  369. MCGINLEY MP, Cola PA, Fox RJ, Cohen JA, et al
    Perspectives of individuals with multiple sclerosis on discontinuation of disease-modifying therapies.
    Mult Scler. 2019 Aug 1:1352458519867314. doi: 10.1177/1352458519867314.
    PubMed     Abstract available


  370. BOVE R, Rankin K, Lin C, Zhao C, et al
    Effect of assisted reproductive technology on multiple sclerosis relapses: Case series and meta-analysis.
    Mult Scler. 2019 Aug 1:1352458519865118. doi: 10.1177/1352458519865118.
    PubMed     Abstract available


  371. BEECHAM AH, Amezcua L, Chinea A, Manrique CP, et al
    The genetic diversity of multiple sclerosis risk among Hispanic and African American populations living in the United States.
    Mult Scler. 2019 Aug 1:1352458519863764. doi: 10.1177/1352458519863764.
    PubMed     Abstract available


  372. KILLESTEIN J, van Oosten B
    Emerging safety issues in alemtuzumab-treated MS patients.
    Mult Scler. 2019;25:1206-1208.
    PubMed    


    July 2019
  373. SOTIRCHOS ES, Filippatou A, Fitzgerald KC, Salama S, et al
    Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinning.
    Mult Scler. 2019 Jul 31:1352458519864928. doi: 10.1177/1352458519864928.
    PubMed     Abstract available


  374. SCHWEHR NA, Kuntz KM, Butler M, Enns EA, et al
    Age-related decreases in relapses among adults with relapsing-onset multiple sclerosis.
    Mult Scler. 2019 Jul 29:1352458519866613. doi: 10.1177/1352458519866613.
    PubMed     Abstract available


  375. CAMPBELL JA, Simpson S Jr, Ahmad H, Taylor BV, et al
    Change in multiple sclerosis prevalence over time in Australia 2010-2017 utilising disease-modifying therapy prescription data.
    Mult Scler. 2019 Jul 26:1352458519861270. doi: 10.1177/1352458519861270.
    PubMed     Abstract available


  376. LARSSON D, Akerfeldt T, Carlson K, Burman J, et al
    Intrathecal immunoglobulins and neurofilament light after autologous haematopoietic stem cell transplantation for multiple sclerosis.
    Mult Scler. 2019 Jul 26:1352458519863983. doi: 10.1177/1352458519863983.
    PubMed     Abstract available


  377. PRAVATA E, Valsasina P, Gobbi C, Zecca C, et al
    Influence of CNS T2-focal lesions on cervical cord atrophy and disability in multiple sclerosis.
    Mult Scler. 2019 Jul 26:1352458519865989. doi: 10.1177/1352458519865989.
    PubMed     Abstract available


  378. CALLESEN J, Cattaneo D, Brincks J, Kjeldgaard Jorgensen ML, et al
    How do resistance training and balance and motor control training affect gait performance and fatigue impact in people with multiple sclerosis? A randomized controlled multi-center study.
    Mult Scler. 2019 Jul 24:1352458519865740. doi: 10.1177/1352458519865740.
    PubMed     Abstract available


  379. BRIGGS FB, Hill E
    Estimating the prevalence of multiple sclerosis using 56.6 million electronic health records from the United States.
    Mult Scler. 2019 Jul 24:1352458519864681. doi: 10.1177/1352458519864681.
    PubMed     Abstract available


  380. HACOHEN Y, Brownlee W, Mankad K, Chong WK', et al
    Improved performance of the 2017 McDonald criteria for diagnosis of multiple sclerosis in children in a real-life cohort.
    Mult Scler. 2019 Jul 18:1352458519863781. doi: 10.1177/1352458519863781.
    PubMed     Abstract available


  381. CAMARA-LEMARROY CR, Silva C, Greenfield J, Liu WQ, et al
    Biomarkers of intestinal barrier function in multiple sclerosis are associated with disease activity.
    Mult Scler. 2019 Jul 18:1352458519863133. doi: 10.1177/1352458519863133.
    PubMed     Abstract available


  382. WARNKE C, Hartung HP
    Challenging a concept: Pulsed treatment regimen-No risk of PML?
    Mult Scler. 2019;25:1076-1078.
    PubMed    


  383. GEREVINI S, Capra R, Bertoli D, Sottini A, et al
    Immune profiling of a patient with alemtuzumab-associated progressive multifocal leukoencephalopathy.
    Mult Scler. 2019;25:1196-1201.
    PubMed     Abstract available


  384. PREZIOSA P, Rocca MA, Filippi M
    PET is necessary to make the next step forward in understanding MS pathophysiology - No.
    Mult Scler. 2019;25:1088-1090.
    PubMed    


  385. BODINI B, Stankoff B
    PET is necessary to make the next step forward in understanding MS pathophysiology - Yes.
    Mult Scler. 2019;25:1086-1087.
    PubMed    


  386. COMBES B, Kerbrat A, Ferre JC, Callot V, et al
    Focal and diffuse cervical spinal cord damage in patients with early relapsing-remitting MS: A multicentre magnetisation transfer ratio study.
    Mult Scler. 2019;25:1113-1123.
    PubMed     Abstract available


  387. KANG Y, Gauthier SA
    PET is necessary to make the next step forward in understanding MS pathophysiology - Commentary.
    Mult Scler. 2019;25:1090-1091.
    PubMed    


    June 2019
  388. DE LOTT LB, Zerafa S, Shedden K, Dunietz GL, et al
    Multiple sclerosis relapse risk in the postoperative period: Effects of invasive surgery and anesthesia.
    Mult Scler. 2019 Jun 25:1352458519860304. doi: 10.1177/1352458519860304.
    PubMed     Abstract available


  389. INEICHEN BV, Moridi T, Granberg T, Piehl F, et al
    Rituximab treatment for multiple sclerosis.
    Mult Scler. 2019 Jun 25:1352458519858604. doi: 10.1177/1352458519858604.
    PubMed     Abstract available


  390. LEAVITT VM, Brandstadter R, Fabian M, Katz Sand I, et al
    Dissociable cognitive patterns related to depression and anxiety in multiple sclerosis.
    Mult Scler. 2019 Jun 24:1352458519860319. doi: 10.1177/1352458519860319.
    PubMed     Abstract available


  391. PERONI S, Sorosina M, Malhotra S, Clarelli F, et al
    A pharmacogenetic study implicates NINJ2 in the response to Interferon-beta in multiple sclerosis.
    Mult Scler. 2019 Jun 21:1352458519851428. doi: 10.1177/1352458519851428.
    PubMed     Abstract available


  392. MARCK CH, das Nair R, Grech LB, Borland R, et al
    Modifiable risk factors for poor health outcomes in multiple sclerosis: The urgent need for research to maximise smoking cessation success.
    Mult Scler. 2019 Jun 20:1352458519858730. doi: 10.1177/1352458519858730.
    PubMed     Abstract available


  393. FUCHS TA, Benedict RH, Wilding G, Wojcik C, et al
    Trait Conscientiousness predicts rate of brain atrophy in multiple sclerosis.
    Mult Scler. 2019 Jun 20:1352458519858605. doi: 10.1177/1352458519858605.
    PubMed     Abstract available


  394. CHATAWAY J, Weir CJ, Fox RJ
    The FLUOX-PMS trial: Underestimating the challenge in progressive multiple sclerosis trials.
    Mult Scler. 2019 Jun 20:1352458519856985. doi: 10.1177/1352458519856985.
    PubMed    


  395. CAMBRON M, Mostert J, D'Hooghe M, Nagels G, et al
    Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trial.
    Mult Scler. 2019 Jun 20:1352458519843051. doi: 10.1177/1352458519843051.
    PubMed     Abstract available


  396. SPRENGER T, Kappos L, Radue EW, Gaetano L, et al
    Association of brain volume loss and long-term disability outcomes in patients with multiple sclerosis treated with teriflunomide.
    Mult Scler. 2019 Jun 14:1352458519855722. doi: 10.1177/1352458519855722.
    PubMed     Abstract available


  397. GABR RE, Coronado I, Robinson M, Sujit SJ, et al
    Brain and lesion segmentation in multiple sclerosis using fully convolutional neural networks: A large-scale study.
    Mult Scler. 2019 Jun 13:1352458519856843. doi: 10.1177/1352458519856843.
    PubMed     Abstract available


  398. KLINEOVA S, Brandstadter R, Fabian MT, Sand IK, et al
    Psychological resilience is linked to motor strength and gait endurance in early multiple sclerosis.
    Mult Scler. 2019 Jun 7:1352458519852725. doi: 10.1177/1352458519852725.
    PubMed     Abstract available


  399. BROWN JWL, Prados Carrasco F, Eshaghi A, Sudre CH, et al
    Periventricular magnetisation transfer ratio abnormalities in multiple sclerosis improve after alemtuzumab.
    Mult Scler. 2019 Jun 6:1352458519852093. doi: 10.1177/1352458519852093.
    PubMed     Abstract available


  400. MARRIE RA, Dufault B, Tyry T, Cutter GR, et al
    Developing a crosswalk between the RAND-12 and the health utilities index for multiple sclerosis.
    Mult Scler. 2019 Jun 4:1352458519852722. doi: 10.1177/1352458519852722.
    PubMed     Abstract available


  401. STAMPANONI BASSI M, Iezzi E, Buttari F, Gilio L, et al
    Obesity worsens central inflammation and disability in multiple sclerosis.
    Mult Scler. 2019 Jun 4:1352458519853473. doi: 10.1177/1352458519853473.
    PubMed     Abstract available


  402. MESCHERIAKOVA JY, Verkerk J, Amin N, Uitterlinden AG, et al
    Response to Vilarino-Guell et al.
    Mult Scler. 2019;25:1013-1015.
    PubMed    


  403. SCALFARI A
    MS progression is predominantly driven by age-related mechanisms - YES.
    Mult Scler. 2019;25:902-904.
    PubMed    


  404. MCGINLEY M, Ontaneda D
    MS progression is predominantly driven by age-related mechanisms - NO.
    Mult Scler. 2019;25:904-906.
    PubMed    


  405. ZEYDAN B, Kantarci OH
    MS progression is predominantly driven by age-related mechanisms - Commentary.
    Mult Scler. 2019;25:906-908.
    PubMed    


    May 2019
  406. AKGUN K, Ziemssen T
    Response to Hyun J.W. et al. "Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis".
    Mult Scler. 2019 May 30:1352458519854263. doi: 10.1177/1352458519854263.
    PubMed    


  407. PELLEGRINI F, Copetti M, Bovis F, Cheng D, et al
    A proof-of-concept application of a novel scoring approach for personalized medicine in multiple sclerosis.
    Mult Scler. 2019 May 30:1352458519849513. doi: 10.1177/1352458519849513.
    PubMed     Abstract available


  408. ARROYO R, Bury DP, Guo JD, Margolin DH, et al
    Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis.
    Mult Scler. 2019 May 30:1352458519849796. doi: 10.1177/1352458519849796.
    PubMed     Abstract available


  409. MOBERG JY, Laursen B, Thygesen LC, Magyari M, et al
    Reproductive history of the Danish multiple sclerosis population: A register-based study.
    Mult Scler. 2019 May 30:1352458519851245. doi: 10.1177/1352458519851245.
    PubMed     Abstract available


  410. CAPONE F, Collorone S, Cortese R, Di Lazzaro V, et al
    Fatigue in multiple sclerosis: The role of thalamus.
    Mult Scler. 2019 May 29:1352458519851247. doi: 10.1177/1352458519851247.
    PubMed     Abstract available


  411. MCCOMBE PA
    Women who contributed to past research in multiple sclerosis.
    Mult Scler. 2019 May 28:1352458519846101. doi: 10.1177/1352458519846101.
    PubMed     Abstract available


  412. MARRIE RA
    Recognizing the diversity gap in multiple sclerosis.
    Mult Scler. 2019 May 28:1352458519850070. doi: 10.1177/1352458519850070.
    PubMed    


  413. AHRWEILLER K, Rousseau C, Le Page E, Bajeux E, et al
    Decreasing impact of late relapses on disability worsening in secondary progressive multiple sclerosis.
    Mult Scler. 2019 May 16:1352458519848090. doi: 10.1177/1352458519848090.
    PubMed     Abstract available


  414. MURPHY OC, Kwakyi O, Iftikhar M, Zafar S, et al
    Alterations in the retinal vasculature occur in multiple sclerosis and exhibit novel correlations with disability and visual function measures.
    Mult Scler. 2019 May 16:1352458519845116. doi: 10.1177/1352458519845116.
    PubMed     Abstract available


  415. PUGLIATTI M
    Changes in the sex ratio are a good indicator of changes in multiple sclerosis incidence - Commentary.
    Mult Scler. 2019 May 15:1352458519845114. doi: 10.1177/1352458519845114.
    PubMed    


  416. KOPP TI, Blinkenberg M, Chalmer TA, Petersen T, et al
    Predictors of treatment outcome in patients with paediatric onset multiple sclerosis.
    Mult Scler. 2019 May 13:1352458519846100. doi: 10.1177/1352458519846100.
    PubMed     Abstract available


  417. CONTE A, Gianni C, Belvisi D, Cortese A, et al
    Deep grey matter involvement and altered sensory gating in multiple sclerosis.
    Mult Scler. 2019 May 13:1352458519845287. doi: 10.1177/1352458519845287.
    PubMed     Abstract available


  418. FITZGERALD KC, Salter A, Tyry T, Fox RJ, et al
    Measures of general and abdominal obesity and disability severity in a large population of people with multiple sclerosis.
    Mult Scler. 2019 May 13:1352458519845836. doi: 10.1177/1352458519845836.
    PubMed     Abstract available


  419. MOSS BP, Cohen JA
    The emergence of follow-on disease-modifying therapies for multiple sclerosis.
    Mult Scler. 2019 May 10:1352458519845106. doi: 10.1177/1352458519845106.
    PubMed     Abstract available


  420. TUR C, Grussu F, Prados F, Charalambous T, et al
    A multi-shell multi-tissue diffusion study of brain connectivity in early multiple sclerosis.
    Mult Scler. 2019 May 10:1352458519845105. doi: 10.1177/1352458519845105.
    PubMed     Abstract available


  421. FALET JR, Deshmukh S, Al-Jassim A, Sigler G, et al
    The neurologist's role in disabling multiple sclerosis: A qualitative study of patient and care provider perspectives.
    Mult Scler. 2019 May 10:1352458519845107. doi: 10.1177/1352458519845107.
    PubMed     Abstract available


  422. FAZEKAS F
    Instead of tweaking the diagnostic criteria for MS in those with CIS, we should develop diagnostic criteria that distinguish MS from other conditions - Commentary.
    Mult Scler. 2019;25:770-771.
    PubMed    


  423. SOLOMON AJ
    Instead of tweaking the diagnostic criteria for MS in those with CIS, we should develop diagnostic criteria that distinguish MS from other conditions - Yes.
    Mult Scler. 2019;25:766-768.
    PubMed    


  424. BROWNLEE WJ
    Instead of tweaking the diagnostic criteria for MS in those with CIS, we should develop diagnostic criteria that distinguish MS from other conditions - No.
    Mult Scler. 2019;25:768-770.
    PubMed    


  425. TRIPLETT J, Vijayan S, Prince R, Kermode A, et al
    Dimethyl fumarate-associated transient bone marrow oedema syndrome.
    Mult Scler. 2019;25:876-879.
    PubMed     Abstract available


  426. ROSATO R, Testa S, Bertolotto A, Scavelli F, et al
    eMSQOL-29: Prospective validation of the abbreviated, electronic version of MSQOL-54.
    Mult Scler. 2019;25:856-866.
    PubMed     Abstract available


  427. GOODIN DS, Reder AT, Traboulsee AL, Li DK, et al
    Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b.
    Mult Scler. 2019;25:837-847.
    PubMed     Abstract available


  428. DUROZARD P, Maarouf A, Boutiere C, Ruet A, et al
    Efficacy of rituximab in refractory RRMS.
    Mult Scler. 2019;25:828-836.
    PubMed     Abstract available


    April 2019
  429. PHELPS R, Winston JA, Wynn D, Habek M, et al
    Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis.
    Mult Scler. 2019 Apr 15:1352458519841829. doi: 10.1177/1352458519841829.
    PubMed     Abstract available


  430. BARLETTA VT, Herranz E, Treaba CA, Ouellette R, et al
    Evidence of diffuse cerebellar neuroinflammation in multiple sclerosis by (11)C-PBR28 MR-PET.
    Mult Scler. 2019 Apr 11:1352458519843048. doi: 10.1177/1352458519843048.
    PubMed     Abstract available


  431. VUKUSIC S, Coyle PK, Jurgensen S, Truffinet P, et al
    Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: Clinical study data and 5 years of post-marketing experience.
    Mult Scler. 2019 Apr 10:1352458519843055. doi: 10.1177/1352458519843055.
    PubMed     Abstract available


  432. BROWN JWL, Chowdhury A, Kanber B, Prados Carrasco F, et al
    Magnetisation transfer ratio abnormalities in primary and secondary progressive multiple sclerosis.
    Mult Scler. 2019 Apr 8:1352458519841810. doi: 10.1177/1352458519841810.
    PubMed     Abstract available


  433. BANWELL B
    Are children with multiple sclerosis really "old" adults.
    Mult Scler. 2019 Apr 4:1352458519841505. doi: 10.1177/1352458519841505.
    PubMed    


  434. BARTELS F, Nobis K, Cooper G, Wendel E, et al
    Childhood multiple sclerosis is associated with reduced brain volumes at first clinical presentation and brain growth failure.
    Mult Scler. 2019 Apr 4:1352458519829698. doi: 10.1177/1352458519829698.
    PubMed     Abstract available


  435. LAVIE C, Rollot F, Durand-Dubief F, Marignier R, et al
    Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS.
    Mult Scler. 2019;25:591-600.
    PubMed     Abstract available


  436. BUCK D, Andlauer TF, Igl W, Wicklein EM, et al
    Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials.
    Mult Scler. 2019;25:565-573.
    PubMed     Abstract available


  437. HYUN JW, Huh SY, Shin HJ, Woodhall M, et al
    Evaluation of brain lesion distribution criteria at disease onset in differentiating MS from NMOSD and MOG-IgG-associated encephalomyelitis.
    Mult Scler. 2019;25:585-590.
    PubMed     Abstract available


  438. ZELEK WM, Watkins LM, Howell OW, Evans R, et al
    Measurement of soluble CD59 in CSF in demyelinating disease: Evidence for an intrathecal source of soluble CD59.
    Mult Scler. 2019;25:523-531.
    PubMed     Abstract available


  439. MANOUSAKI D, Richards JB
    Vitamin D deficiency is an etiological factor for MS - Yes.
    Mult Scler. 2019;25:637-639.
    PubMed    


  440. LANGER-GOULD A, Lucas RM
    Vitamin D deficiency is an etiological factor for MS - No.
    Mult Scler. 2019;25:639-641.
    PubMed    


  441. WILLIAMS T, Chataway J
    Immune-mediated encephalitis with daclizumab: The final nail.
    Mult Scler. 2019;25:753-754.
    PubMed     Abstract available


  442. THOUVENOT E, Hinsinger G, Demattei C, Uygunoglu U, et al
    Cerebrospinal fluid chitinase-3-like protein 1 level is not an independent predictive factor for the risk of clinical conversion in radiologically isolated syndrome.
    Mult Scler. 2019;25:669-677.
    PubMed     Abstract available


    March 2019
  443. HYUN JW, Kim Y, Kim G, Kim SH, et al
    Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis.
    Mult Scler. 2019 Mar 26:1352458519840757. doi: 10.1177/1352458519840757.
    PubMed     Abstract available


  444. BOONSTRA FM, Noffs G, Perera T, Jokubaitis VG, et al
    Functional neuroplasticity in response to cerebello-thalamic injury underpins the clinical presentation of tremor in multiple sclerosis.
    Mult Scler. 2019 Mar 25:1352458519837706. doi: 10.1177/1352458519837706.
    PubMed     Abstract available


  445. BAGNATO F, Franco G, Ye F, Fan R, et al
    Selective inversion recovery quantitative magnetization transfer imaging: Toward a 3 T clinical application in multiple sclerosis.
    Mult Scler. 2019 Mar 25:1352458519833018. doi: 10.1177/1352458519833018.
    PubMed     Abstract available


  446. D'AMBROSIO A, Valsasina P, Gallo A, De Stefano N, et al
    Reduced dynamics of functional connectivity and cognitive impairment in multiple sclerosis.
    Mult Scler. 2019 Mar 19:1352458519837707. doi: 10.1177/1352458519837707.
    PubMed     Abstract available


  447. RUSSO CV, Sacca F, Paternoster M, Buonomo AR, et al
    Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis.
    Mult Scler. 2019 Mar 18:1352458518813110. doi: 10.1177/1352458518813110.
    PubMed    


  448. MEYER CE, Gao JL, Cheng JY, Oberoi MR, et al
    Axonal damage in spinal cord is associated with gray matter atrophy in sensorimotor cortex in experimental autoimmune encephalomyelitis.
    Mult Scler. 2019 Mar 7:1352458519830614. doi: 10.1177/1352458519830614.
    PubMed     Abstract available


  449. STRAUDI S, Manfredini F, Lamberti N, Martinuzzi C, et al
    Robot-assisted gait training is not superior to intensive overground walking in multiple sclerosis with severe disability (the RAGTIME study): A randomized controlled trial.
    Mult Scler. 2019 Mar 4:1352458519833901. doi: 10.1177/1352458519833901.
    PubMed     Abstract available


  450. BARANZINI SE
    Insights into microbiome research 6: The role of consortia in studying the role of microbes in health and disease.
    Mult Scler. 2019;25:336-337.
    PubMed     Abstract available


  451. WATTJES MP, Killestein J
    Imaging of meningeal inflammation should become part of the routine MRI protocol - No.
    Mult Scler. 2019;25:331-333.
    PubMed    


  452. ABSINTA M, Reich DS
    Imaging of meningeal inflammation should become part of the routine MRI protocol - Yes.
    Mult Scler. 2019;25:330-331.
    PubMed    


  453. DEISENHAMMER F, Jank M, Lauren A, Sjodin A, et al
    Prediction of natalizumab anti-drug antibodies persistency.
    Mult Scler. 2019;25:392-398.
    PubMed     Abstract available


  454. ROCCA MA, Riccitelli GC, Meani A, Pagani E, et al
    Cognitive reserve, cognition, and regional brain damage in MS: A 2 -year longitudinal study.
    Mult Scler. 2019;25:372-381.
    PubMed     Abstract available


  455. AL-LOUZI O, Sotirchos ES, Vidal-Jordana A, Beh SC, et al
    Characteristics of morphologic macular abnormalities in neuroimmunology practice.
    Mult Scler. 2019;25:361-371.
    PubMed     Abstract available


    February 2019
  456. PALMER AJ, van der Mei I, Taylor BV, Clarke PM, et al
    Modelling the impact of multiple sclerosis on life expectancy, quality-adjusted life years and total lifetime costs: Evidence from Australia.
    Mult Scler. 2019 Feb 26:1352458519831213. doi: 10.1177/1352458519831213.
    PubMed     Abstract available


  457. URRU SA, Antonelli A, Sechi GM
    Prevalence of multiple sclerosis in Sardinia: A systematic cross-sectional multi-source survey.
    Mult Scler. 2019 Feb 22:1352458519828600. doi: 10.1177/1352458519828600.
    PubMed     Abstract available


  458. PORTACCIO E, Amato MP
    Breastfeeding and post-partum relapses in multiple sclerosis patients.
    Mult Scler. 2019 Feb 22:1352458519830588. doi: 10.1177/1352458519830588.
    PubMed     Abstract available


  459. CUKER A, Bass AD, Nadj C, Agius MA, et al
    Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.
    Mult Scler. 2019 Feb 20:1352458518816612. doi: 10.1177/1352458518816612.
    PubMed     Abstract available


  460. JAKIMOVSKI D, Ramanathan M, Weinstock-Guttman B, Bergsland N, et al
    Higher EBV response is associated with more severe gray matter and lesion pathology in relapsing multiple sclerosis patients: A case-controlled magnetization transfer ratio study.
    Mult Scler. 2019 Feb 13:1352458519828667. doi: 10.1177/1352458519828667.
    PubMed     Abstract available


  461. SOTIRCHOS ES, Gonzalez-Caldito N, Dewey BE, Fitzgerald KC, et al
    Effect of disease-modifying therapies on subcortical gray matter atrophy in multiple sclerosis.
    Mult Scler. 2019 Feb 11:1352458519826364. doi: 10.1177/1352458519826364.
    PubMed     Abstract available


  462. CICERO CE, Patti F, Lo Fermo S, Giuliano L, et al
    Lack of association between Toxocara canis and multiple sclerosis: A population-based case-control study.
    Mult Scler. 2019 Feb 11:1352458518825394. doi: 10.1177/1352458518825394.
    PubMed    


  463. LEFEUVRE JA, Guy JR, Luciano NJ, Ha SK, et al
    The spectrum of spinal cord lesions in a primate model of multiple sclerosis.
    Mult Scler. 2019 Feb 7:1352458518822408. doi: 10.1177/1352458518822408.
    PubMed     Abstract available


  464. NICOLETTI CG, Monteleone F, Marfia GA, Usiello A, et al
    Oral D-Aspartate enhances synaptic plasticity reserve in progressive multiple sclerosis.
    Mult Scler. 2019 Feb 7:1352458519828294. doi: 10.1177/1352458519828294.
    PubMed     Abstract available


  465. RAIMO S, Spitaleri D, Trojano L, Santangelo G, et al
    Apathy as a herald of cognitive changes in multiple sclerosis: A 2-year follow-up study.
    Mult Scler. 2019 Feb 7:1352458519828296. doi: 10.1177/1352458519828296.
    PubMed     Abstract available


  466. PLANCHE V, Su JH, Mournet S, Saranathan M, et al
    White-matter-nulled MPRAGE at 7T reveals thalamic lesions and atrophy of specific thalamic nuclei in multiple sclerosis.
    Mult Scler. 2019 Feb 7:1352458519828297. doi: 10.1177/1352458519828297.
    PubMed     Abstract available


  467. CHARD DT
    Commentary on Al Hussona et al. 'New-onset seizures as a sole clinical presentation of multiple sclerosis'.
    Mult Scler. 2019;25:298-299.
    PubMed     Abstract available


  468. BARANZINI SE
    Insights into microbiome research 5: Mapping is first but function must come next.
    Mult Scler. 2019;25:193-195.
    PubMed     Abstract available


  469. HELLWIG K
    We need to conduct clinical trials of disease-modifying therapy in pregnancy to optimize care of women with MS - No.
    Mult Scler. 2019;25:189-190.
    PubMed    


  470. ALVAREZ E, Mowry EM
    We need to conduct clinical trials of disease-modifying therapy in pregnancy to optimize care of women with MS - Yes.
    Mult Scler. 2019;25:187-188.
    PubMed    


  471. BOVE R
    We need to conduct clinical trials of disease-modifying therapy in pregnancy to optimize care of women with MS - Commentary.
    Mult Scler. 2019;25:190-192.
    PubMed    


  472. HEDSTROM AK
    Smoking and its interaction with genetics in MS etiology.
    Mult Scler. 2019;25:180-186.
    PubMed     Abstract available


  473. BSTEH G, Hegen H, Ladstatter F, Berek K, et al
    Change of olfactory function as a marker of inflammatory activity and disability progression in MS.
    Mult Scler. 2019;25:267-274.
    PubMed     Abstract available


  474. BOVIS F, De Stefano N, Steinerman JR, Knappertz V, et al
    Validating the use of brain volume cutoffs to identify clinically relevant atrophy in RRMS.
    Mult Scler. 2019;25:217-223.
    PubMed     Abstract available


    January 2019
  475. STORK L, Bruck W, von Gottberg P, Pulkowski U, et al
    Severe meningo-/encephalitis after daclizumab therapy for multiple sclerosis.
    Mult Scler. 2019 Jan 18:1352458518819098. doi: 10.1177/1352458518819098.
    PubMed     Abstract available


  476. CORDANI C, Meani A, Esposito F, Valsasina P, et al
    Imaging correlates of hand motor performance in multiple sclerosis: A multiparametric structural and functional MRI study.
    Mult Scler. 2019 Jan 18:1352458518822145. doi: 10.1177/1352458518822145.
    PubMed     Abstract available


  477. VALENCIA-SANCHEZ C, Goodman BP, Carter JL, Wingerchuk DM, et al
    The spectrum of acute cardiopulmonary events associated with multiple sclerosis exacerbations.
    Mult Scler. 2019 Jan 18:1352458518823482. doi: 10.1177/1352458518823482.
    PubMed     Abstract available


  478. VAN MUNSTER CE, Kaya L, Obura M, Kalkers NF, et al
    Minimal clinically important difference of improvement on the Arm Function in Multiple Sclerosis Questionnaire (AMSQ).
    Mult Scler. 2019 Jan 18:1352458518823489. doi: 10.1177/1352458518823489.
    PubMed     Abstract available


  479. BARIN L, Kamm CP, Salmen A, Dressel H, et al
    How do patients enter the healthcare system after the first onset of multiple sclerosis symptoms? The influence of setting and physician specialty on speed of diagnosis.
    Mult Scler. 2019 Jan 18:1352458518823955. doi: 10.1177/1352458518823955.
    PubMed     Abstract available


  480. MARRODAN M, Alessandro L, Farez MF, Correale J, et al
    The role of infections in multiple sclerosis.
    Mult Scler. 2019 Jan 14:1352458518823940. doi: 10.1177/1352458518823940.
    PubMed     Abstract available


  481. PAGANI E, Rocca MA, De Meo E, Horsfield MA, et al
    Structural connectivity in multiple sclerosis and modeling of disconnection.
    Mult Scler. 2019 Jan 9:1352458518820759. doi: 10.1177/1352458518820759.
    PubMed     Abstract available


  482. JAKIMOVSKI D, Benedict RH, Marr K, Gandhi S, et al
    Lower total cerebral arterial flow contributes to cognitive performance in multiple sclerosis patients.
    Mult Scler. 2019 Jan 9:1352458518819608. doi: 10.1177/1352458518819608.
    PubMed     Abstract available


  483. FUCHS TA, Wojcik C, Wilding GE, Pol J, et al
    Trait Conscientiousness predicts rate of longitudinal SDMT decline in multiple sclerosis.
    Mult Scler. 2019 Jan 7:1352458518820272. doi: 10.1177/1352458518820272.
    PubMed     Abstract available


  484. BARANZINI SE
    Insights into microbiome research 4: The computational analysis.
    Mult Scler. 2019;25:21-22.
    PubMed     Abstract available


  485. THOMPSON AJ, Antel J, Carroll WB, Geurts J, et al
    MSJ 2019 - Editorial comment.
    Mult Scler. 2019;25:4-5.
    PubMed    


  486. PITT D, Ponath G
    Astrocytes play a crucial role in the formation and evolution of MS lesions - Yes.
    Mult Scler. 2019;25:15-17.
    PubMed    


  487. KERLERO DE ROSBO N
    Astrocytes play a crucial role in the formation and evolution of MS lesions - No.
    Mult Scler. 2019;25:17-19.
    PubMed    


  488. VIJAYASINGHAM L, Viswanathan S
    A call for more research and global collaboration in South-East Asia to address challenges of DMT access and MS management in the region.
    Mult Scler. 2019;25:130-131.
    PubMed    


  489. PATEL VP, Feinstein A
    The link between depression and performance on the Symbol Digit Modalities Test: Mechanisms and clinical significance.
    Mult Scler. 2019;25:118-121.
    PubMed     Abstract available


  490. MAZZOLA MA, Raheja R, Regev K, Beynon V, et al
    Monomethyl fumarate treatment impairs maturation of human myeloid dendritic cells and their ability to activate T cells.
    Mult Scler. 2019;25:63-71.
    PubMed     Abstract available


  491. QUINTANA FJ
    Astrocytes play a crucial role in the formation and evolution of MS lesions - Commentary.
    Mult Scler. 2019;25:19-20.
    PubMed    


    December 2018
  492. HOGEL H, Rissanen E, Barro C, Matilainen M, et al
    Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity.
    Mult Scler. 2018 Dec 20:1352458518819380. doi: 10.1177/1352458518819380.
    PubMed     Abstract available


  493. SATCHIDANAND N, Drake A, Smerbeck A, Hojnacki D, et al
    Dalfampridine benefits ambulation but not cognition in multiple sclerosis.
    Mult Scler. 2018 Dec 19:1352458518815795. doi: 10.1177/1352458518815795.
    PubMed     Abstract available


  494. ELLIOTT C, Wolinsky JS, Hauser SL, Kappos L, et al
    Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions.
    Mult Scler. 2018 Dec 19:1352458518814117. doi: 10.1177/1352458518814117.
    PubMed     Abstract available


  495. MATTHEWS L
    Clinical commentary on 'Relapsing remitting multiple sclerosis in progressive external ophthalmoplegia: A report of two cases'.
    Mult Scler. 2018 Dec 17:1352458518816621. doi: 10.1177/1352458518816621.
    PubMed    


  496. PATEL KR, Karaa A, Mateen FJ
    Relapsing remitting multiple sclerosis in progressive external ophthalmoplegia: A report of two cases.
    Mult Scler. 2018 Dec 17:1352458518800794. doi: 10.1177/1352458518800794.
    PubMed     Abstract available


  497. POURCHER V, Todesco E, Dubois C, Pallier C, et al
    False hepatitis B and C viral serologies in patients with multiple sclerosis receiving high-dose biotin.
    Mult Scler. 2018 Dec 11:1352458518818294. doi: 10.1177/1352458518818294.
    PubMed    


  498. BSTEH G, Algrang L, Hegen H, Auer M, et al
    Pregnancy and multiple sclerosis in the DMT era: A cohort study in Western Austria.
    Mult Scler. 2018 Dec 3:1352458518816614. doi: 10.1177/1352458518816614.
    PubMed     Abstract available


  499. VAUGHN CB, Kavak KS, Dwyer MG, Bushra A, et al
    Fatigue at enrollment predicts EDSS worsening in the New York State Multiple Sclerosis Consortium.
    Mult Scler. 2018 Dec 3:1352458518816619. doi: 10.1177/1352458518816619.
    PubMed     Abstract available


    November 2018
  500. BSTEH G, Berek K, Hegen H, Teuchner B, et al
    Smelling multiple sclerosis: Different qualities of olfactory function reflect either inflammatory activity or neurodegeneration.
    Mult Scler. 2018 Nov 22:1352458518814113. doi: 10.1177/1352458518814113.
    PubMed     Abstract available


  501. WOJCIK CM, Rao SM, Schembri AJ, Drake AS, et al
    Necessity of technicians for computerized neuropsychological assessment devices in multiple sclerosis.
    Mult Scler. 2018 Nov 22:1352458518813287. doi: 10.1177/1352458518813287.
    PubMed     Abstract available


  502. WALLECZEK NK, Frommlet F, Bsteh G, Eggers C, et al
    Month-of-birth-effect in multiple sclerosis in Austria.
    Mult Scler. 2018 Nov 22:1352458518810924. doi: 10.1177/1352458518810924.
    PubMed     Abstract available


  503. SEGAL BM
    Enhancing natural killer cells is beneficial in multiple sclerosis - Commentary.
    Mult Scler. 2018 Nov 13:1352458518809296. doi: 10.1177/1352458518809296.
    PubMed    


  504. LIU Q, Shi FD
    Enhancing natural killer cells is beneficial in multiple sclerosis - No.
    Mult Scler. 2018 Nov 13:1352458518799591. doi: 10.1177/1352458518799591.
    PubMed    


  505. LARONI A
    Enhancing natural killer cells is beneficial in multiple sclerosis - Yes.
    Mult Scler. 2018 Nov 13:1352458518800776. doi: 10.1177/1352458518800776.
    PubMed    


  506. RAATS J, Lamers I, Baert I, Willekens B, et al
    Cognitive-motor interference in persons with multiple sclerosis during five upper limb motor tasks with different complexity.
    Mult Scler. 2018 Nov 12:1352458518808194. doi: 10.1177/1352458518808194.
    PubMed     Abstract available


  507. FOX EJ, Markowitz C, Applebee A, Montalban X, et al
    Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial.
    Mult Scler. 2018 Nov 12:1352458518808189. doi: 10.1177/1352458518808189.
    PubMed     Abstract available


  508. LUIJTEN MA, Eekhout I, D'Hooghe M, Uitdehaag BM, et al
    Development of the Arm Function in Multiple Sclerosis Questionnaire-Short Form (AMSQ-SF): A static 10-item version.
    Mult Scler. 2018 Nov 9:1352458518808197. doi: 10.1177/1352458518808197.
    PubMed     Abstract available


  509. LAMERS I, Feys P
    Patient reported outcome measures of upper limb function in multiple sclerosis: A critical overview.
    Mult Scler. 2018 Nov 9:1352458518809294. doi: 10.1177/1352458518809294.
    PubMed    


  510. HYUN JW, Kim Y, Kim G, Kim SH, et al
    Severe B cell-mediated disease activation despite two cycles of alemtuzumab in a patient with multiple sclerosis.
    Mult Scler. 2018 Nov 7:1352458518810261. doi: 10.1177/1352458518810261.
    PubMed     Abstract available


  511. ACHIRON A, Sarova-Pinhas I, Magalashvili D, Stern Y, et al
    Residual disability after severe relapse in people with multiple sclerosis treated with disease-modifying therapy.
    Mult Scler. 2018 Nov 1:1352458518809903. doi: 10.1177/1352458518809903.
    PubMed     Abstract available


  512. HOBART J, Bowen A, Pepper G, Crofts H, et al
    International consensus on quality standards for brain health-focused care in multiple sclerosis.
    Mult Scler. 2018 Nov 1:1352458518809326. doi: 10.1177/1352458518809326.
    PubMed     Abstract available


  513. HEALY BC, Zurawski J, Gonzalez CT, Chitnis T, et al
    Assessment of computer adaptive testing version of the Neuro-QOL for people with multiple sclerosis.
    Mult Scler. 2018 Nov 1:1352458518810159. doi: 10.1177/1352458518810159.
    PubMed     Abstract available


  514. PEETERS LM, van Munster CE, Van Wijmeersch B, Bruyndonckx R, et al
    Multidisciplinary data infrastructures in multiple sclerosis: Why they are needed and can be done!
    Mult Scler. 2018 Nov 1:1352458518807076. doi: 10.1177/1352458518807076.
    PubMed     Abstract available


    October 2018
  515. FARRELL R
    Clinical commentary on "De novo convulsive status epilepticus in patients with multiple sclerosis treated with dalfampridine".
    Mult Scler. 2018 Oct 30:1352458518810661. doi: 10.1177/1352458518810661.
    PubMed    


  516. PANICUCCI E, Cohen M, Bourg V, Rocher F, et al
    De novo convulsive status epilepticus in patients with multiple sclerosis treated with dalfampridine.
    Mult Scler. 2018 Oct 30:1352458518790379. doi: 10.1177/1352458518790379.
    PubMed     Abstract available


  517. DOBSON R
    Clinical commentary on 'Life-threatening vitamin D intoxication due to intake of ultra-high doses in multiple sclerosis: a note of caution'.
    Mult Scler. 2018 Oct 25:1352458518807053. doi: 10.1177/1352458518807053.
    PubMed    


  518. FEIGE J, Salmhofer H, Hecker C, Kunz AB, et al
    Life-threatening vitamin D intoxication due to intake of ultra-high doses in multiple sclerosis: A note of caution.
    Mult Scler. 2018 Oct 25:1352458518807059. doi: 10.1177/1352458518807059.
    PubMed     Abstract available


  519. AHMAD H, van der Mei I, Taylor BV, Lucas RM, et al
    Estimation of annual probabilities of changing disability levels in Australians with relapsing-remitting multiple sclerosis.
    Mult Scler. 2018 Oct 23:1352458518806103. doi: 10.1177/1352458518806103.
    PubMed     Abstract available


  520. SOELBERG SORENSEN P, Giovannoni G, Montalban X, Thalheim C, et al
    The Multiple Sclerosis Care Unit.
    Mult Scler. 2018 Oct 23:1352458518807082. doi: 10.1177/1352458518807082.
    PubMed     Abstract available


  521. ROTSTEIN DL, Cortese M, Fung TT, Chitnis T, et al
    Diet quality and risk of multiple sclerosis in two cohorts of US women.
    Mult Scler. 2018 Oct 23:1352458518807061. doi: 10.1177/1352458518807061.
    PubMed     Abstract available


  522. STROBER L, DeLuca J, Benedict RH, Jacobs A, et al
    Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis.
    Mult Scler. 2018 Oct 18:1352458518808204. doi: 10.1177/1352458518808204.
    PubMed     Abstract available


  523. BURROWS DJ, McGown A, Jain SA, De Felice M, et al
    Animal models of multiple sclerosis: From rodents to zebrafish.
    Mult Scler. 2018 Oct 15:1352458518805246. doi: 10.1177/1352458518805246.
    PubMed     Abstract available


  524. DUBUISSON N, Marta M, Gnanapavan S, Turner B, et al
    Inclusion criteria used in trials of people with progressive multiple sclerosis.
    Mult Scler. 2018 Oct 15:1352458518803769. doi: 10.1177/1352458518803769.
    PubMed    


  525. GRAF J, Ringelstein M, Lepka K, Schaller J, et al
    Acute sarcoidosis in a multiple sclerosis patient after alemtuzumab treatment.
    Mult Scler. 2018 Oct 11:1352458518771276. doi: 10.1177/1352458518771276.
    PubMed     Abstract available


  526. WILLIS MD, Hope-Gill B, Flood-Page P, Joseph F, et al
    Sarcoidosis following alemtuzumab treatment for multiple sclerosis.
    Mult Scler. 2018 Oct 11:1352458518790391. doi: 10.1177/1352458518790391.
    PubMed     Abstract available


  527. PFEUFFER S
    Sarcoidosis following alemtuzumab treatment: Autoimmunity mediated by T cells and interferon-gamma.
    Mult Scler. 2018 Oct 11:1352458518804124. doi: 10.1177/1352458518804124.
    PubMed    


  528. CONWAY BL, Zeydan B, Uygunoglu U, Novotna M, et al
    Age is a critical determinant in recovery from multiple sclerosis relapses.
    Mult Scler. 2018 Oct 10:1352458518800815. doi: 10.1177/1352458518800815.
    PubMed     Abstract available


  529. KALB R, Beier M, Benedict RH, Charvet L, et al
    Recommendations for cognitive screening and management in multiple sclerosis care.
    Mult Scler. 2018 Oct 10:1352458518803785. doi: 10.1177/1352458518803785.
    PubMed     Abstract available


  530. VILARINO-GUELL C, Encarnacion M, Bernales CQ, Sadovnick AD, et al
    Analysis of Canadian multiple sclerosis patients does not support a role for FKBP6 in disease.
    Mult Scler. 2018 Oct 9:1352458518803789. doi: 10.1177/1352458518803789.
    PubMed    


  531. KREMER D, Akkermann R, Kury P, Dutta R, et al
    Current advancements in promoting remyelination in multiple sclerosis.
    Mult Scler. 2018 Oct 1:1352458518800827. doi: 10.1177/1352458518800827.
    PubMed     Abstract available


  532. TATEO F, Grassivaro F, Ermani M, Puthenparampil M, et al
    PM2.5 levels strongly associate with multiple sclerosis prevalence in the Province of Padua, Veneto Region, North-East Italy.
    Mult Scler. 2018 Oct 1:1352458518803273. doi: 10.1177/1352458518803273.
    PubMed     Abstract available


    September 2018
  533. BOSE G, Atkins HL, Bowman M, Freedman MS, et al
    Autologous hematopoietic stem cell transplantation improves fatigue in multiple sclerosis.
    Mult Scler. 2018 Sep 25:1352458518802544. doi: 10.1177/1352458518802544.
    PubMed     Abstract available


  534. MIN M, Spelman T, Lugaresi A, Boz C, et al
    Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosis.
    Mult Scler. 2018 Sep 20:1352458518798147. doi: 10.1177/1352458518798147.
    PubMed     Abstract available


  535. LAVORGNA L, Brigo F, Moccia M, Leocani L, et al
    e-Health and multiple sclerosis: An update.
    Mult Scler. 2018 Sep 19:1352458518799629. doi: 10.1177/1352458518799629.
    PubMed     Abstract available


  536. ANTONAZZO IC, Poluzzi E, Forcesi E, Riise T, et al
    Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System.
    Mult Scler. 2018 Sep 19:1352458518799598. doi: 10.1177/1352458518799598.
    PubMed     Abstract available


  537. ROMMER PS, Eichstadt K, Ellenberger D, Flachenecker P, et al
    Symptomatology and symptomatic treatment in multiple sclerosis: Results from a nationwide MS registry.
    Mult Scler. 2018 Sep 19:1352458518799580. doi: 10.1177/1352458518799580.
    PubMed     Abstract available


  538. O'GRADY KP, Dula AN, Lyttle BD, Thompson LM, et al
    Glutamate-sensitive imaging and evaluation of cognitive impairment in multiple sclerosis.
    Mult Scler. 2018 Sep 19:1352458518799583. doi: 10.1177/1352458518799583.
    PubMed     Abstract available


  539. BENJAMIN LA
    A tale of two demyelinating diseases and Zika virus.
    Mult Scler. 2018 Sep 18:1352458518799584. doi: 10.1177/1352458518799584.
    PubMed    


    August 2018
  540. VAN ROSSUM JA, Killestein J, Villar LM, Riskind PN, et al
    gMS-Classifier1 does not predict disability progression in multiple sclerosis.
    Mult Scler. 2018 Aug 31:1352458518798048. doi: 10.1177/1352458518798048.
    PubMed    


  541. VAN MUNSTER CE, D'Souza M, Steinheimer S, Kamm CP, et al
    Tasks of activities of daily living (ADL) are more valuable than the classical neurological examination to assess upper extremity function and mobility in multiple sclerosis.
    Mult Scler. 2018 Aug 31:1352458518796690. doi: 10.1177/1352458518796690.
    PubMed     Abstract available


  542. O'MAHONY J, Marrie RA, Laporte A, Bar-Or A, et al
    Pediatric-onset multiple sclerosis is associated with reduced parental health-related quality of life and family functioning.
    Mult Scler. 2018 Aug 30:1352458518796676. doi: 10.1177/1352458518796676.
    PubMed     Abstract available


  543. BOVE R, Bevan C, Crabtree E, Zhao C, et al
    Toward a low-cost, in-home, telemedicine-enabled assessment of disability in multiple sclerosis.
    Mult Scler. 2018 Aug 24:1352458518793527. doi: 10.1177/1352458518793527.
    PubMed     Abstract available


  544. NICHOLAS RS, Han E, Raffel J, Chataway J, et al
    Over three decades study populations in progressive multiple sclerosis have become older and more disabled, but have lower on-trial progression rates: A systematic review and meta-analysis of 43 randomised placebo-controlled trials.
    Mult Scler. 2018 Aug 24:1352458518794063. doi: 10.1177/1352458518794063.
    PubMed     Abstract available


  545. SKJERBAEK AG, Boesen F, Petersen T, Rasmussen PV, et al
    Can we trust self-reported walking distance when determining EDSS scores in patients with multiple sclerosis? The Danish MS hospitals rehabilitation study.
    Mult Scler. 2018 Aug 20:1352458518795416. doi: 10.1177/1352458518795416.
    PubMed     Abstract available


  546. ANDERSEN C, Sondergaard HB, Bang Oturai D, Laursen JH, et al
    Alcohol consumption in adolescence is associated with a lower risk of multiple sclerosis in a Danish cohort.
    Mult Scler. 2018 Aug 20:1352458518795418. doi: 10.1177/1352458518795418.
    PubMed     Abstract available


  547. GAUZZI MC
    Vitamin D-binding protein and multiple sclerosis: Evidence, controversies, and needs.
    Mult Scler. 2018 Aug 16:1352458518792433. doi: 10.1177/1352458518792433.
    PubMed     Abstract available


  548. SELLEBJERG F, Royen L, Soelberg Sorensen P, Oturai AB, et al
    Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis.
    Mult Scler. 2018 Aug 16:1352458518794308. doi: 10.1177/1352458518794308.
    PubMed     Abstract available


  549. VISWANATHAN S, Wah LM
    A nationwide epidemiological study on the prevalence of multiple sclerosis and neuromyelitis optica spectrum disorder with important multi-ethnic differences in Malaysia.
    Mult Scler. 2018 Aug 16:1352458518792430. doi: 10.1177/1352458518792430.
    PubMed     Abstract available


  550. SEEBACHER B, Kuisma R, Glynn A, Berger T, et al
    Effects and mechanisms of differently cued and non-cued motor imagery in people with multiple sclerosis: A randomised controlled trial.
    Mult Scler. 2018 Aug 14:1352458518795332. doi: 10.1177/1352458518795332.
    PubMed     Abstract available


  551. PIETROBONI AM, Caprioli M, Carandini T, Scarioni M, et al
    CSF beta-amyloid predicts prognosis in patients with multiple sclerosis.
    Mult Scler. 2018 Aug 7:1352458518791709. doi: 10.1177/1352458518791709.
    PubMed     Abstract available


  552. ROCCA MA, Meani A, Fumagalli S, Pagani E, et al
    Functional and structural plasticity following action observation training in multiple sclerosis.
    Mult Scler. 2018 Aug 7:1352458518792771. doi: 10.1177/1352458518792771.
    PubMed     Abstract available


  553. KUSPINAR A, Mayo NE
    Validation of the preference-based multiple sclerosis index.
    Mult Scler. 2018 Aug 2:1352458518792423. doi: 10.1177/1352458518792423.
    PubMed     Abstract available


  554. TOMASSINI V, Fanelli F, Prosperini L, Cerqua R, et al
    Predicting the profile of increasing disability in multiple sclerosis.
    Mult Scler. 2018 Aug 2:1352458518790397. doi: 10.1177/1352458518790397.
    PubMed     Abstract available


  555. PETERSEN ER, Sondergaard HB, Laursen JH, Olsson AG, et al
    Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis.
    Mult Scler. 2018 Aug 2:1352458518791753. doi: 10.1177/1352458518791753.
    PubMed     Abstract available


  556. DI STADIO A, Ralli M
    Inner ear involvement in multiple sclerosis: An underestimated condition?
    Mult Scler. 2018;24:1264-1265.
    PubMed    


  557. BHAN A, Jacobsen C, Myhr KM, Dalen I, et al
    Neurofilaments and 10-year follow-up in multiple sclerosis.
    Mult Scler. 2018 Aug 1:1352458518782005. doi: 10.1177/1352458518782005.
    PubMed     Abstract available


    July 2018
  558. YANG R, Dunn JF
    Multiple sclerosis disease progression: Contributions from a hypoxia-inflammation cycle.
    Mult Scler. 2018 Jul 27:1352458518791683. doi: 10.1177/1352458518791683.
    PubMed     Abstract available


  559. SACCA F, Lanzillo R, Signori A, Maniscalco GT, et al
    Determinants of therapy switch in multiple sclerosis treatment-naive patients: A real-life study.
    Mult Scler. 2018 Jul 25:1352458518790390. doi: 10.1177/1352458518790390.
    PubMed     Abstract available


  560. HYUN JW, Kim W, Huh SY, Park MS, et al
    Application of the 2017 McDonald diagnostic criteria for multiple sclerosis in Korean patients with clinically isolated syndrome.
    Mult Scler. 2018 Jul 25:1352458518790702. doi: 10.1177/1352458518790702.
    PubMed     Abstract available


  561. HOLM HANSEN R, Hojsgaard Chow H, Sellebjerg F, Rode von Essen M, et al
    Dimethyl fumarate therapy suppresses B cell responses and follicular helper T cells in relapsing-remitting multiple sclerosis.
    Mult Scler. 2018 Jul 25:1352458518790417. doi: 10.1177/1352458518790417.
    PubMed     Abstract available


  562. COHEN JA, Comi G, Arnold DL, Bar-Or A, et al
    Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.
    Mult Scler. 2018 Jul 25:1352458518789884. doi: 10.1177/1352458518789884.
    PubMed     Abstract available


  563. LIN F, Zivadinov R, Hagemeier J, Weinstock-Guttman B, et al
    Altered nuclei-specific thalamic functional connectivity patterns in multiple sclerosis and their associations with fatigue and cognition.
    Mult Scler. 2018 Jul 1:1352458518788218. doi: 10.1177/1352458518788218.
    PubMed     Abstract available


  564. SENDERS A, Hanes D, Bourdette D, Carson K, et al
    Impact of mindfulness-based stress reduction for people with multiple sclerosis at 8 weeks and 12 months: A randomized clinical trial.
    Mult Scler. 2018 Jul 1:1352458518786650. doi: 10.1177/1352458518786650.
    PubMed     Abstract available


  565. FISSOLO N, Cervera-Carles L, Villar Guimerans LM, Lleo A, et al
    Cerebrospinal fluid mitochondrial DNA levels in patients with multiple sclerosis.
    Mult Scler. 2018 Jul 1:1352458518786055. doi: 10.1177/1352458518786055.
    PubMed     Abstract available


  566. OSHIMA Y, Tanimoto T, Yuji K, Tojo A, et al
    Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
    Mult Scler. 2018 Jul 1:1352458518786075. doi: 10.1177/1352458518786075.
    PubMed     Abstract available


  567. WIJNANDS JM, Zhu F, Kingwell E, Zhao Y, et al
    Five years before multiple sclerosis onset: Phenotyping the prodrome.
    Mult Scler. 2018 Jul 1:1352458518783662. doi: 10.1177/1352458518783662.
    PubMed     Abstract available


  568. WONG YYM, van der Vuurst de Vries RM, van Pelt ED, Ketelslegers IA, et al
    T-cell activation marker sCD27 is associated with clinically definite multiple sclerosis in childhood-acquired demyelinating syndromes.
    Mult Scler. 2018 Jul 1:1352458518786655. doi: 10.1177/1352458518786655.
    PubMed     Abstract available


  569. KEARNEY H
    Clinical monitoring of multiple sclerosis should routinely include spinal cord imaging - No.
    Mult Scler. 2018 Jul 1:1352458518770279. doi: 10.1177/1352458518770279.
    PubMed    


  570. SASTRE-GARRIGA J
    Clinical monitoring of multiple sclerosis should routinely include spinal cord imaging - Commentary.
    Mult Scler. 2018 Jul 1:1352458518783362. doi: 10.1177/1352458518783362.
    PubMed    


  571. CORTESE R, Ciccarelli O
    Clinical monitoring of multiple sclerosis should routinely include spinal cord imaging - Yes.
    Mult Scler. 2018 Jul 1:1352458518778010. doi: 10.1177/1352458518778010.
    PubMed    


    June 2018
  572. MESCHERIAKOVA JY, Verkerk AJ, Amin N, Uitterlinden AG, et al
    Linkage analysis and whole exome sequencing identify a novel candidate gene in a Dutch multiple sclerosis family.
    Mult Scler. 2018 Jun 1:1352458518777202. doi: 10.1177/1352458518777202.
    PubMed     Abstract available


  573. PUTHENPARAMPIL M, Zito A, Pantano G, Federle L, et al
    Peripheral imbalanced TFH/TFR ratio correlates with intrathecal IgG synthesis in multiple sclerosis at clinical onset.
    Mult Scler. 2018 Jun 1:1352458518779951. doi: 10.1177/1352458518779951.
    PubMed     Abstract available


  574. AL HUSSONA M, Kearney H, Fisher A, Lynch J, et al
    New onset seizures as a sole clinical presentation of multiple sclerosis.
    Mult Scler. 2018 Jun 1:1352458518781994. doi: 10.1177/1352458518781994.
    PubMed     Abstract available


  575. REDDEL SW, Barnett MH, Riminton S, Dugal T, et al
    Successful implementation of an automated electronic support system for patient safety monitoring: The alemtuzumab in multiple sclerosis safety systems (AMS3) study.
    Mult Scler. 2018 Jun 1:1352458518783673. doi: 10.1177/1352458518783673.
    PubMed     Abstract available


  576. CHEN J, Taylor B, Palmer AJ, Kirk-Brown A, et al
    Estimating MS-related work productivity loss and factors associated with work productivity loss in a representative Australian sample of people with multiple sclerosis.
    Mult Scler. 2018 Jun 1:1352458518781971. doi: 10.1177/1352458518781971.
    PubMed     Abstract available


  577. MANOUCHEHRINIA A, Zhu F, Piani-Meier D, Lange M, et al
    Predicting risk of secondary progression in multiple sclerosis: A nomogram.
    Mult Scler. 2018 Jun 1:1352458518783667. doi: 10.1177/1352458518783667.
    PubMed     Abstract available


  578. GALLAGHER LG, Ilango S, Wundes A, Stobbe GA, et al
    Lifetime exposure to ultraviolet radiation and the risk of multiple sclerosis in the US radiologic technologists cohort study.
    Mult Scler. 2018 Jun 1:1352458518783343. doi: 10.1177/1352458518783343.
    PubMed     Abstract available


  579. MAGALHAES S, Banwell B, Bar-Or A, Fortier I, et al
    A framework for measurement and harmonization of pediatric multiple sclerosis etiologic research studies: The Pediatric MS Tool-Kit.
    Mult Scler. 2018 Jun 1:1352458518783345. doi: 10.1177/1352458518783345.
    PubMed     Abstract available


  580. ALVES-LEON SV, Lima MDR, Nunes PCG, Chimelli LMC, et al
    Zika virus found in brain tissue of a multiple sclerosis patient undergoing an acute disseminated encephalomyelitis-like episode.
    Mult Scler. 2018 Jun 1:1352458518781992. doi: 10.1177/1352458518781992.
    PubMed     Abstract available


    May 2018
  581. FROEHLICH A, Schmidt S, Landsberg J, Bieber T, et al
    Spontaneous regression of tumor-stage cutaneous T-cell lymphoma in a multiple sclerosis patient after discontinuing fingolimod.
    Mult Scler. 2018 May 1:1352458518774444. doi: 10.1177/1352458518774444.
    PubMed    


  582. NAUTA IM, Balk LJ, Sonder JM, Hulst HE, et al
    The clinical value of the patient-reported multiple sclerosis neuropsychological screening questionnaire.
    Mult Scler. 2018 May 1:1352458518777295. doi: 10.1177/1352458518777295.
    PubMed     Abstract available


  583. ROMME CHRISTENSEN J, Komori M, von Essen MR, Ratzer R, et al
    CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage.
    Mult Scler. 2018 May 1:1352458518774880. doi: 10.1177/1352458518774880.
    PubMed     Abstract available


  584. MILLS EA, Mao-Draayer Y
    Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients.
    Mult Scler. 2018 May 1:1352458518775550. doi: 10.1177/1352458518775550.
    PubMed     Abstract available


  585. VAN DER VUURST DE VRIES RM, Wong YYM, Mescheriakova JY, van Pelt ED, et al
    High neurofilament levels are associated with clinically definite multiple sclerosis in children and adults with clinically isolated syndrome.
    Mult Scler. 2018 May 1:1352458518775303. doi: 10.1177/1352458518775303.
    PubMed     Abstract available


  586. SCHEE JP, Viswanathan S
    Pure spinal multiple sclerosis: A possible novel entity within the multiple sclerosis disease spectrum.
    Mult Scler. 2018 May 1:1352458518775912. doi: 10.1177/1352458518775912.
    PubMed     Abstract available


  587. BOESEN MS, Koch-Henriksen N, Thygesen LC, Eriksson F, et al
    Infections seem to be more frequent before onset of pediatric multiple sclerosis: A Danish nationwide nested case-control study.
    Mult Scler. 2018 May 1:1352458518771871. doi: 10.1177/1352458518771871.
    PubMed     Abstract available


  588. BAKER G, Nair KPS, Baster K, Rosato R, et al
    Reliability and acceptability of the Multiple Sclerosis Quality of Life-29 questionnaire in an English-speaking cohort.
    Mult Scler. 2018 May 1:1352458518776583. doi: 10.1177/1352458518776583.
    PubMed     Abstract available


  589. BEESLEY R, Anderson V, Harding KE, Joseph F, et al
    Impact of the 2017 revisions to McDonald criteria on the diagnosis of multiple sclerosis.
    Mult Scler. 2018 May 1:1352458518778007. doi: 10.1177/1352458518778007.
    PubMed    


  590. HUGOS CL, Cameron MH, Chen Z, Chen Y, et al
    A multicenter randomized controlled trial of two group education programs for fatigue in multiple sclerosis: Long-term (12-month) follow-up at one site.
    Mult Scler. 2018 May 1:1352458518775920. doi: 10.1177/1352458518775920.
    PubMed     Abstract available


  591. TSAGKAS C, Magon S, Gaetano L, Pezold S, et al
    Preferential spinal cord volume loss in primary progressive multiple sclerosis.
    Mult Scler. 2018 May 1:1352458518775006. doi: 10.1177/1352458518775006.
    PubMed     Abstract available


  592. MARANZANO J, Till C, Assemlal HE, Fonov V, et al
    Detection and clinical correlation of leukocortical lesions in pediatric-onset multiple sclerosis on multi-contrast MRI.
    Mult Scler. 2018 May 1:1352458518779952. doi: 10.1177/1352458518779952.
    PubMed     Abstract available


  593. BJORNEVIK K, Myhr KM, Beiske A, Bjerve KS, et al
    alpha-Linolenic acid is associated with MRI activity in a prospective cohort of multiple sclerosis patients.
    Mult Scler. 2018 May 1:1352458518779925. doi: 10.1177/1352458518779925.
    PubMed     Abstract available


    April 2018
  594. ALMEIDA KJ, Barreto-Soares RV, Campos-Sousa RN, Campos-Sousa MG, et al
    Pulmonary paracoccidioidomycosis associated with the use of natalizumab in multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518763091. doi: 10.1177/1352458518763091.
    PubMed     Abstract available


  595. MCNICHOLAS N, Lockhart A, Yap SM, O'Connell K, et al
    New versus old: Implications of evolving diagnostic criteria for relapsing-remitting multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518770088. doi: 10.1177/1352458518770088.
    PubMed     Abstract available


  596. KREMER D, Kury P, Hartung HP
    ECTRIMS/ACTRIMS 2017: Closing in on neurorepair in progressive multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518768770. doi: 10.1177/1352458518768770.
    PubMed     Abstract available


  597. KOBELT G, Langdon D, Jonsson L
    The effect of self-assessed fatigue and subjective cognitive impairment on work capacity: The case of multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518769837. doi: 10.1177/1352458518769837.
    PubMed     Abstract available


  598. VAVASOUR IM, Tam R, Li DK, Laule C, et al
    A 24-month advanced magnetic resonance imaging study of multiple sclerosis patients treated with alemtuzumab.
    Mult Scler. 2018 Apr 1:1352458518770085. doi: 10.1177/1352458518770085.
    PubMed     Abstract available


  599. MARRIE RA, Montalban X
    Disease-modifying therapy in multiple sclerosis: Two guidelines (almost) passing in the night.
    Mult Scler. 2018;24:558-562.
    PubMed    


  600. LORSCHEIDER J, Benkert P, Lienert C, Hanni P, et al
    Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518768433. doi: 10.1177/1352458518768433.
    PubMed     Abstract available


  601. SAUL A, Taylor B, Simpson S Jr, Ponsonby AL, et al
    Polymorphism in the serotonin transporter gene polymorphisms ( 5-HTTLPR) modifies the association between significant life events and depression in people with multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518770021. doi: 10.1177/1352458518770021.
    PubMed     Abstract available


  602. LLUFRIU S, Rocca MA, Pagani E, Riccitelli GC, et al
    Hippocampal-related memory network in multiple sclerosis: A structural connectivity analysis.
    Mult Scler. 2018 Apr 1:1352458518771838. doi: 10.1177/1352458518771838.
    PubMed     Abstract available


  603. CREARY LE, Mallempati KC, Gangavarapu S, Caillier SJ, et al
    Deconstruction of HLA-DRB1*04:01:01 and HLA-DRB1*15:01:01 class II haplotypes using next-generation sequencing in European-Americans with multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518770019. doi: 10.1177/1352458518770019.
    PubMed     Abstract available


  604. MCCLURG D, Bugge C, Elders A, Irshad T, et al
    Factors affecting continuation of clean intermittent catheterisation in people with multiple sclerosis: Results of the COSMOS mixed-methods study.
    Mult Scler. 2018 Apr 1:1352458518768722. doi: 10.1177/1352458518768722.
    PubMed     Abstract available


  605. WAGLEY S, Bokori-Brown M, Morcrette H, Malaspina A, et al
    Evidence of Clostridium perfringens epsilon toxin associated with multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518767327. doi: 10.1177/1352458518767327.
    PubMed     Abstract available


  606. GIOVANNONI G, Soelberg Sorensen P, Cook S, Rammohan KW, et al
    Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study.
    Mult Scler. 2018 Apr 1:1352458518771875. doi: 10.1177/1352458518771875.
    PubMed     Abstract available


  607. GIORDANA MT, Cavalla P, Uccelli A, Laroni A, et al
    Overexpression of sphingosine-1-phosphate receptors on reactive astrocytes drives neuropathology of multiple sclerosis rebound after fingolimod discontinuation.
    Mult Scler. 2018 Apr 1:1352458518763095. doi: 10.1177/1352458518763095.
    PubMed     Abstract available


  608. GIACOMINI PS
    Rebound disease in multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518772913. doi: 10.1177/1352458518772913.
    PubMed    


  609. HARMEL P, Schlunk F, Harms L
    Fulminant rebound of relapsing-remitting multiple sclerosis after discontinuation of dimethyl fumarate: A case report.
    Mult Scler. 2018 Apr 1:1352458517741191. doi: 10.1177/1352458517741191.
    PubMed     Abstract available


    March 2018
  610. KOENIG KA, Rao SM, Lowe MJ, Lin J, et al
    The role of the thalamus and hippocampus in episodic memory performance in patients with multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518760716. doi: 10.1177/1352458518760716.
    PubMed     Abstract available


  611. GOBEL K, Ruck T, Meuth SG
    Cytokine signaling in multiple sclerosis: Lost in translation.
    Mult Scler. 2018 Mar 1:1352458518763094. doi: 10.1177/1352458518763094.
    PubMed     Abstract available


  612. LEE JY, De Jager PL
    What is the epigenome and is it involved in multiple sclerosis?
    Mult Scler. 2018;24:268-269.
    PubMed    


  613. SILLER N, Kuhle J, Muthuraman M, Barro C, et al
    Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518765666. doi: 10.1177/1352458518765666.
    PubMed     Abstract available


  614. SOWA P, Harbo HF, White NS, Celius EG, et al
    Restriction spectrum imaging of white matter and its relation to neurological disability in multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518765671. doi: 10.1177/1352458518765671.
    PubMed     Abstract available


  615. CORTI L, Ayrignac X, Carra Dalliere C, Charif M, et al
    Late activity rebound in non-active multiple sclerosis: A rare event.
    Mult Scler. 2018 Mar 1:1352458518765670. doi: 10.1177/1352458518765670.
    PubMed    


  616. CASTELLI L, Prosperini L, Pozzilli C
    Balance worsening associated with nabiximols in multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518765649. doi: 10.1177/1352458518765649.
    PubMed     Abstract available


  617. GRAETZ C, Groger A, Luessi F, Salmen A, et al
    Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518763541. doi: 10.1177/1352458518763541.
    PubMed     Abstract available


  618. HUA LH, Fan TH, Conway D, Thompson N, et al
    Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60.
    Mult Scler. 2018 Mar 1:1352458518765656. doi: 10.1177/1352458518765656.
    PubMed     Abstract available


  619. LANZILLO R, Moccia M, Criscuolo C, Cennamo G, et al
    Optical coherence tomography angiography detects retinal vascular alterations in different phases of multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518768060. doi: 10.1177/1352458518768060.
    PubMed    


  620. VAN GEEST Q, Boeschoten RE, Keijzer MJ, Steenwijk MD, et al
    Fronto-limbic disconnection in patients with multiple sclerosis and depression.
    Mult Scler. 2018 Mar 1:1352458518767051. doi: 10.1177/1352458518767051.
    PubMed     Abstract available


  621. TOLEDANO M, Weinshenker BG, Kaufmann TJ, Parisi JE, et al
    Demographics and clinical characteristics of episodic hypothermia in multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518767045. doi: 10.1177/1352458518767045.
    PubMed     Abstract available


  622. LEIBOVITCH EC, Lin CM, Billioux BJ, Graves J, et al
    Prevalence of salivary human herpesviruses in pediatric multiple sclerosis cases and controls.
    Mult Scler. 2018 Mar 1:1352458518765654. doi: 10.1177/1352458518765654.
    PubMed     Abstract available


    February 2018
  623. JAEGER S, Paul F, Scheel M, Brandt A, et al
    Multiple sclerosis-related fatigue: Altered resting-state functional connectivity of the ventral striatum and dorsolateral prefrontal cortex.
    Mult Scler. 2018 Feb 1:1352458518758911. doi: 10.1177/1352458518758911.
    PubMed     Abstract available


  624. DE STEFANO N, Giorgio A, Tintore M, Pia Amato M, et al
    Radiologically isolated syndrome or subclinical multiple sclerosis: MAGNIMS consensus recommendations.
    Mult Scler. 2018;24:214-221.
    PubMed    


  625. ROOSTAEI T, Sadaghiani S, Mashhadi R, Falahatian M, et al
    Convergent effects of a functional C3 variant on brain atrophy, demyelination, and cognitive impairment in multiple sclerosis.
    Mult Scler. 2018 Feb 1:1352458518760715. doi: 10.1177/1352458518760715.
    PubMed     Abstract available


  626. CAVALERA C, Rovaris M, Mendozzi L, Pugnetti L, et al
    Online meditation training for people with multiple sclerosis: A randomized controlled trial.
    Mult Scler. 2018 Feb 1:1352458518761187. doi: 10.1177/1352458518761187.
    PubMed     Abstract available


  627. CAMARA-LEMARROY CR, Castillo J, Sastre-Garriga J, Tintore M, et al
    Severe hypertriglyceridemia associated with teriflunomide in a patient with multiple sclerosis: A case report.
    Mult Scler. 2018 Feb 1:1352458518761185. doi: 10.1177/1352458518761185.
    PubMed     Abstract available


  628. PIEHL F, Hillert J
    Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - Yes.
    Mult Scler. 2018 Feb 1:1352458518757930. doi: 10.1177/1352458518757930.
    PubMed    


  629. CREE BA
    Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - Commentary.
    Mult Scler. 2018 Feb 1:1352458518760717. doi: 10.1177/1352458518760717.
    PubMed    


  630. WALLIN MT
    Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - No.
    Mult Scler. 2018 Feb 1:1352458518757931. doi: 10.1177/1352458518757931.
    PubMed    


  631. BARKHOF F
    The optic nerve should be included as one of the typical CNS regions for establishing dissemination in space when diagnosing MS - Commentary.
    Mult Scler. 2018;24:125-126.
    PubMed    


  632. PORTER B
    Commentary on "Localized pigmentation disorder after subcutaneous pegylated interferon beta 1a injection" by Coghe et al.
    Mult Scler. 2018;24:233-235.
    PubMed    


    January 2018
  633. HILVEN K, Vandebergh M, Smets I, Mallants K, et al
    Genetic basis for relapse rate in multiple sclerosis: Association with LRP2 genetic variation.
    Mult Scler. 2018 Jan 1:1352458517749894. doi: 10.1177/1352458517749894.
    PubMed     Abstract available


  634. FEUCHT N, Maier M, Lepennetier G, Pettenkofer M, et al
    Optical coherence tomography angiography indicates associations of the retinal vascular network and disease activity in multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458517750009. doi: 10.1177/1352458517750009.
    PubMed     Abstract available


  635. DI STADIO A, Ralli M
    Inner ear involvement in multiple sclerosis: An underestimated condition?
    Mult Scler. 2018 Jan 1:1352458518750010. doi: 10.1177/1352458518750010.
    PubMed    


  636. DAMOTTE V, Lizee A, Tremblay M, Agrawal A, et al
    Harnessing electronic medical records to advance research on multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458517747407. doi: 10.1177/1352458517747407.
    PubMed     Abstract available


  637. DE STEFANO N, Giorgio A
    Response to 'Does cladribine have an impact on brain atrophy in people with relapsing remitting multiple sclerosis?' by Schiffmann et al.
    Mult Scler. 2018 Jan 1:1352458517748476. doi: 10.1177/1352458517748476.
    PubMed    


  638. SCHIFFMANN I, Scheiderbauer J, Riemann-Lorenz K, Heesen C, et al
    Does cladribine have an impact on brain atrophy in people with relapsing remitting multiple sclerosis?
    Mult Scler. 2018 Jan 1:1352458517749895. doi: 10.1177/1352458517749895.
    PubMed    


  639. SEGAL BM, Cohen JA, Antel J
    Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2017: Environmental factors, genetics, and epigenetics in MS susceptibility and clinical course.
    Mult Scler. 2018;24:4-5.
    PubMed     Abstract available


  640. TREMLETT H, Waubant E
    Gut microbiome and pediatric multiple sclerosis.
    Mult Scler. 2018;24:64-68.
    PubMed     Abstract available


  641. CASTRO K, Casaccia P
    Epigenetic modifications in brain and immune cells of multiple sclerosis patients.
    Mult Scler. 2018;24:69-74.
    PubMed     Abstract available


  642. TANKOU SK, Regev K, Healy BC, Cox LM, et al
    Investigation of probiotics in multiple sclerosis.
    Mult Scler. 2018;24:58-63.
    PubMed     Abstract available


  643. VOSKUHL RR, Sawalha AH, Itoh Y
    Sex chromosome contributions to sex differences in multiple sclerosis susceptibility and progression.
    Mult Scler. 2018;24:22-31.
    PubMed     Abstract available


  644. HAASE S, Haghikia A, Gold R, Linker RA, et al
    Dietary fatty acids and susceptibility to multiple sclerosis.
    Mult Scler. 2018;24:12-16.
    PubMed     Abstract available


  645. HARROUD A, Richards JB
    Mendelian randomization in multiple sclerosis: A causal role for vitamin D and obesity?
    Mult Scler. 2018;24:80-85.
    PubMed     Abstract available


  646. DOLEI A
    The aliens inside us: HERV-W endogenous retroviruses and multiple sclerosis.
    Mult Scler. 2018;24:42-47.
    PubMed     Abstract available


  647. CANTO E, Oksenberg JR
    Multiple sclerosis genetics.
    Mult Scler. 2018;24:75-79.
    PubMed     Abstract available


  648. WAUBANT E
    Effect of puberty on multiple sclerosis risk and course.
    Mult Scler. 2018;24:32-35.
    PubMed     Abstract available


  649. HODEL J, Bapst B, Outteryck O, Verclytte S, et al
    Magnetic resonance imaging changes following natalizumab discontinuation in multiple sclerosis patients with progressive multifocal leukoencephalopathy.
    Mult Scler. 2018 Jan 1:1352458517750765. doi: 10.1177/1352458517750765.
    PubMed     Abstract available


  650. BOVE R, Healy BC, Musallam A, Soltany P, et al
    Fatty acid binding protein-4 is associated with disability in multiple sclerosis patients.
    Mult Scler. 2018 Jan 1:1352458517750768. doi: 10.1177/1352458517750768.
    PubMed     Abstract available


  651. RIMKUS CM, Schoonheim MM, Steenwijk MD, Vrenken H, et al
    Gray matter networks and cognitive impairment in multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458517751650. doi: 10.1177/1352458517751650.
    PubMed     Abstract available


  652. COHEN JA, Hunter SF, Brown TR, Gudesblatt M, et al
    Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial.
    Mult Scler. 2018 Jan 1:1352458518754716. doi: 10.1177/1352458518754716.
    PubMed     Abstract available


  653. FORD HL, Wicks CR, Stroud A, Tennant A, et al
    Psychological determinants of job retention in multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458518754362. doi: 10.1177/1352458518754362.
    PubMed     Abstract available


  654. ROY S, Drake A, Fuchs T, Dwyer MG, et al
    Longitudinal personality change associated with cognitive decline in multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458517753720. doi: 10.1177/1352458517753720.
    PubMed     Abstract available


  655. HAUPTS MR, Spill-Askeridis P, Humpert M, Seidel D, et al
    Acute exacerbations after decades of non-active chronic multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458518754365. doi: 10.1177/1352458518754365.
    PubMed    


  656. DI IOIA M, Farina D, di Tommaso V, Travaglini D, et al
    Simultaneous early-onset severe autoimmune hemolytic anemia and albuminuria during alemtuzumab treatment for multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458517743093. doi: 10.1177/1352458517743093.
    PubMed     Abstract available


  657. MEUNIER B, Rico A, Seguier J, Boutiere C, et al
    Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab.
    Mult Scler. 2018 Jan 1:1352458517729766. doi: 10.1177/1352458517729766.
    PubMed     Abstract available


  658. MONTALBAN X, Gold R, Thompson AJ, Otero-Romero S, et al
    ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458517751049. doi: 10.1177/1352458517751049.
    PubMed     Abstract available


  659. LAVERY AM, Collins BN, Waldman AT, Hart CN, et al
    The contribution of secondhand tobacco smoke exposure to pediatric multiple sclerosis risk.
    Mult Scler. 2018 Jan 1:1352458518757089. doi: 10.1177/1352458518757089.
    PubMed     Abstract available


  660. BARONCINI D, Zaffaroni M, Moiola L, Lorefice L, et al
    Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study.
    Mult Scler. 2018 Jan 1:1352458518754364. doi: 10.1177/1352458518754364.
    PubMed     Abstract available


    December 2017
  661. KROTH J, Ciolac D, Fleischer V, Koirala N, et al
    Increased cerebrospinal fluid albumin and immunoglobulin A fractions forecast cortical atrophy and longitudinal functional deterioration in relapsing-remitting multiple sclerosis.
    Mult Scler. 2017 Dec 1:1352458517748474. doi: 10.1177/1352458517748474.
    PubMed     Abstract available


  662. HUGOS CL, Chen Z, Chen Y, Turner AP, et al
    A multicenter randomized controlled trial of two group education programs for fatigue in multiple sclerosis: Short- and medium-term benefits.
    Mult Scler. 2017 Dec 1:1352458517745723. doi: 10.1177/1352458517745723.
    PubMed     Abstract available


  663. CALLESEN J, Richter C, Kristensen C, Sunesen I, et al
    Test-retest agreement and reliability of the Six Spot Step Test in persons with multiple sclerosis.
    Mult Scler. 2017 Dec 1:1352458517745725. doi: 10.1177/1352458517745725.
    PubMed     Abstract available


  664. PEETERS LM
    Fair data for next-generation management of multiple sclerosis.
    Mult Scler. 2017 Dec 1:1352458517748475. doi: 10.1177/1352458517748475.
    PubMed     Abstract available


    November 2017
  665. GRAN-RUAZ S, Mani A, O'Quinn S
    An overview of biosimilars and non-biologic complex drugs in Europe, the United States, and Canada and their relevance to multiple sclerosis.
    Mult Scler. 2017 Nov 1:1352458517739976. doi: 10.1177/1352458517739976.
    PubMed     Abstract available


  666. MANCARDI G, Sormani MP, Muraro PA, Boffa G, et al
    Intense immunosuppression followed by autologous haematopoietic stem cell transplantation as a therapeutic strategy in aggressive forms of multiple sclerosis.
    Mult Scler. 2017 Nov 1:1352458517742532. doi: 10.1177/1352458517742532.
    PubMed     Abstract available


  667. PIETROBONI AM, Dell'Arti L, Caprioli M, Scarioni M, et al
    The loss of macular ganglion cells begins from the early stages of disease and correlates with brain atrophy in multiple sclerosis patients.
    Mult Scler. 2017 Nov 1:1352458517740214. doi: 10.1177/1352458517740214.
    PubMed     Abstract available


  668. MALHOTRA S, Sorosina M, Rio J, Peroni S, et al
    NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis patients.
    Mult Scler. 2017 Nov 1:1352458517739137. doi: 10.1177/1352458517739137.
    PubMed     Abstract available


  669. MALINOVA TS, Dijkstra CD, de Vries HE
    Serotonin: A mediator of the gut-brain axis in multiple sclerosis.
    Mult Scler. 2017 Nov 1:1352458517739975. doi: 10.1177/1352458517739975.
    PubMed     Abstract available


  670. ABBOUD H, Hill E, Siddiqui J, Serra A, et al
    Neuromodulation in multiple sclerosis.
    Mult Scler. 2017;23:1663-1676.
    PubMed     Abstract available


  671. FEYS P, Moumdjian L, Van Halewyck F, Wens I, et al
    Effects of an individual 12-week community-located "start-to-run" program on physical capacity, walking, fatigue, cognitive function, brain volumes, and structures in persons with multiple sclerosis.
    Mult Scler. 2017 Nov 1:1352458517740211. doi: 10.1177/1352458517740211.
    PubMed     Abstract available


  672. LOREFICE L, Fenu G, Sardu C, Frau J, et al
    Multiple sclerosis and HLA genotypes: A possible influence on brain atrophy.
    Mult Scler. 2017 Nov 1:1352458517739989. doi: 10.1177/1352458517739989.
    PubMed     Abstract available


  673. WINGES KM, Murchison CF, Bourdette DN, Spain RI, et al
    Longitudinal optical coherence tomography study of optic atrophy in secondary progressive multiple sclerosis: Results from a clinical trial cohort.
    Mult Scler. 2017 Nov 1:1352458517739136. doi: 10.1177/1352458517739136.
    PubMed     Abstract available


  674. UHER T, Vaneckova M, Krasensky J, Sobisek L, et al
    Pathological cut-offs of global and regional brain volume loss in multiple sclerosis.
    Mult Scler. 2017 Nov 1:1352458517742739. doi: 10.1177/1352458517742739.
    PubMed     Abstract available


  675. KAVALIUNAS A, Danylaite Karrenbauer V, Gyllensten H, Manouchehrinia A, et al
    Cognitive function is a major determinant of income among multiple sclerosis patients in Sweden acting independently from physical disability.
    Mult Scler. 2017 Nov 1:1352458517740212. doi: 10.1177/1352458517740212.
    PubMed     Abstract available


  676. AGIUS MA, Klodowska-Duda G, Maciejowski M, Potemkowski A, et al
    Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study.
    Mult Scler. 2017 Nov 1:1352458517740641. doi: 10.1177/1352458517740641.
    PubMed     Abstract available


  677. SPITERI S, Hassa T, Claros-Salinas D, Dettmers C, et al
    Neural correlates of effort-dependent and effort-independent cognitive fatigue components in patients with multiple sclerosis.
    Mult Scler. 2017 Nov 1:1352458517743090. doi: 10.1177/1352458517743090.
    PubMed     Abstract available


  678. RICCITELLI GC, Pagani E, Rodegher M, Colombo B, et al
    Imaging patterns of gray and white matter abnormalities associated with PASAT and SDMT performance in relapsing-remitting multiple sclerosis.
    Mult Scler. 2017 Nov 1:1352458517743091. doi: 10.1177/1352458517743091.
    PubMed     Abstract available


    October 2017
  679. MOSS-MORRIS R, Norton S
    Aerobic exercise, cognitive behavioural therapy and energy conservation management for multiple sclerosis (MS) fatigue: Are three trials better than one?
    Mult Scler. 2017;23:1436-1440.
    PubMed    


  680. ZETTERBERG H, Teunissen C
    Fluid biomarkers for disease activity in multiple sclerosis.
    Mult Scler. 2017 Oct 1:1352458517736151. doi: 10.1177/1352458517736151.
    PubMed    


  681. GIANFRANCESCO MA, Stridh P, Shao X, Rhead B, et al
    Genetic risk factors for pediatric-onset multiple sclerosis.
    Mult Scler. 2017 Oct 1:1352458517733551. doi: 10.1177/1352458517733551.
    PubMed     Abstract available


  682. FOX RJ, Chataway J
    Advancing trial design in progressive multiple sclerosis.
    Mult Scler. 2017;23:1573-1578.
    PubMed     Abstract available


  683. MILLER DH, Thompson AJ
    Advancing trial design in progressive multiple sclerosis.
    Mult Scler. 2017;23:1571-1572.
    PubMed    


  684. MOCCIA M, de Stefano N, Barkhof F
    Imaging outcome measures for progressive multiple sclerosis trials.
    Mult Scler. 2017;23:1614-1626.
    PubMed     Abstract available


  685. PICHLER A, Khalil M, Langkammer C, Pinter D, et al
    The impact of vascular risk factors on brain volume and lesion load in patients with early multiple sclerosis.
    Mult Scler. 2017 Oct 1:1352458517736149. doi: 10.1177/1352458517736149.
    PubMed     Abstract available


  686. GLAZER CH, Tottenborg SS, Giwercman A, Brauner EV, et al
    Male factor infertility and risk of multiple sclerosis: A register-based cohort study.
    Mult Scler. 2017 Oct 1:1352458517734069. doi: 10.1177/1352458517734069.
    PubMed     Abstract available


  687. TINELLI M, Kanavos P, Efthymiadou O, Visintin E, et al
    Using IMPrESS to guide policy change in multiple sclerosis.
    Mult Scler. 2017 Oct 1:1352458517737388. doi: 10.1177/1352458517737388.
    PubMed     Abstract available


  688. DONADIEU M, Le Fur Y, Maarouf A, Gherib S, et al
    Metabolic counterparts of sodium accumulation in multiple sclerosis: A whole brain 23Na-MRI and fast 1H-MRSI study.
    Mult Scler. 2017 Oct 1:1352458517736146. doi: 10.1177/1352458517736146.
    PubMed     Abstract available


  689. FLEMING J, Hernandez G, Hartman L, Maksimovic J, et al
    Safety and efficacy of helminth treatment in relapsing-remitting multiple sclerosis: Results of the HINT 2 clinical trial.
    Mult Scler. 2017 Oct 1:1352458517736377. doi: 10.1177/1352458517736377.
    PubMed     Abstract available


  690. BSTEH G, Hegen H, Teuchner B, Amprosi M, et al
    Peripapillary retinal nerve fibre layer as measured by optical coherence tomography is a prognostic biomarker not only for physical but also for cognitive disability progression in multiple sclerosis.
    Mult Scler. 2017 Oct 1:1352458517740216. doi: 10.1177/1352458517740216.
    PubMed     Abstract available


  691. LEAVITT VM, Blanchard AR, Guo CY, Gelernt E, et al
    Aspirin is an effective pretreatment for exercise in multiple sclerosis: A double-blind randomized controlled pilot trial.
    Mult Scler. 2017 Oct 1:1352458517739138. doi: 10.1177/1352458517739138.
    PubMed     Abstract available


  692. DEKKER I, Sombekke MH, Witte BI, Geurts JJ, et al
    Asymptomatic spinal cord lesions do not predict the time to disability in patients with early multiple sclerosis.
    Mult Scler. 2017 Oct 1:1352458517736147. doi: 10.1177/1352458517736147.
    PubMed     Abstract available


  693. BOESEN F, Norgaard M, Trenel P, Rasmussen PV, et al
    Longer term effectiveness of inpatient multidisciplinary rehabilitation on health-related quality of life in MS patients: a pragmatic randomized controlled trial - The Danish MS Hospitals Rehabilitation Study.
    Mult Scler. 2017 Oct 1:1352458517735188. doi: 10.1177/1352458517735188.
    PubMed     Abstract available


    September 2017
  694. TOBYNE SM, Ochoa WB, Bireley JD, Smith VM, et al
    Cognitive impairment and the regional distribution of cerebellar lesions in multiple sclerosis.
    Mult Scler. 2017 Sep 1:1352458517730132. doi: 10.1177/1352458517730132.
    PubMed     Abstract available


  695. FAZIA T, Pastorino R, Foco L, Han L, et al
    Investigating multiple sclerosis genetic susceptibility on the founder population of east-central Sardinia via association and linkage analysis of immune-related loci.
    Mult Scler. 2017 Sep 1:1352458517732841. doi: 10.1177/1352458517732841.
    PubMed     Abstract available


  696. HUPPKE P, Huppke B, Ellenberger D, Rostasy K, et al
    Therapy of highly active pediatric multiple sclerosis.
    Mult Scler. 2017 Sep 1:1352458517732843. doi: 10.1177/1352458517732843.
    PubMed     Abstract available


  697. LANZILLO R, Cennamo G, Criscuolo C, Carotenuto A, et al
    Optical coherence tomography angiography retinal vascular network assessment in multiple sclerosis.
    Mult Scler. 2017 Sep 1:1352458517729463. doi: 10.1177/1352458517729463.
    PubMed     Abstract available


  698. COMBER L, Quinn G, McGuigan C, Galvin R, et al
    Medication usage and falls in people with multiple sclerosis.
    Mult Scler. 2017 Sep 1:1352458517731912. doi: 10.1177/1352458517731912.
    PubMed     Abstract available


  699. MEINL I, Havla J, Hohlfeld R, Kumpfel T, et al
    Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis.
    Mult Scler. 2017 Sep 1:1352458517731913. doi: 10.1177/1352458517731913.
    PubMed     Abstract available


  700. GIOVANNONI G, Wiendl H, Turner B, Umans K, et al
    Circulating lymphocyte levels and relationship with infection status in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta.
    Mult Scler. 2017 Sep 1:1352458517729464. doi: 10.1177/1352458517729464.
    PubMed     Abstract available


  701. KAPPOS L, Arnold DL, Bar-Or A, Camm AJ, et al
    Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis.
    Mult Scler. 2017 Sep 1:1352458517728343. doi: 10.1177/1352458517728343.
    PubMed     Abstract available


  702. BISECCO A, Nardo FD, Docimo R, Caiazzo G, et al
    Fatigue in multiple sclerosis: The contribution of resting-state functional connectivity reorganization.
    Mult Scler. 2017 Sep 1:1352458517730932. doi: 10.1177/1352458517730932.
    PubMed     Abstract available


  703. CHARVET LE, Dobbs B, Shaw MT, Bikson M, et al
    Remotely supervised transcranial direct current stimulation for the treatment of fatigue in multiple sclerosis: Results from a randomized, sham-controlled trial.
    Mult Scler. 2017 Sep 1:1352458517732842. doi: 10.1177/1352458517732842.
    PubMed     Abstract available


    August 2017
  704. BRUNDIN L, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Sweden.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  705. BATTAGLIA M, Kobelt G, Ponzio M, Berg J, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Italy.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  706. BERGER T, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Austria.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  707. DUBOIS B, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Belgium.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  708. OREJA-GUEVARA C, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Spain.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  709. CALABRESE P, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Switzerland.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  710. UITDEHAAG B, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for the Netherlands.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  711. FLACHENECKER P, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Germany.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  712. KOBELT G, Eriksson J, Phillips G, Berg J, et al
    The burden of multiple sclerosis 2015: Methods of data collection, assessment and analysis of costs, quality of life and symptoms.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  713. PENTEK M, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Hungary.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  714. BOYKO A, Kobelt G, Berg J, Boyko O, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Russia.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  715. RASMUSSEN PV, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Denmark.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  716. LEBRUN-FRENAY C, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for France.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  717. THOMPSON A, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for the United Kingdom.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  718. SELMAJ K, Kobelt G, Berg J, Orlewska E, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Poland.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  719. SA MJ, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Portugal.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  720. HAVRDOVA E, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results of the Czech Republic.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  721. VERMOHLEN V, Schiller P, Schickendantz S, Drache M, et al
    Hippotherapy for patients with multiple sclerosis: A multicenter randomized controlled trial (MS-HIPPO).
    Mult Scler. 2017 Aug 1:1352458517721354. doi: 10.1177/1352458517721354.
    PubMed     Abstract available


  722. RUHRMANN S, Ewing E, Piket E, Kular L, et al
    Hypermethylation of MIR21 in CD4+ T cells from patients with relapsing-remitting multiple sclerosis associates with lower miRNA-21 levels and concomitant up-regulation of its target genes.
    Mult Scler. 2017 Aug 1:1352458517721356. doi: 10.1177/1352458517721356.
    PubMed     Abstract available


  723. LAROCCA NG, Hudson LD, Rudick R, Amtmann D, et al
    The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability.
    Mult Scler. 2017 Aug 1:1352458517723718. doi: 10.1177/1352458517723718.
    PubMed     Abstract available


  724. VAVASOUR IM, Huijskens SC, Li DK, Traboulsee AL, et al
    Global loss of myelin water over 5 years in multiple sclerosis normal-appearing white matter.
    Mult Scler. 2017 Aug 1:1352458517723717. doi: 10.1177/1352458517723717.
    PubMed     Abstract available


  725. BERGAMASCHI R, Cortese A, Pichiecchio A, Berzolari FG, et al
    Air pollution is associated to the multiple sclerosis inflammatory activity as measured by brain MRI.
    Mult Scler. 2017 Aug 1:1352458517726866. doi: 10.1177/1352458517726866.
    PubMed     Abstract available


  726. LOUAPRE C, Govindarajan ST, Gianni C, Madigan N, et al
    Heterogeneous pathological processes account for thalamic degeneration in multiple sclerosis: Insights from 7 T imaging.
    Mult Scler. 2017 Aug 1:1352458517726382. doi: 10.1177/1352458517726382.
    PubMed     Abstract available


  727. SELLEBJERG F, Bornsen L, Ammitzboll C, Nielsen JE, et al
    Defining active progressive multiple sclerosis.
    Mult Scler. 2017 Aug 1:1352458517726592. doi: 10.1177/1352458517726592.
    PubMed     Abstract available


  728. ZIMMER P, Bloch W, Schenk A, Oberste M, et al
    High-intensity interval exercise improves cognitive performance and reduces matrix metalloproteinases-2 serum levels in persons with multiple sclerosis: A randomized controlled trial.
    Mult Scler. 2017 Aug 1:1352458517728342. doi: 10.1177/1352458517728342.
    PubMed     Abstract available


  729. SOLOMON AJ, Watts R, Ontaneda D, Absinta M, et al
    Diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.
    Mult Scler. 2017 Aug 1:1352458517726383. doi: 10.1177/1352458517726383.
    PubMed     Abstract available


  730. AFOLABI D, Albor C, Zalewski L, Altmann DR, et al
    Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis.
    Mult Scler. 2017 Aug 1:1352458517726380. doi: 10.1177/1352458517726380.
    PubMed     Abstract available


  731. FAISSNER S, Mahjoub Y, Mishra M, Haupeltshofer S, et al
    Unexpected additive effects of minocycline and hydroxychloroquine in models of multiple sclerosis: Prospective combination treatment for progressive disease?
    Mult Scler. 2017 Aug 1:1352458517728811. doi: 10.1177/1352458517728811.
    PubMed     Abstract available


  732. KALINCIK T, Jokubaitis V, Spelman T, Horakova D, et al
    Cladribine versus fingolimod, natalizumab and interferon beta for multiple sclerosis.
    Mult Scler. 2017 Aug 1:1352458517728812. doi: 10.1177/1352458517728812.
    PubMed     Abstract available


  733. BOVE R, Chitnis T, Cree BA, Tintore M, et al
    SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts.
    Mult Scler. 2017 Aug 1:1352458517726657. doi: 10.1177/1352458517726657.
    PubMed     Abstract available


  734. GIOVANNONI G, Soelberg Sorensen P, Cook S, Rammohan K, et al
    Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.
    Mult Scler. 2017 Aug 1:1352458517727603. doi: 10.1177/1352458517727603.
    PubMed     Abstract available


  735. SEHR T, Proschmann U, Thomas K, Ziemssen T, et al
    Letter to the editor on the paper: "The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing".
    Mult Scler. 2017 Aug 1:1352458517726384. doi: 10.1177/1352458517726384.
    PubMed    


  736. LEURS CE, van Kempen ZL, Dekker I, Balk LJ, et al
    Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients.
    Mult Scler. 2017 Aug 1:1352458517726381. doi: 10.1177/1352458517726381.
    PubMed     Abstract available


    July 2017
  737. MIGLIORE S, Curcio G, Couyoumdjian A, Ghazaryan A, et al
    Executive functioning in relapsing-remitting multiple sclerosis patients without cognitive impairment: A task-switching protocol.
    Mult Scler. 2017 Jul 1:1352458517719149. doi: 10.1177/1352458517719149.
    PubMed     Abstract available


  738. KJOLHEDE T, Siemonsen S, Wenzel D, Stellmann JP, et al
    Can resistance training impact MRI outcomes in relapsing-remitting multiple sclerosis?
    Mult Scler. 2017 Jul 1:1352458517722645. doi: 10.1177/1352458517722645.
    PubMed     Abstract available


  739. TANAKA M, Kinoshita M, Tanaka K
    Intermittent drug holidays in fingolimod therapy for multiple sclerosis.
    Mult Scler. 2017 Jul 1:1352458517722647. doi: 10.1177/1352458517722647.
    PubMed    


  740. STAMPANONI BASSI M, Leocani L, Comi G, Iezzi E, et al
    Can pharmacological manipulation of LTP favor the effects of motor rehabilitation in multiple sclerosis?
    Mult Scler. 2017 Jul 1:1352458517721358. doi: 10.1177/1352458517721358.
    PubMed     Abstract available


  741. ROLF L, Muris AH, Mathias A, Du Pasquier R, et al
    Exploring the effect of vitamin D3 supplementation on the anti-EBV antibody response in relapsing-remitting multiple sclerosis.
    Mult Scler. 2017 Jul 1:1352458517722646. doi: 10.1177/1352458517722646.
    PubMed     Abstract available


  742. BALDASSARI LE, Salter AR, Longbrake EE, Cross AH, et al
    Streamlined EDSS for use in multiple sclerosis clinical practice: Development and cross-sectional comparison to EDSS.
    Mult Scler. 2017 Jul 1:1352458517721357. doi: 10.1177/1352458517721357.
    PubMed     Abstract available


  743. DUNN N, Juto A, Ryner M, Manouchehrinia A, et al
    Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies.
    Mult Scler. 2017 Jul 1:1352458517720044. doi: 10.1177/1352458517720044.
    PubMed     Abstract available


  744. CANCELLI A, Cottone C, Giordani A, Migliore S, et al
    Personalized, bilateral whole-body somatosensory cortex stimulation to relieve fatigue in multiple sclerosis.
    Mult Scler. 2017 Jul 1:1352458517720528. doi: 10.1177/1352458517720528.
    PubMed     Abstract available


  745. RODRIGUEZ-LEAL FA, Haase R, Thomas K, Eisele JC, et al
    Fampridine response in MS patients with gait impairment in a real-world setting: Need for new response criteria?
    Mult Scler. 2017 Jul 1:1352458517720043. doi: 10.1177/1352458517720043.
    PubMed     Abstract available


    June 2017
  746. CHOI IY, Lee P, Adany P, Hughes AJ, et al
    In vivo evidence of oxidative stress in brains of patients with progressive multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517711568. doi: 10.1177/1352458517711568.
    PubMed     Abstract available


  747. SATTARNEZHAD N, Farrow S, Kimbrough D, Glanz B, et al
    Agreement analysis comparing iPad LCVA and Sloan testing in multiple sclerosis patients.
    Mult Scler. 2017 Jun 1:1352458517713667. doi: 10.1177/1352458517713667.
    PubMed     Abstract available


  748. LEE H, Nakamura K, Narayanan S, Brown R, et al
    Impact of immunoablation and autologous hematopoietic stem cell transplantation on gray and white matter atrophy in multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517715811. doi: 10.1177/1352458517715811.
    PubMed     Abstract available


  749. BOESEN MS, Magyari M, Koch-Henriksen N, Thygesen LC, et al
    Pediatric-onset multiple sclerosis and other acquired demyelinating syndromes of the central nervous system in Denmark during 1977-2015: A nationwide population-based incidence study.
    Mult Scler. 2017 Jun 1:1352458517713669. doi: 10.1177/1352458517713669.
    PubMed     Abstract available


  750. PAKPOOR J, Seminatore B, Graves JS, Schreiner T, et al
    Dietary factors and pediatric multiple sclerosis: A case-control study.
    Mult Scler. 2017 Jun 1:1352458517713343. doi: 10.1177/1352458517713343.
    PubMed     Abstract available


  751. SALMEN A
    Clinical commentary on "Varicella-zoster meningovasculitis in a multiple sclerosis patient treated with natalizumab".
    Mult Scler. 2017 Jun 1:1352458517717810. doi: 10.1177/1352458517717810.
    PubMed    


  752. MULERO P, Auger C, Parolin L, Fonseca E, et al
    Varicella-zoster meningovasculitis in a multiple sclerosis patient treated with natalizumab.
    Mult Scler. 2017 Jun 1:1352458517711569. doi: 10.1177/1352458517711569.
    PubMed     Abstract available


  753. FOLEY RW, Tagg NT, Schindler MK, Fenton KM, et al
    Recurrent natalizumab-related aseptic meningitis in a patient with multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517702533. doi: 10.1177/1352458517702533.
    PubMed     Abstract available


  754. DOBRYAKOVA E, Hulst HE, Spirou A, Chiaravalloti ND, et al
    Fronto-striatal network activation leads to less fatigue in multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517717087. doi: 10.1177/1352458517717087.
    PubMed     Abstract available


  755. RANGANATHAN U, Kaunzner U, Foster S, Vartanian T, et al
    Thrombocytopenia at the time of alemtuzumab infusion in relapsing-remitting multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517719152. doi: 10.1177/1352458517719152.
    PubMed    


  756. YAP SM, McNicholas N, Hutchinson M, McGuigan C, et al
    Immediate thrombocytopenia at time of alemtuzumab infusion for multiple sclerosis - Not always self-limiting, fully reversible or predictable.
    Mult Scler. 2017 Jun 1:1352458517719151. doi: 10.1177/1352458517719151.
    PubMed    


  757. WEYGANDT M, Wakonig K, Behrens J, Meyer-Arndt L, et al
    Brain activity, regional gray matter loss, and decision-making in multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517717089. doi: 10.1177/1352458517717089.
    PubMed     Abstract available


  758. HIDALGO DE LA CRUZ M, d'Ambrosio A, Valsasina P, Pagani E, et al
    Abnormal functional connectivity of thalamic sub-regions contributes to fatigue in multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517717807. doi: 10.1177/1352458517717807.
    PubMed     Abstract available


  759. RUANO L, Branco M, Portaccio E, Goretti B, et al
    Patients with paediatric-onset multiple sclerosis are at higher risk of cognitive impairment in adulthood: An Italian collaborative study.
    Mult Scler. 2017 Jun 1:1352458517717341. doi: 10.1177/1352458517717341.
    PubMed     Abstract available


  760. BOZ C, Terzi M, Zengin Karahan S, Sen S, et al
    Safety of IV pulse methylprednisolone therapy during breastfeeding in patients with multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517717806. doi: 10.1177/1352458517717806.
    PubMed     Abstract available


    May 2017
  761. GOVEROVER Y, Chiaravalloti N, Genova H, DeLuca J, et al
    A randomized controlled trial to treat impaired learning and memory in multiple sclerosis: The self-GEN trial.
    Mult Scler. 2017 May 1:1352458517709955. doi: 10.1177/1352458517709955.
    PubMed     Abstract available


  762. BENEDICT RH, Cohan S, Lynch SG, Riester K, et al
    Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study.
    Mult Scler. 2017 May 1:1352458517707345. doi: 10.1177/1352458517707345.
    PubMed     Abstract available


  763. FREILICH J, Manouchehrinia A, Trusheim M, Baird LG, et al
    Characterization of annual disease progression of multiple sclerosis patients: A population-based study.
    Mult Scler. 2017 May 1:1352458517706252. doi: 10.1177/1352458517706252.
    PubMed     Abstract available


  764. ZEYDAN B, Lowe VJ, Schwarz CG, Przybelski SA, et al
    Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517707346. doi: 10.1177/1352458517707346.
    PubMed     Abstract available


  765. SHINODA K, Matsushita T, Nakamura Y, Masaki K, et al
    HLA-DRB1*04:05 allele is associated with intracortical lesions on three-dimensional double inversion recovery images in Japanese patients with multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517707067. doi: 10.1177/1352458517707067.
    PubMed     Abstract available


  766. SALTER A, Thomas NP, Tyry T, Cutter GR, et al
    A contemporary profile of primary progressive multiple sclerosis participants from the NARCOMS Registry.
    Mult Scler. 2017 May 1:1352458517711274. doi: 10.1177/1352458517711274.
    PubMed     Abstract available


  767. SUMOWSKI JF, Leavitt VM, Rocca MA, Inglese M, et al
    Mesial temporal lobe and subcortical grey matter volumes differentially predict memory across stages of multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517708873. doi: 10.1177/1352458517708873.
    PubMed     Abstract available


  768. CAWLEY N, Tur C, Prados F, Plantone D, et al
    Spinal cord atrophy as a primary outcome measure in phase II trials of progressive multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517709954. doi: 10.1177/1352458517709954.
    PubMed     Abstract available


  769. BALK LJ, Coric D, Nij Bijvank JA, Killestein J, et al
    Retinal atrophy in relation to visual functioning and vision-related quality of life in patients with multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517708463. doi: 10.1177/1352458517708463.
    PubMed     Abstract available


  770. PRINEAS JW, Parratt JDE
    Multiple sclerosis: Serum anti-CNS autoantibodies.
    Mult Scler. 2017 May 1:1352458517706037. doi: 10.1177/1352458517706037.
    PubMed     Abstract available


  771. PALOTAI M, Mike A, Cavallari M, Strammer E, et al
    Changes to the septo-fornical area might play a role in the pathogenesis of anxiety in multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517711273. doi: 10.1177/1352458517711273.
    PubMed     Abstract available


  772. MARINO M, Frisullo G, Di Sante G, Samengo DM, et al
    Low reliability of anti-KIR4.183-120 peptide auto-antibodies in multiple sclerosis patients.
    Mult Scler. 2017 May 1:1352458517711275. doi: 10.1177/1352458517711275.
    PubMed     Abstract available


  773. REDONDO J, Sarkar P, Kemp K, Virgo PF, et al
    Reduced cellularity of bone marrow in multiple sclerosis with decreased MSC expansion potential and premature ageing in vitro.
    Mult Scler. 2017 May 1:1352458517711276. doi: 10.1177/1352458517711276.
    PubMed     Abstract available


  774. BIBERACHER V, Schmidt P, Selter RC, Pernpeinter V, et al
    Fatigue in multiple sclerosis: Associations with clinical, MRI and CSF parameters.
    Mult Scler. 2017 May 1:1352458517712078. doi: 10.1177/1352458517712078.
    PubMed     Abstract available


  775. SMOOT K, Spinelli KJ, Stuchiner T, Lucas L, et al
    Three-year clinical outcomes of relapsing multiple sclerosis patients treated with dimethyl fumarate in a United States community health center.
    Mult Scler. 2017 May 1:1352458517709956. doi: 10.1177/1352458517709956.
    PubMed     Abstract available


  776. TORTORELLA C, Direnzo V, Ruggieri M, Zoccolella S, et al
    Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517711774. doi: 10.1177/1352458517711774.
    PubMed     Abstract available


  777. VAN DER VUURST DE VRIES RM, van den Dorpel JJ, Mescheriakova JY, Runia TF, et al
    Fatigue after a first attack of suspected multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517709348. doi: 10.1177/1352458517709348.
    PubMed     Abstract available


  778. VAN DEN AKKER LE, Beckerman H, Collette EH, Twisk JW, et al
    Cognitive behavioral therapy positively affects fatigue in patients with multiple sclerosis: Results of a randomized controlled trial.
    Mult Scler. 2017 May 1:1352458517709361. doi: 10.1177/1352458517709361.
    PubMed     Abstract available


  779. HEINE M, Verschuren O, Hoogervorst EL, van Munster E, et al
    Does aerobic training alleviate fatigue and improve societal participation in patients with multiple sclerosis? A randomized controlled trial.
    Mult Scler. 2017 May 1:1352458517696596. doi: 10.1177/1352458517696596.
    PubMed     Abstract available


  780. BLIKMAN LJ, van Meeteren J, Twisk JW, de Laat FA, et al
    Effectiveness of energy conservation management on fatigue and participation in multiple sclerosis: A randomized controlled trial.
    Mult Scler. 2017 May 1:1352458517702751. doi: 10.1177/1352458517702751.
    PubMed     Abstract available


  781. KAPPOS L, Butzkueven H, Wiendl H, Spelman T, et al
    Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study.
    Mult Scler. 2017 May 1:1352458517709619. doi: 10.1177/1352458517709619.
    PubMed     Abstract available


  782. SORMANI MP
    Why non-inferiority is more challenging than superiority?
    Mult Scler. 2017;23:790-791.
    PubMed     Abstract available


  783. HOEPNER R, Kolb EM, Dahlhaus S, Hellwig K, et al
    Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy.
    Mult Scler. 2017;23:830-835.
    PubMed     Abstract available


  784. PITTERI M, Romualdi C, Magliozzi R, Monaco S, et al
    Cognitive impairment predicts disability progression and cortical thinning in MS: An 8-year study.
    Mult Scler. 2017;23:848-854.
    PubMed     Abstract available


  785. VAN KEMPEN ZL, Leurs CE, Witte BI, de Vries A, et al
    The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing.
    Mult Scler. 2017 May 1:1352458517708464. doi: 10.1177/1352458517708464.
    PubMed     Abstract available


    April 2017
  786. COETZEE T, Thompson A
    When are we going to take modifiable risk factors more seriously in multiple sclerosis?
    Mult Scler. 2017;23:494-495.
    PubMed    


  787. AL-LOUZI O, Button J, Newsome SD, Calabresi PA, et al
    Retrograde trans-synaptic visual pathway degeneration in multiple sclerosis: A case series.
    Mult Scler. 2017 Apr 1:1352458516679035. doi: 10.1177/1352458516679035.
    PubMed     Abstract available


  788. SOLARI A, Giordano A, Patti F, Grasso MG, et al
    Randomized controlled trial of a home-based palliative approach for people with severe multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458517704078. doi: 10.1177/1352458517704078.
    PubMed     Abstract available


  789. COHEN JA, Imrey PB, Planchon SM, Bermel RA, et al
    Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458517703802. doi: 10.1177/1352458517703802.
    PubMed     Abstract available


  790. GIOVANNONI G, Tomic D, Bright JR, Havrdova E, et al
    "No evident disease activity": The use of combined assessments in the management of patients with multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458517703193. doi: 10.1177/1352458517703193.
    PubMed     Abstract available


  791. MORANDI E, Tarlinton RE, Tanasescu R, Gran B, et al
    Human endogenous retroviruses and multiple sclerosis: Causation, association, or after-effect?
    Mult Scler. 2017 Apr 1:1352458517704711. doi: 10.1177/1352458517704711.
    PubMed     Abstract available


  792. KLAUSER AM, Wiebenga OT, Eijlers AJ, Schoonheim MM, et al
    Metabolites predict lesion formation and severity in relapsing-remitting multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458517702534. doi: 10.1177/1352458517702534.
    PubMed     Abstract available


  793. AMATO MP
    The diagnostic dilemma of multiple sclerosis presenting with isolated cognitive and behavioral disorders.
    Mult Scler. 2017 Apr 1:1352458517705002. doi: 10.1177/1352458517705002.
    PubMed     Abstract available


  794. ZAMBON AA, Cecchetti G, Caso F, Santangelo R, et al
    Primary progressive multiple sclerosis presenting with severe predominant cognitive impairment and psychiatric symptoms: A challenging case.
    Mult Scler. 2017 Apr 1:1352458517702550. doi: 10.1177/1352458517702550.
    PubMed     Abstract available


  795. CIAMPI E, Uribe-San-Martin R, Godoy-Santin J, Cruz JP, et al
    Secondary paroxysmal dyskinesia in multiple sclerosis: Clinical-radiological features and treatment. Case report of seven patients.
    Mult Scler. 2017 Apr 1:1352458517702968. doi: 10.1177/1352458517702968.
    PubMed     Abstract available


  796. POP R, Kipfer S
    Paroxysmal kinesigenic dyskinesia-like phenotype in multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458517702535. doi: 10.1177/1352458517702535.
    PubMed     Abstract available


  797. PAREES I
    Clinical commentary on "Paroxysmal kinesigenic dyskinesia-like phenotype in multiple sclerosis" and "Secondary paroxysmal dyskinesia in multiple sclerosis: Clinical-radiological features and treatment. Case report of seven patients".
    Mult Scler. 2017 Apr 1:1352458517702555. doi: 10.1177/1352458517702555.
    PubMed     Abstract available


  798. BODINI B, Branzoli F, Poirion E, Garcia-Lorenzo D, et al
    Dysregulation of energy metabolism in multiple sclerosis measured in vivo with diffusion-weighted spectroscopy.
    Mult Scler. 2017 Apr 1:1352458517698249. doi: 10.1177/1352458517698249.
    PubMed     Abstract available


  799. KOLBER P, Droby A, Roebroeck A, Goebel R, et al
    A "kissing lesion": In-vivo 7T evidence of meningeal inflammation in early multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458516683267. doi: 10.1177/1352458516683267.
    PubMed     Abstract available


  800. KILSDONK ID, Schoonheim M, Wattjes MP
    In-vivo imaging of meningeal inflammation in multiple sclerosis: Presence of evidence or evidence of presence?
    Mult Scler. 2017 Apr 1:1352458517704924. doi: 10.1177/1352458517704924.
    PubMed    


  801. TOUSSAINT-DUYSTER LC, Wong YYM, Van der Cammen-van Zijp MH, Van Pelt-Gravesteijn D, et al
    Fatigue and physical functioning in children with multiple sclerosis and acute disseminated encephalomyelitis.
    Mult Scler. 2017 Apr 1:1352458517706038. doi: 10.1177/1352458517706038.
    PubMed     Abstract available


  802. HAGENS MH, Killestein J, Yaqub MM, van Dongen GA, et al
    Cerebral rituximab uptake in multiple sclerosis: A 89Zr-immunoPET pilot study.
    Mult Scler. 2017 Apr 1:1352458517704507. doi: 10.1177/1352458517704507.
    PubMed     Abstract available


  803. SORMANI MP
    Indirect comparisons of treatment effects: Network meta-analyses.
    Mult Scler. 2017;23:510-512.
    PubMed     Abstract available


  804. BOUDOT DE LA MOTTE M, Louapre C, Bertrand A, Reach P, et al
    Extensive white matter lesions after 2 years of fingolimod: Progressive multifocal leukoencephalopathy or MS relapse?
    Mult Scler. 2017;23:614-616.
    PubMed     Abstract available


  805. AIRAS L, Rissanen E, Rinne J
    Imaging of microglial activation in MS using PET: Research use and potential future clinical application.
    Mult Scler. 2017;23:496-504.
    PubMed     Abstract available


  806. HUM S, Lapierre Y, Scott SC, Duquette P, et al
    Trajectory of MS disease course for men and women over three eras.
    Mult Scler. 2017;23:534-545.
    PubMed     Abstract available


  807. D'SOUZA M, Yaldizli O, John R, Vogt DR, et al
    Neurostatus e-Scoring improves consistency of Expanded Disability Status Scale assessments: A proof of concept study.
    Mult Scler. 2017;23:597-603.
    PubMed     Abstract available


  808. VERMERSCH P, Hobart J, Dive-Pouletty C, Bozzi S, et al
    Measuring treatment satisfaction in MS: Is the Treatment Satisfaction Questionnaire for Medication fit for purpose?
    Mult Scler. 2017;23:604-613.
    PubMed     Abstract available


  809. CIAMPI E, Pareto D, Sastre-Garriga J, Vidal-Jordana A, et al
    Grey matter atrophy is associated with disability increase in natalizumab-treated patients.
    Mult Scler. 2017;23:556-566.
    PubMed     Abstract available


  810. BROWNLEE WJ, Altmann DR, Alves Da Mota P, Swanton JK, et al
    Association of asymptomatic spinal cord lesions and atrophy with disability 5 years after a clinically isolated syndrome.
    Mult Scler. 2017;23:665-674.
    PubMed     Abstract available


  811. SORMANI MP, Kappos L, Radue EW, Cohen J, et al
    Defining brain volume cutoffs to identify clinically relevant atrophy in RRMS.
    Mult Scler. 2017;23:656-664.
    PubMed     Abstract available


  812. SIGNORI A, Izquierdo G, Lugaresi A, Hupperts R, et al
    Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis.
    Mult Scler. 2017 Apr 1:1352458517703800. doi: 10.1177/1352458517703800.
    PubMed     Abstract available


    March 2017
  813. BOGIE JF, Boelen E, Louagie E, Delputte P, et al
    CD169 is a marker for highly pathogenic phagocytes in multiple sclerosis.
    Mult Scler. 2017 Mar 1:1352458517698759. doi: 10.1177/1352458517698759.
    PubMed     Abstract available


  814. PITAROKOILI K, Hellwig K, Lukas C, Gold R, et al
    Successful pregnancy after natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis.
    Mult Scler. 2017;23:483-486.
    PubMed     Abstract available


  815. ARRAMBIDE G
    Commentary on "Successful pregnancy after natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis".
    Mult Scler. 2017;23:486-487.
    PubMed    


  816. MARRIE RA
    What is the risk of suicide in multiple sclerosis?
    Mult Scler. 2017 Mar 1:1352458517699992. doi: 10.1177/1352458517699992.
    PubMed    


  817. KALSON-RAY S, Edan G, Leray E
    An excessive risk of suicide may no longer be a reality for multiple sclerosis patients.
    Mult Scler. 2017 Mar 1:1352458517699873. doi: 10.1177/1352458517699873.
    PubMed     Abstract available


  818. LEURS CE, Podlesniy P, Trullas R, Balk L, et al
    Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment.
    Mult Scler. 2017 Mar 1:1352458517699874. doi: 10.1177/1352458517699874.
    PubMed     Abstract available


  819. ROCCA MA, Valsasina P, Leavitt VM, Rodegher M, et al
    Functional network connectivity abnormalities in multiple sclerosis: Correlations with disability and cognitive impairment.
    Mult Scler. 2017 Mar 1:1352458517699875. doi: 10.1177/1352458517699875.
    PubMed     Abstract available


  820. RIO J, Rovira A, Tintore M, Otero-Romero S, et al
    Disability progression markers over 6-12 years in interferon-beta-treated multiple sclerosis patients.
    Mult Scler. 2017 Mar 1:1352458517698052. doi: 10.1177/1352458517698052.
    PubMed     Abstract available


  821. CORTESE M, Riise T, Bjornevik K, Myhr KM, et al
    Body size and physical exercise, and the risk of multiple sclerosis.
    Mult Scler. 2017 Mar 1:1352458517699289. doi: 10.1177/1352458517699289.
    PubMed     Abstract available


  822. RANGANATHAN U, Kaunzner U, Foster S, Vartanian T, et al
    Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis.
    Mult Scler. 2017 Mar 1:1352458517699876. doi: 10.1177/1352458517699876.
    PubMed     Abstract available


  823. FEINSTEIN A, Pavisian B
    Multiple sclerosis and suicide.
    Mult Scler. 2017 Mar 1:1352458517702553. doi: 10.1177/1352458517702553.
    PubMed     Abstract available


  824. CHARVET LE, Shaw M, Frontario A, Langdon D, et al
    Cognitive impairment in pediatric-onset multiple sclerosis is detected by the Brief International Cognitive Assessment for Multiple Sclerosis and computerized cognitive testing.
    Mult Scler. 2017 Mar 1:1352458517701588. doi: 10.1177/1352458517701588.
    PubMed     Abstract available


  825. HOUTCHENS MK, Zapata LB, Curtis KM, Whiteman MK, et al
    Contraception for women with multiple sclerosis: Guidance for healthcare providers.
    Mult Scler. 2017 Mar 1:1352458517701314. doi: 10.1177/1352458517701314.
    PubMed     Abstract available


  826. RUGGIERI S, Fanelli F, Castelli L, Petsas N, et al
    Lesion symptom map of cognitive-postural interference in multiple sclerosis.
    Mult Scler. 2017 Mar 1:1352458517701313. doi: 10.1177/1352458517701313.
    PubMed     Abstract available


  827. TOURBAH A, Sedel F
    Reply to the letter: Biotinidase deficiency masquerading as multiple sclerosis?
    Mult Scler. 2017 Mar 1:1352458517702554. doi: 10.1177/1352458517702554.
    PubMed    


  828. WOLF B
    Biotinidase deficiency masquerading as multiple sclerosis?
    Mult Scler. 2017 Mar 1:1352458517702551. doi: 10.1177/1352458517702551.
    PubMed    


  829. GYLLENSTEN H, Wiberg M, Alexanderson K, Friberg E, et al
    Comparing costs of illness of multiple sclerosis in three different years: A population-based study.
    Mult Scler. 2017 Mar 1:1352458517702549. doi: 10.1177/1352458517702549.
    PubMed     Abstract available


  830. INEICHEN BV, Schneider MP, Hlavica M, Hagenbuch N, et al
    High EDSS can predict risk for upper urinary tract damage in patients with multiple sclerosis.
    Mult Scler. 2017 Mar 1:1352458517703801. doi: 10.1177/1352458517703801.
    PubMed     Abstract available


  831. SORMANI MP
    Prognostic factors versus markers of response to treatment versus surrogate endpoints: Three different concepts.
    Mult Scler. 2017;23:378-381.
    PubMed     Abstract available


  832. GRAVES JS, Chohan H, Cedars B, Arnow S, et al
    Sex differences and subclinical retinal injury in pediatric-onset MS.
    Mult Scler. 2017;23:447-455.
    PubMed     Abstract available


  833. YAP SM, McGuigan C
    High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - YES.
    Mult Scler. 2017 Mar 1:1352458517697909. doi: 10.1177/1352458517697909.
    PubMed    


  834. ENZINGER C
    High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - NO.
    Mult Scler. 2017 Mar 1:1352458516681505. doi: 10.1177/1352458516681505.
    PubMed    


    February 2017
  835. HEMPEL S, Graham GD, Fu N, Estrada E, et al
    A systematic review of the effects of modifiable risk factor interventions on the progression of multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517690271. doi: 10.1177/1352458517690271.
    PubMed     Abstract available


  836. HEMPEL S, Graham GD, Fu N, Estrada E, et al
    A systematic review of modifiable risk factors in the progression of multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517690270. doi: 10.1177/1352458517690270.
    PubMed     Abstract available


  837. PRAVATA E, Rocca MA, Valsasina P, Riccitelli GC, et al
    Gray matter trophism, cognitive impairment, and depression in patients with multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517692886. doi: 10.1177/1352458517692886.
    PubMed     Abstract available


  838. CARPENTER AF, Goodwin SJ, Bornstein PF, Larson AJ, et al
    Cutaneous cryptococcosis in a patient taking fingolimod for multiple sclerosis: Here come the opportunistic infections?
    Mult Scler. 2017;23:297-299.
    PubMed     Abstract available


  839. CAMERON MH, McMillan G
    Methylphenidate is likely less effective than placebo for improving imbalance, walking, and fatigue in people with multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517692421. doi: 10.1177/1352458517692421.
    PubMed    


  840. SONNENBERG A, Ajdacic-Gross V
    Similar birth-cohort patterns in Crohn's disease and multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517691620. doi: 10.1177/1352458517691620.
    PubMed     Abstract available


  841. BALCER LJ, Raynowska J, Nolan R, Galetta SL, et al
    Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517690822. doi: 10.1177/1352458517690822.
    PubMed     Abstract available


  842. MOTL RW, Cohen JA, Benedict R, Phillips G, et al
    Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517690823. doi: 10.1177/1352458517690823.
    PubMed     Abstract available


  843. BENEDICT RH, DeLuca J, Phillips G, LaRocca N, et al
    Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517690821. doi: 10.1177/1352458517690821.
    PubMed     Abstract available


  844. FEYS P, Lamers I, Francis G, Benedict R, et al
    The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517690824. doi: 10.1177/1352458517690824.
    PubMed     Abstract available


  845. HULST HE, Thompson AJ, Geurts JJ
    The measure tells the tale: Clinical outcome measures in multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517690825. doi: 10.1177/1352458517690825.
    PubMed    


  846. SHOR N, Amador MD, Dormont D, Lubetzki C, et al
    Involvement of peripheral III nerve in multiple sclerosis patient: Report of a new case and discussion of the underlying mechanism.
    Mult Scler. 2017 Feb 1:1352458516687401. doi: 10.1177/1352458516687401.
    PubMed     Abstract available


  847. ROVIRA A
    Peripheral nervous system involvement in multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517693469. doi: 10.1177/1352458517693469.
    PubMed    


  848. CORIC D, Balk LJ, Verrijp M, Eijlers A, et al
    Cognitive impairment in patients with multiple sclerosis is associated with atrophy of the inner retinal layers.
    Mult Scler. 2017 Feb 1:1352458517694090. doi: 10.1177/1352458517694090.
    PubMed     Abstract available


  849. GIACOMINI E, Rizzo F, Etna MP, Cruciani M, et al
    Thymosin-alpha1 expands deficient IL-10-producing regulatory B cell subsets in relapsing-remitting multiple sclerosis patients.
    Mult Scler. 2017 Feb 1:1352458517695892. doi: 10.1177/1352458517695892.
    PubMed     Abstract available


  850. GALAZKA G, Mycko MP, Selmaj I, Raine CS, et al
    Multiple sclerosis: Serum-derived exosomes express myelin proteins.
    Mult Scler. 2017 Feb 1:1352458517696597. doi: 10.1177/1352458517696597.
    PubMed     Abstract available


  851. MAILLEUX J, Vanmierlo T, Bogie JF, Wouters E, et al
    Active liver X receptor signaling in phagocytes in multiple sclerosis lesions.
    Mult Scler. 2017 Feb 1:1352458517696595. doi: 10.1177/1352458517696595.
    PubMed     Abstract available


  852. ROY S, Drake AS, Eizaguirre MB, Zivadinov R, et al
    Trait neuroticism, extraversion, and conscientiousness in multiple sclerosis: Link to cognitive impairment?
    Mult Scler. 2017 Feb 1:1352458517695467. doi: 10.1177/1352458517695467.
    PubMed     Abstract available


  853. SCHWARTZ CE, Grover SA, Powell VE, Noguera A, et al
    Risk factors for non-adherence to disease-modifying therapy in pediatric multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517695469. doi: 10.1177/1352458517695469.
    PubMed     Abstract available


  854. CACAO G, Santos E, Martins Silva A
    Concurrent autoimmune hepatitis in multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517692885. doi: 10.1177/1352458517692885.
    PubMed     Abstract available


  855. GOLAN D, Doniger GM, Wissemann K, Zarif M, et al
    The impact of subjective cognitive fatigue and depression on cognitive function in patients with multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517695470. doi: 10.1177/1352458517695470.
    PubMed     Abstract available


  856. ZECCA C, Merlini A, Disanto G, Rodegher M, et al
    Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study.
    Mult Scler. 2017 Feb 1:1352458517694089. doi: 10.1177/1352458517694089.
    PubMed     Abstract available


  857. KOBELT G, Thompson A, Berg J, Gannedahl M, et al
    New insights into the burden and costs of multiple sclerosis in Europe.
    Mult Scler. 2017 Feb 1:1352458517694432. doi: 10.1177/1352458517694432.
    PubMed     Abstract available


  858. WESNES K, Myhr KM, Riise T, Cortese M, et al
    Physical activity is associated with a decreased multiple sclerosis risk: The EnvIMS study.
    Mult Scler. 2017 Feb 1:1352458517694088. doi: 10.1177/1352458517694088.
    PubMed     Abstract available


  859. PATEL VP, Walker LA, Feinstein A
    Revisiting cognitive reserve and cognition in multiple sclerosis: A closer look at depression.
    Mult Scler. 2017 Feb 1:1352458517692887. doi: 10.1177/1352458517692887.
    PubMed     Abstract available


  860. CLERICO M, De Mercanti S, Artusi CA, Durelli L, et al
    Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab.
    Mult Scler. 2017 Feb 1:1352458516688350. doi: 10.1177/1352458516688350.
    PubMed     Abstract available


  861. SHEIKH-TAHA M, Corman LC
    Pulmonary Nocardia beijingensis infection associated with the use of alemtuzumab in a patient with multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517694431. doi: 10.1177/1352458517694431.
    PubMed     Abstract available


  862. BACCHETTA F, Mathias A, Schluep M, Du Pasquier R, et al
    Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: An intriguing coincidence.
    Mult Scler. 2017;23:300-303.
    PubMed     Abstract available


  863. SORMANI MP, Bruzzi P
    Estimating a treatment effect: Choosing between relative and absolute measures.
    Mult Scler. 2017;23:197-200.
    PubMed     Abstract available


  864. SORMANI MP, Muraro PA, Saccardi R, Mancardi G, et al
    NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs.
    Mult Scler. 2017;23:201-204.
    PubMed     Abstract available


    January 2017
  865. AMATO MP, Derfuss T, Hemmer B, Liblau R, et al
    Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop.
    Mult Scler. 2017 Jan 6:1352458516686847. doi: 10.1177/1352458516686847.
    PubMed     Abstract available


  866. GONZALEZ TORRE JA, Cruz-Gomez AJ, Belenguer A, Sanchis-Segura C, et al
    Hippocampal dysfunction is associated with memory impairment in multiple sclerosis: A volumetric and functional connectivity study.
    Mult Scler. 2017 Jan 1:1352458516688349. doi: 10.1177/1352458516688349.
    PubMed     Abstract available


  867. MUNOZ MA, Kulick CG, Kortepeter CM, Levin RL, et al
    Liver injury associated with dimethyl fumarate in multiple sclerosis patients.
    Mult Scler. 2017 Jan 1:1352458516688351. doi: 10.1177/1352458516688351.
    PubMed     Abstract available


  868. MOTL RW, Mowry EM, Ehde DM, LaRocca NG, et al
    Wellness and multiple sclerosis: The National MS Society establishes a Wellness Research Working Group and research priorities.
    Mult Scler. 2017 Jan 1:1352458516687404. doi: 10.1177/1352458516687404.
    PubMed     Abstract available


  869. SUN H
    Temperature dependence of multiple sclerosis mortality rates in the United States.
    Mult Scler. 2017 Jan 1:1352458516688954. doi: 10.1177/1352458516688954.
    PubMed     Abstract available


  870. LEAVITT VM, Buyukturkoglu K, Inglese M, Sumowski JF, et al
    Protective personality traits: High openness and low neuroticism linked to better memory in multiple sclerosis.
    Mult Scler. 2017 Jan 1:1352458516685417. doi: 10.1177/1352458516685417.
    PubMed     Abstract available


  871. SONG J, Karrenbauer V, Manouchehrinia A, Almqvist C, et al
    Similar familial risk in multiple sclerosis subgroups.
    Mult Scler. 2017 Jan 1:1352458516684214. doi: 10.1177/1352458516684214.
    PubMed     Abstract available


  872. DE STEFANO N, Giorgio A, Battaglini M, De Leucio A, et al
    Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets.
    Mult Scler. 2017 Jan 1:1352458517690269. doi: 10.1177/1352458517690269.
    PubMed     Abstract available


  873. MA AY, Vitorino RC, Hojjat SP, Mulholland AD, et al
    The relationship between white matter fiber damage and gray matter perfusion in large-scale functionally defined networks in multiple sclerosis.
    Mult Scler. 2017 Jan 1:1352458517691149. doi: 10.1177/1352458517691149.
    PubMed     Abstract available


  874. BJORNEVIK K, Chitnis T, Ascherio A, Munger KL, et al
    Polyunsaturated fatty acids and the risk of multiple sclerosis.
    Mult Scler. 2017 Jan 1:1352458517691150. doi: 10.1177/1352458517691150.
    PubMed     Abstract available


  875. GOPAL S, Mikulskis A, Gold R, Fox RJ, et al
    Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the Phase 3 DEFINE and CONFIRM studies.
    Mult Scler. 2017 Jan 1:1352458517690617. doi: 10.1177/1352458517690617.
    PubMed     Abstract available


  876. MANOUCHEHRINIA A, Westerlind H, Kingwell E, Zhu F, et al
    Age Related Multiple Sclerosis Severity Score: Disability ranked by age.
    Mult Scler. 2017 Jan 1:1352458517690618. doi: 10.1177/1352458517690618.
    PubMed     Abstract available


  877. DECARD BF, Thone J, Haghikia A, Bornke C, et al
    Listeria rhombencephalitis mimicking a demyelinating event in an immunocompetent young patient.
    Mult Scler. 2017;23:123-125.
    PubMed     Abstract available


  878. LAROCHELLE C, Metz I, Lecuyer MA, Terouz S, et al
    Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawal.
    Mult Scler. 2017;23:72-81.
    PubMed     Abstract available


  879. BURTON JM, Eliasziw M, Trufyn J, Tung C, et al
    A prospective cohort study of vitamin D in optic neuritis recovery.
    Mult Scler. 2017;23:82-93.
    PubMed     Abstract available


  880. HAAS J, Schneider K, Schwarz A, Korporal-Kuhnke M, et al
    Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?
    Mult Scler. 2017;23:114-118.
    PubMed     Abstract available


  881. KALINCIK T, Sormani MP
    Reporting treatment outcomes in observational data: A fine balance.
    Mult Scler. 2017;23:21-22.
    PubMed     Abstract available


  882. SORMANI MP
    Subgroup analysis in MS trials.
    Mult Scler. 2017;23:34-35.
    PubMed     Abstract available


    December 2016
  883. MANOUCHEHRINIA A, Beiki O, Hillert J
    Clinical course of multiple sclerosis: A nationwide cohort study.
    Mult Scler. 2016 Dec 12. pii: 1352458516681197.
    PubMed     Abstract available


  884. BUDHRAM A, Parvathy S, Kremenchutzky M, Silverman M, et al
    Breaking down the gut microbiome composition in multiple sclerosis.
    Mult Scler. 2016 Dec 12. pii: 1352458516682105.
    PubMed     Abstract available


  885. KAPPOS L, Havrdova E, Giovannoni G, Khatri BO, et al
    No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study.
    Mult Scler. 2016 Dec 1:1352458516683266. doi: 10.1177/1352458516683266.
    PubMed     Abstract available


  886. CRISTOFANILLI M, Gratch D, Pagano B, McDermott K, et al
    Transglutaminase-6 is an autoantigen in progressive multiple sclerosis and is upregulated in reactive astrocytes.
    Mult Scler. 2016 Dec 1:1352458516684022. doi: 10.1177/1352458516684022.
    PubMed     Abstract available


  887. WIJNANDS JM, Kingwell E, Zhu F, Zhao Y, et al
    Infection-related health care utilization among people with and without multiple sclerosis.
    Mult Scler. 2016 Dec 1:1352458516681198. doi: 10.1177/1352458516681198.
    PubMed     Abstract available


  888. IKRAM MA, Vernooij MW, Roshchupkin GV, Hofman A, et al
    Genetic susceptibility to multiple sclerosis: Brain structure and cognitive function in the general population.
    Mult Scler. 2016 Dec 1:1352458516682104. doi: 10.1177/1352458516682104.
    PubMed     Abstract available


  889. BATISTA S, d'Almeida OC, Afonso A, Freitas S, et al
    Impairment of social cognition in multiple sclerosis: Amygdala atrophy is the main predictor.
    Mult Scler. 2016 Dec 1:1352458516680750. doi: 10.1177/1352458516680750.
    PubMed     Abstract available


  890. GHEZZI A
    Randomized clinical trials (RCTs) in pediatric multiple sclerosis: Are they really necessary?
    Mult Scler. 2016 Dec 1:1352458516684025. doi: 10.1177/1352458516684025.
    PubMed    


    November 2016
  891. GOLDMAN MD, Ward MD, Motl RW, Jones DE, et al
    Identification and validation of clinically meaningful benchmarks in the 12-item Multiple Sclerosis Walking Scale.
    Mult Scler. 2016 Nov 30. pii: 1352458516680749.
    PubMed     Abstract available


  892. HARRISON AM, das Nair R, Moss-Morris R
    Operationalising cognitive fatigability in multiple sclerosis: A Gordian knot that can be cut?
    Mult Scler. 2016 Nov 30. pii: 1352458516681862.
    PubMed     Abstract available


  893. SEPULVEDA M, Fernandez-Diez B, Martinez-Lapiscina EH, Llufriu S, et al
    Impairment of decision-making in multiple sclerosis: A neuroeconomic approach.
    Mult Scler. 2016 Nov 30. pii: 1352458516682103.
    PubMed     Abstract available


  894. DEVORAK J, Mokry LE, Morris JA, Forgetta V, et al
    Large differences in adiponectin levels have no clear effect on multiple sclerosis risk: A Mendelian randomization study.
    Mult Scler. 2016 Nov 30. pii: 1352458516681196.
    PubMed     Abstract available


  895. DATTA G, Violante IR, Scott G, Zimmerman K, et al
    Translocator positron-emission tomography and magnetic resonance spectroscopic imaging of brain glial cell activation in multiple sclerosis.
    Mult Scler. 2016 Nov 30. pii: 1352458516681504.
    PubMed     Abstract available


  896. VOORTMAN MM, Stojakovic T, Pirpamer L, Jehna M, et al
    Prognostic value of free light chains lambda and kappa in early multiple sclerosis.
    Mult Scler. 2016 Nov 29. pii: 1352458516681503.
    PubMed     Abstract available


  897. VENTURA RE, Antezana AO, Bacon T, Kister I, et al
    Hispanic Americans and African Americans with multiple sclerosis have more severe disease course than Caucasian Americans.
    Mult Scler. 2016 Nov 29. pii: 1352458516679894.
    PubMed     Abstract available


  898. ROY S, Frndak S, Drake AS, Irwin L, et al
    Differential effects of aging on motor and cognitive functioning in multiple sclerosis.
    Mult Scler. 2016 Nov 24. pii: 1352458516679036.
    PubMed     Abstract available


  899. VAN DIJK PA, Kirk-Brown AK, Taylor B, van der Mei I, et al
    Closing the gap: Longitudinal changes in employment for Australians with multiple sclerosis.
    Mult Scler. 2016 Nov 24. pii: 1352458516678934.
    PubMed     Abstract available


  900. ARROYO GONZALEZ R, Kita M, Crayton H, Havrdova E, et al
    Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis.
    Mult Scler. 2016 Nov 24. pii: 1352458516677589.
    PubMed     Abstract available


  901. ABDOLLAHPOUR I, Nedjat S, Sahraian MA, Mansournia MA, et al
    Waterpipe smoking associated with multiple sclerosis: A population-based incident case-control study.
    Mult Scler. 2016 Nov 10. pii: 1352458516677867.
    PubMed     Abstract available


  902. CARLING A, Forsberg A, Gunnarsson M, Nilsagard Y, et al
    CoDuSe group exercise programme improves balance and reduces falls in people with multiple sclerosis: A multi-centre, randomized, controlled pilot study.
    Mult Scler. 2016 Nov 10. pii: 1352458516677591.
    PubMed     Abstract available


  903. SACCA F, Costabile T, Carotenuto A, Lanzillo R, et al
    The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests.
    Mult Scler. 2016 Nov 3. pii: 1352458516677592.
    PubMed     Abstract available


  904. MIKOLAJCZAK J, Zimmermann H, Kheirkhah A, Kadas EM, et al
    Patients with multiple sclerosis demonstrate reduced subbasal corneal nerve fibre density.
    Mult Scler. 2016 Nov 3. pii: 1352458516677590.
    PubMed     Abstract available


  905. CHATAWAY J
    Biotin in progressive multiple sclerosis: A new lead?
    Mult Scler. 2016;22:1640-1641.
    PubMed    


  906. GABILONDO I, Rilo O, Ojeda N, Pena J, et al
    The influence of posterior visual pathway damage on visual information processing speed in multiple sclerosis.
    Mult Scler. 2016 Nov 1:1352458516676642. doi: 10.1177/1352458516676642.
    PubMed     Abstract available


  907. CARUANA P, Lemmert K, Ribbons K, Lea R, et al
    Natural killer cell subpopulations are associated with MRI activity in a relapsing-remitting multiple sclerosis patient cohort from Australia.
    Mult Scler. 2016 Nov 1:1352458516679267. doi: 10.1177/1352458516679267.
    PubMed     Abstract available


    October 2016
  908. PLANCHE V, Ruet A, Coupe P, Lamargue-Hamel D, et al
    Hippocampal microstructural damage correlates with memory impairment in clinically isolated syndrome suggestive of multiple sclerosis.
    Mult Scler. 2016 Oct 25. pii: 1352458516675750.
    PubMed     Abstract available


  909. BSTEH G, Feige J, Ehling R, Auer M, et al
    Discontinuation of disease-modifying therapies in multiple sclerosis - Clinical outcome and prognostic factors.
    Mult Scler. 2016 Oct 20. pii: 1352458516675751.
    PubMed     Abstract available


  910. D'AMBROSIO A, Pagani E, Riccitelli GC, Colombo B, et al
    Cerebellar contribution to motor and cognitive performance in multiple sclerosis: An MRI sub-regional volumetric analysis.
    Mult Scler. 2016 Oct 19. pii: 1352458516674567.
    PubMed     Abstract available


  911. KAVALIUNAS A, Manouchehrinia A, Stawiarz L, Ramanujam R, et al
    Importance of early treatment initiation in the clinical course of multiple sclerosis.
    Mult Scler. 2016 Oct 17. pii: 1352458516675039.
    PubMed     Abstract available


  912. PIETROBONI AM, Schiano di Cola F, Scarioni M, Fenoglio C, et al
    CSF beta-amyloid as a putative biomarker of disease progression in multiple sclerosis.
    Mult Scler. 2016 Oct 17. pii: 1352458516674566.
    PubMed     Abstract available


  913. RUANO L, Portaccio E, Goretti B, Niccolai C, et al
    Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes.
    Mult Scler. 2016 Oct 13. pii: 1352458516674367.
    PubMed     Abstract available


  914. WICKSTROM A, Fagerstrom M, Wickstrom L, Granasen G, et al
    The impact of adjusted work conditions and disease-modifying drugs on work ability in multiple sclerosis.
    Mult Scler. 2016 Oct 6. pii: 1352458516671818.
    PubMed     Abstract available


  915. AHMAD H, Taylor BV, van der Mei I, Colman S, et al
    The impact of multiple sclerosis severity on health state utility values: Evidence from Australia.
    Mult Scler. 2016 Oct 3. pii: 1352458516672014.
    PubMed     Abstract available


  916. LUBRINI G, Rios Lago M, Perianez JA, Tallon Barranco A, et al
    The contribution of depressive symptoms to slowness of information processing in relapsing remitting multiple sclerosis.
    Mult Scler. 2016;22:1607-1615.
    PubMed     Abstract available


  917. ARNETT P
    Lubrini et al.'s study, "The contribution of depressive symptoms to slowness of information processing in relapsing remitting multiple sclerosis".
    Mult Scler. 2016;22:1512-1513.
    PubMed    


    September 2016
  918. MOBERG JY, Laursen B, Koch-Henriksen N, Thygesen LC, et al
    Employment, disability pension and income for children with parental multiple sclerosis.
    Mult Scler. 2016 Sep 28. pii: 1352458516672016.
    PubMed     Abstract available


  919. BOESCHOTEN RE, Dekker J, Uitdehaag BM, Beekman AT, et al
    Internet-based treatment for depression in multiple sclerosis: A randomized controlled trial.
    Mult Scler. 2016 Sep 28. pii: 1352458516671820.
    PubMed     Abstract available


  920. RIBBONS K, Lea R, Tiedeman C, Mackenzie L, et al
    Ongoing increase in incidence and prevalence of multiple sclerosis in Newcastle, Australia: A 50-year study.
    Mult Scler. 2016 Sep 28. pii: 1352458516671819.
    PubMed     Abstract available


  921. SCHLEMM L, Chien C, Bellmann-Strobl J, Dorr J, et al
    Gadopentetate but not gadobutrol accumulates in the dentate nucleus of multiple sclerosis patients.
    Mult Scler. 2016 Sep 27. pii: 1352458516670738.
    PubMed     Abstract available


  922. GAFSON A, Craner MJ, Matthews PM
    Personalised medicine for multiple sclerosis care.
    Mult Scler. 2016 Sep 26. pii: 1352458516672017.
    PubMed     Abstract available


  923. BJORNEVIK K, Riise T, Bostrom I, Casetta L, et al
    Negative interaction between smoking and EBV in the risk of multiple sclerosis: The EnvIMS study.
    Mult Scler. 2016 Sep 23. pii: 1352458516671028.
    PubMed     Abstract available


  924. COLLIGAN E, Metzler A, Tiryaki E
    Shared decision-making in multiple sclerosis: A review.
    Mult Scler. 2016 Sep 23. pii: 1352458516671204.
    PubMed     Abstract available


  925. HENGSTMAN GJ
    Controversies in MS: All relapsing multiple sclerosis patients should be managed at a specialist clinic - Combine the best of two worlds!
    Mult Scler. 2016 Sep 21. pii: 1352458516670737.
    PubMed    


  926. LANDFELDT E, Castelo-Branco A, Svedbom A, Lofroth E, et al
    Sick leave and disability pension before and after diagnosis of multiple sclerosis.
    Mult Scler. 2016 Sep 20. pii: 1352458516667567.
    PubMed     Abstract available


  927. CHOI IY, Lee P, Hughes AJ, Denney DR, et al
    Longitudinal changes of cerebral glutathione (GSH) levels associated with the clinical course of disease progression in patients with secondary progressive multiple sclerosis.
    Mult Scler. 2016 Sep 12. pii: 1352458516669441.
    PubMed     Abstract available


  928. ORPEZ-ZAFRA T, Pavia J, Hurtado-Guerrero I, Pinto-Medel MJ, et al
    Decreased soluble IFN-beta receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarker.
    Mult Scler. 2016 Sep 9. pii: 1352458516667564.
    PubMed     Abstract available


  929. HAKOBYAN S, Luppe S, Evans DR, Harding K, et al
    Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder.
    Mult Scler. 2016 Sep 9. pii: 1352458516669002.
    PubMed     Abstract available


  930. NELSON F, Akhtar MA, Zuniga E, Perez CA, et al
    Novel fMRI working memory paradigm accurately detects cognitive impairment in multiple sclerosis.
    Mult Scler. 2016 Sep 9. pii: 1352458516666186.
    PubMed     Abstract available


    August 2016
  931. VERMERSCH P, Smets L, Gold R
    Conclusions: Calls to action for improving the life of MS patients and their families.
    Mult Scler. 2016;22.
    PubMed     Abstract available


  932. VERMERSCH P, Faller A, Czarnota-Szalkowska D, Meesen B, et al
    The patient's perspective: How to create awareness for improving access to care and treatment of MS patients?
    Mult Scler. 2016;22.
    PubMed     Abstract available


    May 2016
  933. UHER T, Havrdova E, Sobisek L, Krasensky J, et al
    Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?
    Mult Scler. 2016 May 26. pii: 1352458516650525.
    PubMed     Abstract available


    April 2016
  934. MODVIG S, Degn M, Sander B, Horwitz H, et al
    Cerebrospinal fluid neurofilament light chain levels predict visual outcome after optic neuritis.
    Mult Scler. 2016;22:590-8.
    PubMed     Abstract available


  935. HADHOUM N, Hodel J, Defoort-Dhellemmes S, Duhamel A, et al
    Length of optic nerve double inversion recovery hypersignal is associated with retinal axonal loss.
    Mult Scler. 2016;22:649-58.
    PubMed     Abstract available


  936. NEMECEK A, Zimmermann H, Rubenthaler J, Fleischer V, et al
    Flow cytometric analysis of T cell/monocyte ratio in clinically isolated syndrome identifies patients at risk of rapid disease progression.
    Mult Scler. 2016;22:483-93.
    PubMed     Abstract available


    March 2016
  937. BEVER CT JR, Wallin MT
    Tribute to John F. Kurtzke, MD, FACP, FAAN: 1926-2015.
    Mult Scler. 2016;22:267-8.
    PubMed    


  938. ENZINGER C, Pinter D, Rocca MA, De Luca J, et al
    Longitudinal fMRI studies: Exploring brain plasticity and repair in MS.
    Mult Scler. 2016;22:269-78.
    PubMed     Abstract available


  939. PEKCEVIK Y, Mitchell CH, Mealy MA, Orman G, et al
    Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging.
    Mult Scler. 2016;22:302-11.
    PubMed     Abstract available


  940. MAKHANI N, Banwell B, Tellier R, Yea C, et al
    Viral exposures and MS outcome in a prospective cohort of children with acquired demyelination.
    Mult Scler. 2016;22:385-8.
    PubMed     Abstract available


  941. VAN SCHEPENDOM J, Gielen J, Laton J, Nagels G, et al
    Assessing PML risk under immunotherapy: if all you have is a hammer, everything looks like a nail.
    Mult Scler. 2016;22:389-92.
    PubMed     Abstract available


    February 2016
  942. JARIUS S, Metz I, Konig FB, Ruprecht K, et al
    Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in 'pattern II multiple sclerosis' and brain biopsy findings in a MOG-IgG-positive case.
    Mult Scler. 2016 Feb 11. pii: 1352458515622986.
    PubMed     Abstract available


  943. BERGAMASCHI R, Montomoli C
    Modeling the course and outcomes of MS is statistical twaddle--No.
    Mult Scler. 2016;22:142-4.
    PubMed    


  944. BEAUCHEMIN P, Carruthers R
    MS arising during Tocilizumab therapy for rheumatoid arthritis.
    Mult Scler. 2016;22:254-6.
    PubMed     Abstract available


  945. FERNANDEZ-CARBONELL C, Vargas-Lowy D, Musallam A, Healy B, et al
    Clinical and MRI phenotype of children with MOG antibodies.
    Mult Scler. 2016;22:174-84.
    PubMed     Abstract available


  946. HUPPERTS R, Lycke J, Short C, Gasperini C, et al
    Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial.
    Mult Scler. 2016;22:212-21.
    PubMed     Abstract available


    January 2016
  947. SASTRE-GARRIGA J, Wiendl H
    Highlights from the 31st ECTRIMS congress - Barcelona 2015.
    Mult Scler. 2016;22:7-10.
    PubMed    


  948. REINGOLD SC, Lublin FD
    William Austin Sibley, MD (1925-2015).
    Mult Scler. 2016;22:11-2.
    PubMed    


  949. FREEDMAN MS
    Are we in need of NEDA?
    Mult Scler. 2016;22:5-6.
    PubMed    


  950. ZAJDA M, Kazmierczak B, Zakrzewska-Pniewska B
    Aquaporin-4: A novel diagnostic biomarker for seronegative neuromyelitis optica.
    Mult Scler. 2016;22:125-6.
    PubMed    


    November 2015
  951. WATTJES MP, Wijburg MT, Vennegoor A, Witte BI, et al
    Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients.
    Mult Scler. 2015 Nov 12. pii: 1352458515615225.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: